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ABSTRACT 
The burden of respiratory diseases is large and, due to the mv pandemic and 
increasing tobacco use, growing in many developing countries. In South Africa, 
responsibility for diagnosis, treabnent and referral rests mainly upon primary care 
nurses who may have inadequate skills and training for the increasing clinical 
demand. Syndromic approaches have shown promise across other disease areas in 
similar settings, but have largely been implemented using offsite training courses of 
unknown effectiveness which have interrupted clinical services, limiting 
sustainability and coverage. 
Based upon the World Health Organization's Practical Approach to Lung Health 
concept, P ALSA (Practical Approach to Lung Health in South Africa) combined 
syndromic case management guidelines of priority adult respiratory diseases with 
educational outreach, a knowledge translation strategy known to change the practice 
of physicians towards evidence-based choices. 
This thesis evaluates the effectiveness, cost and cost-effectiveness of the P ALSA 
, intervention on the processes and outcomes of respiratory care using a pragmatic 
cluster randomised controlled trial with prospective economic evaluation in 40 
nurse-practitioner-staffed primary care clinics in the Free State province. Twenty 
clinics received the intervention in addition to usual support and training. 
Information about tests, treabnent received, and costs, during and four months after 
PALSA outreach visits was obtained from 50 patients from each clinic. 
Improvements in tuberculosis case detection (6.4% vs. 3.8%, OR 1.72, 95% confidence 
interval 1.04 to 2.85), inhaled corticosteroid use for obstructive lung disease (13.7% 
vs. 7.7%, OR 1.90,95% confidence interval 1.14 to 3.18) and referral of severe cases 
(7.8% vs. 4.7%, OR 1.71, 95% confidence interval 0.95 to 3.09) suggested improved 
clinical processes. Increased costs associated with the intervention were largely 
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1. INTRODUCTION 
This study evaluates the South African adaptation of the World Health 
Organization's Practical Approach to Lung Health (PAL), specifically its impact on 
the effectiveness, cost and cost-effectiveness of respiratory care. P ALSA, or the 
Practical Approach to Lung Health in South Africa, combined integrated case 
management symptom- and sign-based guidelines with knowledge translation 
approaches to their implementation. It targeted the primary care management of 
common respiratory conditions in adults and adolescents, including tuberculosis. 
The requirement for such an intervention is clear if the burden that respiratory 
diseases impose on primary care services is considered. Section 1.1 describes the 
large and growing burden of respiratory diseases globally, in South Africa and the 
Free State. Section 1.2 describes the burden this imposes on primary care services. 
Section 1.3 briefly describes the organization of primary care services in South Africa 
and their dependence on primary care nurse practitioners who were the targets of 
the P ALSA intervention. 
This study contributes to two specific areas of evidence for primary care 
interventions. The first of these is for syndromic interventions, which use symptoms 
and signs to guide frontline health workers to provide the appropriate diagnosis and 
treatment using integrated case management guidelines. Examples that have been 
widely implemented throughout the developing world, including South Africa, are 
the syndromic management of Sexually Transmitted Infections and the Integrated 
Management of Childhood lllness. A general overview of these, and the PAL 
strategy, is provided in Section 1.4, and a more detailed appraisal of economic 
evaluations of these programmes in Section 1.5. 
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1.1 The burden of respiratory disease 
The burden of respiratory disease is large and growing. The Global Burden of 
Disease Study estimated that in 1990, respiratory'diseases, including lower 
respiratory tract infections, Chronic Obstructive Pulmonary Disease (COPD), 
tuberculosis and lung cancers, were among 4 of the top 10 causes of mortality 
worldwide and together accounted for 19% or 9.4 million deaths (Murray and Lopez 
1997a). Lower respiratory tract infections are the leading cause of disability-adjusted 
life years (DALYs) worldwide, primarily affecting children of the developing world, 
and among adults, tuberculosis is the leading infectious cause of death and disability 
(Murray and Lopez 1997b). The burden of respiratory diseases is particularly severe 
in the low and middle-income countries of the developing world, where it is not 
limited to infectious causes. Chronic respiratory diseases are increasingly common 
and associated with increasing rates of tobacco use, low socio-economic status, 
frequent respiratory infections in childhood, previous tuberculosis, workplace 
pollution and exposure to indoor pollution from biomass fuels (Alt-Khaled et al. 
2001). The spread of HN / AIDS and the increasing consumption of tobacco will 
ensure that the burden imposed by respiratory diseases continues to grow well into 
the 21st century (Murray and Lopez 1997c). 
1.1.1 Tuberculosis 
Annually tuberculosis (fB) is estimated to infect between 7 and 8 million people, and 
to kill between 2 and 3 million, 95% of whom live in the developing world 
(Raviglione 2003). Global efforts to control tuberculosis accelerated during the 1990s 
(Table 1.1), spurred on by a resurgence of tuberculosis among immigrants in the 
United States and Europe during the late 1980s (Reichman 1991; McKenna et al. 
1995). In 1991 the World Health Assembly ratified global targets for TB control: to 
27 
Table 1.1 Milestones in global tuberculosis policy (1989 - 2002) 
1989 Number of staff at the World Health Organization (WHO) assigned to tuberculosis numbers 2. 
1991 World Health Assembly ratifies global targets for TB control: to successfully 
treat 85% of all smear positive cases, and detect 70% of all cases by 2000. 
1993 World Bank endorses TB treatment as one of the most cost-effective health interventions. 
WHO declares TB a global emergency. 
1994 WHO launches the Framework for Effective TB Control. 
1995 The Framework is branded as DOTS (Directly Observed Treatment, Short Course) and 
aggressive marketing begins. 
1997 WHO releases the first global monitoring report. 
South Africa adopts the DOTS strategy as its official national tuberculosis control policy. 
1998 The Stop TB Partnership comprising >150 governments, non-governmental agencies and 
various Institutions is established. 
2000 The Amsterdam Declaration to Stop TB commits governments of high burden countries to 
achieving global TB targets by 2005. 
WHO launches the Global DOTS ExpanSion Plan. 
Millenium Development Goals include those targeting tuberculosis; by 2015 to: 
Reverse, or at least halt, the incidence of TB 
Halve the mortality due to TB compared with 1990 
Halve the prevalence of TB compared with 1990 
2001 The Global Drug Facility, which aims to provide free drugs to countries in need, is established. 
2002 The Global Fund against Tuberculosis, AIDS and Malaria is created. 
The Strategic Framework to Decrease the Burden of TBlHIV is launched. 
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respectively (Raviglione 2003). Presently tuberculosis incidence is rising at 1.0% per 
year (WHO 2005a). Reductions in global prevalence and mortality would be greater, 
were it not for the unprecedented increase in tuberculosis in sub-Saharan Africa 
during the last decade. 
Figure 1.1 DOTS coverage and progress towards global targets (from WHO 1998a, 
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1.1.1.2 The impact ofHIV/AIDS on tuberculosis in sub-Saharan Africa 
Key constraints to achieving the global tuberculosis targets and Millenium 
Development Goals include HIV / AIDS and the lack of skilled health workers (Dye et 
al. 2003). In sub-Saharan Africa the spread of HIV / AIDS has resulted in an 
unprecedented 300-400% increase in tuberculosis cases during the last decade 
(Raviglione et al. 1997), and co-infection rates in excess of 60% (Corbett et al. 2003). 
Mortality attributable to co-infection is high. Tuberculosis is the leading cause of 
death among HIV infected Africans (Grant et al. 1997, Rana et al. 2000, Ansari et al. 
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1.1.1.3 Tuberculosis control in South Africa 
South Africa is currently in the grip of two historically unprecedented epidemics 
Not only is it home to the highest number of HN infected people in the world 
(UNAIDS n.d.), but also to the 8th highest number of incident tuberculosis cases 
(WHO 2005a). Models predict that by the year 2010, 5.2 million South Africans will 
have lost their lives to HN / AIDS (Dorrington et al. 2002), almost 20 times the 
number who died in the South East Asian tsunami of 2004 (Wa112005). Many of 
these will die as a result of tuberculosis, and already tuberculosis and respiratory 
infections are the leading causes of death among young South African adults 
(Bradshaw et al. 2003). 
The South African Department of Health adopted the DOTS strategy as its official 
national policy in 1997, and rapidly expanded the programme to cover 99.5% of the 
population. Notification rates have risen accordingly, but disproportionately to 
improvements in monitoring. Much of this coincides with increasing rates of HN 
prevalence (Figure 1.2) (WHO 2004a; South African National Department of Health, 
2005). HN co-infection rates among tuberculosis cases are presently estimated at 
around 60% (WHO 2oo5a), and the proportion of tuberculosis cases directly 
attributable to HN at one third (Churchyard and Corbett 2005). 
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patients to facilities and delayed diagnosis by health workers have been identified as 
priority challenges (Barr et al. 2005). 
Table 1.3 Tuberculosis incidence, detection and outcomes for South Africa 1997 -
2003 (from WHO 1998a, 1999, 2oooa, 2001a, 2002a, 2003a, 2004a, 2005a) 
Indicator 1997 1998 1999 2000 2001 2002 2003 
DOTS coverage 13 22 66 77 77 98 99.5 
Global rank 8 8 9 9 7 9 8 
Notification rate (all cases! 1 00 000 pop) 271 326 323 344 334 481 505 
Notification rate (ss+*!1 00 000 ~op) 127 157 166 173 189 221 258 
Incidence (all cases! 100 000 pop! year) - 326 495 - 556 558 536 
Detection of all cases (%) 80 90 90 74 68 94 94 
DOTS case detection rate (new ss+, %) 6.2 22 68 91 95 106t 118t 
TB cases aged 15-49yrs HIV positive (%) 45% - 60 60 60 60 61 
New cases multidrug resistant (%) - - 1.5 1.5 1.5 1.5 1.6 
DOTS treatment success (new ss+, %) 69 74 60 66 65 68 
* Smear positive pulmonary tuberculosis case defined as: at least two initial sputum smear 
examinations (direct smear microscopy) acid-fast bacilli (AFB) +; or one sputum examination AFB+ 
and radiographic abnormalities consistent with active pulmonary tuberculosis as determined by a 
clinician; or one sputum specimen AFB+ and culture positive for M. tuberculosis (WHO 2005). 
-
t The case detection rate (reported cases! estimated incidence) may exceed 100% because reported 
cases are derived from the prevalent pool in the community, and may arise from previous years. 
Failure to improve treatment outcomes is also of concern. The percentage 
successfully treated remains well below target at around 65-70%. Rising mortality 
associated with HIV infection is a contributing factor, and at 7% of those starting 
tuberculosis treatment, is considered an under-estimate of the real mortality 
associated with tuberculosis (WHO 2005a). Taken together, low rates of treatment 
success, high rates of treatment interruption and defaulting, and rising incidence, 
suggest that the country's largely nurse-driven tuberculosis service has been 
overwhelmed. 
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nurse co-ordinators, but this has been described as inadequate and rushed Ganse van 
Rensburg-Bonthuyzen 2005). 
Drug supplies are generally secure, but clinics reported frequent difficulties in 
obtaining sputum jars. Among 9 nurse practitioners interviewed, knowledge of the 
National Tuberculosis Control Programme protocols was variable. Not all clinics 
possessed copies of the national treatment guidelines Ganse van Rensburg-
Bonthuyzen 2005). 
Tuberculosis treatment is provided in accordance with the 0015 strategy. Most 
patients attend the clinic daily for directly supervised treatment during the initial 
intensive phase, and twice weekly during the continuation phase. During this time, 
treatment is primarily supervised by lay health workers, known as 001S supporters. 
These lay health workers deliver weekly supplies of medication to patients' homes, 
trace patients who interrupt treatment or do nor return to the clinic for sputum 
results, and are supervised by the clinic nurse practitioners. In the Free State 0015 
supporters are required to register with a NGO recognised by the provincial health 
department, and in return received a monthly stipend of R500 for their services. 
1.1.2 Acute respiratory infections 
Acute respiratory infections (ARI) are one of the most common reasons for 
consulting primary care services worldwide. In a survey of respiratory care in 9 
lower and middle-income countries during the late 199Os, ARI, predominantly upper 
tract infections, accounted for 80% of diagnoses among patients presenting with 
respiratory symptoms (WHO 2004b). Lower respiratory tract infections (LRTI) are 
an important cause of mortality worldwide (Murray and Lopez 1997a). Previously 
this was primarily among children under 5 years and the elderly, although recently 
they have been increasingly responsible for deaths among young adults co-infected 
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Tobacco was responsible for an estimated 3 million deaths worldwide in 1990,4.9 
million in 2000, and is projected to cause 8 million in 2020, making it what has been 
called the Umost important detenninant of human health trends" (Murray and Lopez 
1997c). In the last 2 decades increases in smoking prevalence have been highest in 
countries of the developing world, and have followed aggressive marketing 
campaigns by the tobacco industry. Globally, the World Health Organization's 
Framework Convention on Tobacco Control (FCTC) aims to support national 
governments to develop and implement strategies to reduce smoking (WHO 2003b). 
The FCTC was adopted by the World Health Assembly in 2003. 
1.1.3.1 Smoking prevalence and tobacco control in South Africa 
In the Free State, smoking prevalence among men is slighter higher than the national 
average, and equal to the national average among women (Table 1.5; South African 
National Department of Health 1998a). The prevalence of self-reported emphysema 
was well below the national average for both men and women, although the 
prevalence of symptoms of chronic bronchitis and asthma were similar. Mining is a 
frequent occupation in the Free State, and a risk factor for both chronic respiratory 
disease and tuberculosis (Cowie and Mabena 1996; White and Ehrlich 1996; Cowie 
1998; Steen et al. 1997; Churchyard et al. 2004; te WaterNaude et al. 2(06). 
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sectors. This argument has been refuted by a local study of the economics of tobacco 
control, which concluded that income diverted from tobacco sales would generate 
more jobs than would be lost by the relatively labour un-intensive tobacco industry 
(Eberlee 2001). 
These taxation and legislative measures appear to have impacted positively on 
smoking prevalence in the country (fable 1.6). Two surveys completed in 1995/6 
estimated the national smoking prevalence to be 34% (Reddy et al. 1996, Reddy et al. 
1998); later surveys completed in 1998 found that this had fallen to between 24 and 
25% (South African National Department of Health 1998a; Meyer-Weitz et al. 2000). 
Most reassuring has been the decline in smoking among adolescents, presumably 
because this is the age group least likely to afford the increases in cigarette prices. 
The Global Youth Tobacco Survey completed two surveys of adolescent (ages 13-15 
years) smoking patterns in 1999 and 2002, and found that the prevalence of current 
smokers has fallen from 23.0% to 18.5% and ever smokers from 46.7% to 37.6% 
(Medical Research Council 2003, Swart et al. 2(04). 
Table 1.6 Surveys of Smoking Prevalence in South Africa 
Survey and Reference Year Participants National smoking 
prevalence (%) 
Reddy et al. 1996 1995 2238 adults ~18 years from all 34.0 
9 provinces 
Reddy et al. 1998 1996 - 34.0 
South African Demographic and 1998 13827 adults ~15 years from 24.6 
Health Survey (South African 12 247 households in all 9 
National Department of Health provinces 
1998) 
Meyer-Weitz et al. 2000 1998 - 25.0 
Global Youth Tobacco Survey 1999 6045 learners 13-15 years 23.0 
(Part 1) from schools in all 9 provinces 
(Medical Research Council 2003) 
Global Youth Tobacco Survey 2002 8935 learners 13-15 years 18.5 
(Part 2) from 191 schools in all 9 
(Swart et al. 2004) 
provinces 
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1.2 The burden of respiratory disease in primary 
care 
The increasing prevalence of respiratory diseases in developing countries is 
imposing a growing burden on primary care services. In the developed world, 
respiratory symptoms, primarily those associated with acute respiratory infections, 
have long been recognised as the most common reason for consulting primary care 
providers (Last 1963). In the late 1990s the World Health Organization attempted to 
quantify the burden in low and middle-income countries, and undertook surveys of 
patients 5 years or older attending 76 primary care facilities across 9 countries (WHO 
2004b). They found a wide range in the prevalence of respiratory symptoms among 
primary care attendees from 8.5% in nurse-led facilities in Nepal to 33.7% in doctor 
provider facilities in Argentina. On the whole, it was estimated that respiratory 
symptoms accounted for one in five consultations. The distribution of respiratory 
diagnoses also varied significantly between the countries surveyed, but in general 
acute respiratory infections accounted for most visits, suspected tuberculosis for less 
than 10% of respiratory attendances and confirmed tuberculosis 1.4%. Variation was 
attributed to differences in risk factors (tobacco use, air pollution, HIV prevalence) 
between countries, but also to the lack of standardised diagnostic criteria for 
respiratory diseases. 
In South Africa there are little data on the burden of respiratory conditions in 
primary care. Two surveys completed in private sector general practice in Cape 
Town during the 1960s and 1980s estimated the prevalence at around 25-35% of all 
primary care consultations (Silbert 1970; Bourne et al. 1991). A more recent survey, 
completed in a public sector primary care facility, estimated the prevalence at 28% of 
consultations (Fairall et al. 2(01). Of these, acute respiratory infections accounted for 
34% of consultations, obstructive lung disease for 55%, suspected tuberculosis for 
12% and confirmed tuberculosis 3%. The prevalence of respiratory conditions, in 
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1.3 Organization of primary care services in South 
Mrica 
The South African health service is characterised by gross inequities in the financing 
and distribution of health services. The private healthcare sector services less than 
20% of the country's population, but accounts for 60% of healthcare expenditure and 
employs most of the county's general practitioners, specialists, pharmacists and 
dentists (Blecher and Thomas 2004). Of the 8% of GDP spent on health, more than 
half is accounted for by medical schemes, and contributions towards the the medical 
schemes of civil servants represent a substantial government subsidy to the private 
sector. Prior to 1994, a disproportionate amount of public health expenditure was 
directed towards specialist-staffed urban hospitals, with the result that provinces 
with historically well-resourced urban centres, like Gauteng and the Western Cape, 
have a significantly higher number of health workers and better health infrastructure 
than poorer rural provinces. Since 1994 the ANC-Ied national government has 
sought to address these and other inequities by prioritising the expansion and 
development of primary care services, within a district-based management 
framework (McCoy and Engelbrecht 1999). 
During the first decade of democracy 701 additional primary care clinics were built 
across the country, bringing the total number of primary care facilities close to 4500 
(South African Government 2004). These facilities are for the most part, staffed by 
nurse practitioners with little or no support from doctors. Utilisation increased 
substantially following the announcement of free primary care services to pregnant 
women and children under 6 years in 1995, and to all citizens in 1996, but, at 2.3 
visits per capita per year, remains well below the national target of between 3 and 3.5 
visits per year as recommended by Lehmann and Sanders (2002). 
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primary care. Section 38A of the Nursing Act of 1978 makes provision for nurses to 
supply, administer and prescribe medications for ifprescribed conditions" only if the 
services of a medical practitioner or pharmacist are not available, which is usual in 
primary care (Gray and Strasser 1999). However, it is not clear what is or isn't 
included in these if prescribed conditions", or what qualifications are required before 
a nurse can prescribe. In practice, clinical nurse practitioners have been granted 
Section 38A permits to prescribe medications specified for primary care use in the 
national Essential Drug List (EDL) (South African National Department of Health 
2003a). Training prerequisites for clinical nurse practitioners are highly variable and 
poorly regulated, and range from part-time courses over the period of one year to 
three months or even 6 week short courses. More recently, the situation has become 
even more complex as Section 33 of the Act requires nurse prescribers to obtain 
permits to dispense, which has meant additional training from the Pharmacy 
Council. 
The training demands on primary care nurses, who have been prepared for hospital-
based practice, are therefore substantial, and require that nurses frequently leave 
their clinical posts to attend centralised short courses. This exacerbates already 
critical staff shortages and can also be disruptive to family life, as many nurses are 
women, and mothers of young children (Strachan 2OOOa). Removing nurses from 
clinical practice to attend courses has also limited the pace at which primary care 
nurses can be trained and supported, as nurses often miss out on training 
opportunities because there is no-one available to relieve them of their clinical 
responsibilities. It is therefore usual for only one nurse at a clinic to be selected for 
training in a particular course, the idea being that he/ she will in turn train colleagues 
on returning to the clinic (the ifcascade" model). Donahue (1998) emphasizes the 
requirement that effective trainers must possess both clinical competence and adult 
education skills, and that the assumption that those who are taught can teach others 
is the primary shortcoming of the cascade model. 
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poor compliance with EDL recommendations for prescribing and low levels of 
control of blood pressure and blood glucose. 
In sununary, training in the management of common primary care conditions can 
only be expected to lead to improvements in population health when adequate 
numbers of primary care nurses receive effective training. The demand for training 
is high, as nurses have been ill-equipped to practise as independent clinicians, and 
are facing increasing burdens of infectious and chronic diseases as the HIV epidemic 
unfolds. Decentralised, innovative and effective approaches to in-service training are 
required to skill nurses to provide a quality primary care service (Radebe 2(00). 
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patients, who present with symptoms and signs, and not diagnoses. Syndromic 
approaches also make provision for treating more than one probable diagnosis at a 
time, an important attribute given the prevalence of multiple diagnoses in clinical 
medicine (WHO 2002b). Furthermore, they offer simplified and standardized 
protocols as the basis of training initiatives and clinical care. 
This section provides a brief introduction to the four syndromic management 
programmes developed by the World Health Organization over the last 15 years, 
including the Practical Approach to Lung Health, on which P ALSA is based. 
Although others exist, these four have by far dominated syndromic-approach-based 
training in developing countries. 
1.4.1 Syndromic management of Sexually Transmitted Infections (STls) 
During the late 1980s and 1990s evidence emerged suggesting that sexually 
transmitted infections were an important co-factor in HIV transmission. 
Longitudinal studies showed increased risk of acquiring HIV infection if co-infected 
with other STIs (Stamm et al. 1988; Cameron et al. 1989; Plummer et al. 1991; Laga et 
al. 1993), and increased HIV shedding from the genital tracts of men and women 
with coexisting STIs which decreased when these were treated (Cohen et al. 1997; 
Ghys et al. 1997; Mostad et al.l997). 
These observations prompted debate as to the role of improved treatment of bacterial 
STIs in reducing HIV transmission (Cohen et al. 1997, Pepin et al. 1989). On the basis 
of this, and given the limited availability and high cost of diagnostic tests for STIs, 
the World Health Organisation began to promote syndromic management of SIIs as 
a core component of national strategies to limit HIV transmission in the developing 
world, in particular sub-Saharan Africa where the epidemic was spreading rapidly 
(WHO 1991b). In the 1990s three large community trials in East Africa examined the 
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Table 1.7 Randomised trials of interventions based on the syndromic management of sexually transmitted infections 
Mwanza, Tanzania Rakal, Uganda Muaka, Uganda Lima, Peru lsa, South Africa 
Grosskurth et al. 1995 Wawer et al. 1999 Kamall et al. 2003 Garcia et al. 1997 Harrison et aI. 2000 
Setting (period) 12 rural communities in 10 rural communities in 18 rural communities in 180 phannacies in Lima, 1 0 Prima~ care clinics in 
Mwanza, Tanzania (1991- Rakai, Uganda (1994-1998) Masflka, Uganda (1994- Peru Hlabisa, outh Africa (1996-
19941 2000 1997) 
Intervention Establishment of STI Periodic mass direcUy - Healthcare worker training 8 hour training course on Tralnin~ and supervision of 
reference clinic/laboratory observed home-based STI 
Regular supply of drugs 
STI management and nurses n syndromlc 
treatment of adults with prevention managment of STls 
Healthcare worker training azithromycin, ciprofloxacin & Supervisory visits (3 week course including 2 metronidazole irrespective 1.5 hour on-site training Provision of STI packs 
week's practical) of symptoms (85% eligible Community education: session comprising drugs, condoms, 
Regular supply of drugs and present). meetings, Infonnation 
contact cards, written health 
leaflets, videos & drama infonnation 
Supervisory visits 2 rounds 10 months apart. groups 
6 monthly health edUcation 
visits to villaaes 
Study design Community randomised Community randomised Community randomised Cluster randomised Cluster randomised 
controlled trial with closed controlled trial with open controlled trial with open controlled trial (n = 180, 360 controlled trial (n = 10, 100 
cohort(n =~~2, 12537 cohort(n =~~O,15127 cohort (n = ~~ 8, 20 000 visits by simulated patients) visit by simulated patients) 
participants oarticioants oarticioants 
Baseline STI HIV: low (4%) and rising HIV: 16% and stable HIV: 10% Not reported Not reported 
prevalence 
HSV2: <10% ulcers HSV2: 43% of ulcers 7-10% with genital ulcer in 
Ipreceedina vear 
Effect on HIV Significant 38% reduction in No reduction in HIV No reduction in HIV Not measured Not measured 
incidence HIV incidence after 2 years incidence after 2 rounds of incidence after 3 rounds of 
treatment follow-up 
Effect on No significant effect No significant effect Significant decreases in Not measured Not measured 
prevalence of gonorrohea and active 
other STls in syphilis cases 
general 
DODulation 
Quality of care Not compared with control Not applicable. Not reported No difference in diagnosis, SSPs" significanUy more 
facilities. Compliance with referral, or appropriate likely to be J:iven 
protocols around 63% in treatment. recommen ed drugs in 
intervention facilities. 
Education and counselling 
intervention clinics 
more likely to be given in No difference in provision of 
intervention Dhannacles. adeouate counsellinc. 
* Standardised simulated patients: fieldworkers trained to present to facilities complaining of symptoms from standardised scripts e.g. urethral discharge 
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intervention during the epidemic, and that syndromic management could lead to 
reduced HIV incidence in areas characterised by high risk sexual behaviour and high 
rates of co-factor STIs. 
In spite of the controversies arising from these trials, most countries in sub-Saharan 
Africa, including South Africa, have included syndromic srI treatment programmes 
in their primary care packages. Even if these programmes have a limited effect on 
containing HIV transmission, implementation can be justified by the high burden of 
STIs among women of child-bearing age, second only to maternity related disorders 
(World Bank 1993). 
Two studies have evaluated the impact of educational interventions on the quality of 
syndromic STI care provided in primary care facilities. The first of these completed 
in Lima, Peru, evaluated the impact of an 8 hour long off-site training course 
supplemented by a 1-1.5 hour on-site training session (Garcia et al. 1997). The second 
study completed in Hlabisa, South Africa, evaluated the impact of training for nurse 
practitioners combined with pre-packaged srI treatment packs comprising 
appropriate drugs, condoms, contact cards and written health information (Harrison 
et al. 2000). Both studies evaluated the impact of these interventions within cluster 
randomised controlled trials using standardised simulated patients to assess quality 
of care. Results from the Peru study were disappointing with no difference in 
appropriate diagnosis, treatment or referral. Furthermore, appropriate antibiotics 
were only prescribed in a low number of cases. By contrast, the Hlabisa study 
demonstrated improved prescription and treatment practices among simulated 
patients attending intervention clinics. No biological indicators were measured in 
either study. 
The cost-effectiveness of syndromic treatment programmes for STIs has not been 
widely studied, and is restricted to a cost-effectiveness analysis alongside the 
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feasible, and consistent with national treatment guidelines and policies (WHO 
2000b). Adaptation guides are available from the World Health Organization 
(2002b). 
Health worker training usually lasts 11 days (a minimum of 80 hours is 
recommended), is centralised and combines modular lectures with a practical 
component (of at least 30%), including demonstration of clinical signs in patients, 
and supervised clinical examination (WHO 1998c). 
Table 1.8 Components of the Integrated Management of Childhood Illness 
Strategy (adapted from WHO 1998c). 
Facility-based IMel (primary care): 
Intensive short course training (11 days or 80 hours with a 30% practical component) of health 
workers in locally adapted integrated case management guidelines. 
Health Systems components: 
Improvements required for effective management of childhood illness (e.g. improving supplies of of 
essential drugs required to treat childhood illnesses, maintenance of immunisation cold chain) 
Families and community components: 
Improvement in 12 key family and community practices (including breastfeeding until 6 months of age, 
early care-seeking, compliance with treatments, interventions to improve family nutrition, use of 
insecticide-treated bed nets) 
The Multi-Country Evaluation of lMCl Effectiveness, Cost and Impact (MCE) was 
launched in 1997 with the aim of evaluating the impact of lMCl on child health, and 
its cost-effectiveness (WHO 2002c). After worldwide review of 12 countries, 5 sites 
were selected for implementation studies. These include the United Republic of 
Tanzania, Bangladesh, Uganda, Peru and Brazil. Reasons for excluding countries 
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Schellenberg et al. 2004b). Improvements in observed quality of case management 
may not necessarily translate into population benefits if usual practice differs, and 
especially if health worker coverage remains limited, as in most countries where 
IMO has been implemented (Nsungwa-Sabiiti et al. 2004; Huicho et al. 2005). 
This notwithstanding, IMCI has been adopted by more than 100 developing 
countries, including South Africa (El Arifeen et al. 2004). In South Africa IMCI was 
first introduced in 1997 and training of health workers has followed the 
recommended intensive short course (11 day) model, with the result that coverage 
has been variable. About six years later, national IMCI training coverage, defined as 
the number of facilities with one or more nurses trained in IMCI, was estimated at 
37%, but ranged from 12% in the Western Cape to 81 % in Mpumalanga (Ramkissoon 
et al. 2004). 
1.4.3 Practical Approach to Lung Health (PAL) 
The Practical Approach to Lung Health, originally named Adult Lung Health 
Initiative, was a WHO strategy developed in the late 1990s as one of 5 components of 
the Global DOTS expansion plan designed to address slow progress towards the 
achievement of the global 85/70 tuberculosis target. Other components included 
accelerated DOTS coverage in areas where DOTS has not yet been implemented, 
public-private approaches to extend quality tuberculosis care to patients managed 
outside of national programmes, collaboration between tuberculosis and HIV 
programmes to address high tuberculosis incidence in areas with high HIV 
prevalence, and the involvement of communities in tuberculosis control activities in 
areas where access to health facilities is poor (WHO 2005b). PAL flowed out of 
experience with IMCI, and provided a useful starting point towards the development 
of an equivalent package for adults, now available as the Integrated Management of 
Adolescent and Adult Illness (WHO 2OO3c), because common respiratory conditions 
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reasonable evidence base for almost all interventions contained in the guideline but 
noted that few interventions were informed by studies completed in primary care 
settings in developing countries. 
By 2006 PAL had been implemented in up to 14 countries (Eddine Ottmani -
personal communication), although mainly on a limited scale as feasibility and 
effectiveness evaluations. Besides South Africa, evaluation activities are underway 
in Nepal, Morocco, Chile, Algeria, Tunisia and Kyrgyzstan. Initial results have yet to 
be widely disseminated and so opportunity for comparison with the findings of the 
South African evaluation is limited. 
The impact of PAL on prescribing for respiratory diseases has been reported from 
Morocco, Kyrgyzs~ Tunisia and Nepal (WHO 2005b, Ottmani 2005, Shrestha et al. 
2005). In all 4 countries the introduction of PAL was associated with significant 
reductions in the number of drugs per prescription (fable 1.9). Reduced prescription 
costs were also noted in Morocco, Kyrgyzstan and Tunisia, but not in Nepal. 
Antibiotic prescriptions were reduced in Morocco, Kyrgyzstan and Tunisia where 
baseline antibiotic prescription rates were high (71.7%, 57.5% and 71.5% respectively) 
and the guidelines used by doctors (except Nepal). However, the implementation of 
PAL in Nepal significantly increased generic prescribing and prescribing from the 
essential drugs list. Unfortunately the designs of the studies used to evaluate the 
impact of prescribing means that these results could well be confounded by other 
factors. The Morocco, Kyrgyzstan and Tunisian studies are before-after studies with 
no concurrent controls, and the Nepal study, while a duster randomised controlled 
trial, was dependent on the correct diagnosis being recorded on carbon-copy 
prescription pads; this activity in itself is highly likely to be dependent on the 
intervention, resulting in non-comparability of interventions across different 
diagnostic categories. 
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1.4.4 Integrated Management of Adult and Adolescent Illness (IMAI) 
The Practical Approach to Lung Health has since been incorporated into a new 
package for adolescents and adults called lMAI or Integrated Management of 
Adolescent and Adult lllness (WHO 2003c). Work on lMAI started in the late 1990s, 
and initial guideline drafts were reformulated as part of the World Health 
Organization's "3 by 5" campaign, with a strong focus on the clinical management of 
HIV, including the provision of antiretroviral (ARV) treatment. 
Like IMCI and PAL, lMAI is syndromic and focuses on the clinical management of 
key symptoms. It attempts to balance management of acute illness with chronic 
disease management and prevention. Four modules are available (fable 1.10) for 
local country adaptation prior to implementation. At present implementation is 
underway in 6 African countries, including the Eastern Cape in South Africa (Ramzi 
Asfour - personal communication). Evaluations of its effectiveness are not yet 
underway. 
Table 1.10 The four outpatient guideline modules of lMAI 
• Acute Care 
• General Principles of Good Chronic Care 
• Chronic HIV Care with ARV Therapy 
• Palliative Care 
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1.5.1 Description of studies reviewed 
1.5.1.1 Cost-effectiveness of syndromic STI services in Mwanza, Tanzania 
Gilson and co-workers (1997) completed this cost-effectiveness evaluation based on 
data from the Mwanza community randomised controlled trial which showed 
reduced HIV incidence following the introduction of syndromic STI services in 6 
intervention communities (Grosskurth et al. 1995). Health service cost data were 
collected prospectively and combined with estimates of the prevalence of HIV in the 
community, average life expectancy values and Ugandan disability weights to 
estimate the cost per HIV infection averted, and per disability-adjusted life year 
(D~ saved. These were estimated at 1993 US $217.62 and 1993 US $10.33 
respectively. Sensitivity analysis carefully considered all sources of uncertainty 
arising from the study including the confidence limits for the effectiveness estimate 
(i.e. number of HIV infections averted), and found that the findings were most 
sensitive to the rate used to discount benefits, the estimated size of the catchment 
populations and uncertainty in the reduction of HIV incidence. At worst, the cost 
per DALY averted rose from 1993 US $10.33 to 1993 US $47.86. The study was the 
first to measure empirically the cost-effectiveness of syndromic STI management as a 
HIV control strategy, and concluded that it is highly cost-effective, with results 
applicable to many regions of the developing world. 
1.5.1.2 Cost and consequence analysis of facility-based IMCI in Tanzania 
The Multi-country Evaluation (MCE) of the costs and effects of IMCI team includes 
experienced health economists who devised standardised methods and data 
collection tools for estimating the cost, and cost-effectiveness, of the approach 
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investigators concluded that IMO represents good value for money in the context of 
health sector reform, which in this instance had been facilitated by the TEHIP 
intervention. 
1.5.1.3 Cost-effectiveness of the Practical Approach to Lung Health in 
Nepal 
A prospective economic evaluation was undertaken alongside a 2002/2003 cluster 
randomised controlled trial of the PAL implementation in 40 health facilities in the 
Nawalparasi district of Nepal (Shrestha et al. 2005; Kumar 2006). Cost data and 
utility estimates obtained from the trial were combined with burden of disease 
parameters in a specially developed multi-disease (tuberculosis, pneumonia, COPD, 
asthma) multi-state (acute, chronic) projection model to estimate the cost per quality-
adjusted life year (QAL Y) gained if PAL were implemented throughout Nepal 
(Kumar 2006). At 2003 US $111 per QALY gained, the investigators concluded that 
this represented a cost-effective implementation if compared with benchmarked 
standards of cost per D AL Y averted of per capita income. However, they noted that, 
because of uncertainty arising from data collected from the trial, the conclusion that 
PAL is cost-effective can only be made with a probability of 54 %. 
In a parallel analysis of prescription costs, Shrestha and co-workers (2005) found that 
PAL implementation resulted in a significant reduction in the number of items 
prescribed per visit, and significant increases in prescribing of generic drugs and 
from the essential drug list. These benefits, however, failed to translate into lower 
average prescription costs, and did not reduce wastage costs (defined as the 
difference between expected and actual costs per prescription). 
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IMCI and PAL-Nepal evaluations, but not specified in the STI study. Guideline 
development and implementation costs were treated as capital or start-up costs, and 
annualized over 10 years in both the IMO and PAL-Nepal evaluations. This period 
was not justified in either evaluation, and seems optimistic given that Armstrong-
Schellenberg (2004a) reported improvements in case management of children in 
health workers trained in IMCI up to 3 years previously, although durability beyond 
this has not been evaluated. Only the PAL-Nepal study made provision for 
refresher training after 5 years, but even this may be unrealistic. Furthermore 
Shekelle and co-workers (2001) evaluated the current validity of 17 quality guidelines 
and estimated that half the guidelines were outdated after 5.8 years. Reassuringly, 
the IMCI evaluation varied the period over which capital costs were annualized in a 
sensitivity analysis (5, 10 and 15 years) and found that this made little difference. 
Changes in treatment costs were considered in all three evaluations. The cost of 
primary care staff time was not included in the STI analysis because STI care was 
considered to take up only 2% of staff time, although the impact of the intervention 
on this was not evaluated. The cost of hospital care was not considered in the STI or 
PAL-Nepal evaluations. 
The alternatives being compared were clearly described in the STI and P AL-N epal 
studies. It was more difficult to determine the comparison in the IMO trial, where 
IMO implementation occurred alongside other interventions including health sector 
reform initiatives (TEHIP), basket funding and social marketing of insecticide-treated 
bed nets. Careful reading of multiple sources was required to determine the 
alternatives being compared. 
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the clustered design of the trial. Adjustment for clustering was explicit in the PAL-
Nepal prescription cost analysis. Also, the mortality benefit reported in the IMel 
cost-consequence paper was of borderline significance, and its confidence interval 
included zero, corresponding to no effect, when adjustment for district-level 
clustering was made. 
The PAL-Nepal model was based on differences in acute state utilities between the 
intervention and control groups, yet it was not clear whether this small difference 
was statistically significant (confidence limits not reported, adjustment for clustering 
not clear). The difference of 0.04 also falls short of what is considered the minimally 
important clinical difference (0.05) by the EuroQol group (Roset et al. 1999). 
Furthermore this model did not account for differences in the duration of disease 
states or incidence of acute exacerbations between groups, although both these are 
likely to change as a result of the intervention. The decision not to incorporate the 
differences in chronic state utilities observed in the trial was not justified. 
The PAL-Nepal prescription cost analysis was likely confounded by assuming that 
the diagnosis made by the health worker and recorded alongside the prescription 
was correct, and not biased by the intervention, which it probably was. Also, the 
reason for applying different reference standards to intervention and control group 
prescriptions to determine prescription appropriateness, and therefore expected and 
wastage costs, was not justified. 
Despite collection of economic data from patients and households, none of the 
economic evaluations reviewed used patient level data on costs and outcomes to 
quantify the uncertainty, or random error, of the cost-effectiveness analyses. Instead 
effectiveness estimates were combined with parameters estimated outside of the 
trials to determine cost per QALY gained (PAL-Nepal), or DALY averted (STI). This 
is discussed below. 
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investigation. Price years were reported in all three studies (STI: 1993; IMCI: 1999; 
PAL-Nepal: 2(03) although methods for adjustment for inflation were only provided 
in the IMCI study. Currency conversions were clearly reported in all studies. 
1.5.224 Details of models used 
Both the srI and PAL-Nepal studies used mathematical models to extrapolate trial 
findings to population level. The srI model for estimating DALYs saved was 
relatively simple, combining trial costs and effectiveness estimates with local utility 
weights and average life expectancy values in five steps. All parameters included in 
the model were subjected to testing in the sensitivity analysis. The PAL-Nepal group 
developed a more complex multi-disease multi-state projection model to estimate the 
population benefits, measured in QAL Y s gained, should PAL be implemented at 
country level. In both cases, parameters for the models were well defined, and 
sources carefully documented and justified. 
1.5.2.3 Criteria for evaluating methods of analysis 
1.5.2.3.1 Discounting 
Discounting was undertaken in all three studies, but to variable extents. The most 
comprehensive approach was in the STI evaluation, where a rate of 3% was justified, 
and used in the primary analysis to discount both costs and effects. Rates of 0% and 
6% were explored in the sensitivity analysis. In the IMCI and PAL-Nepal studies, it 
was not clear whether discounting was applied equally across costs and benefits 
even though this was appropriate given that data collection spanned several years in 
both cases. The IMCI evaluation also did not specify whether costs other than capital 
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outcomes in cluster randomised trials are well developed (Donner and KIar 2000), 
but this is not true of economic evaluations conducted alongside cluster trials in 
which individuals' costs as well as outcomes are measured. 
The PAL-Nepal cost effectiveness analysis used non-parametric bootstrapping to 
explore uncertainty related to cost and utility estimates derived from the trial. This is 
recognized as a gold standard for evaluating uncertainty related to patient-level 
economic data, which is typically skewed (Briggs 1999). It involves repeatedly 
sampling from costs and outcomes from the study sample, with replacement, 
assuming that distributions in the study sample are the same as the distributions in 
the population. With cluster randomised data, entire clusters rather than individuals 
should be sampled in keeping with the requirement that hierarchical data should 
only be bootstrap sampled at the highest level (e.g. clusters) to retain the data's 
hierarchical structure (Davison and Hinkley 1997). Most economic evaluations 
which have employed bootstrapping have used individual bootstrap sampling 
(Goodacre et al. 2004, Gilbert et al. 2004, Sullivan et al. 2005). So it is unlikely that 
cluster sampling was used in the PAL-Nepal evaluation. Analyses conducted for this 
thesis will show that intra- cluster correlation of costs and outcomes tends to reduce 
the estimated probability that an intervention is cost effective (Bachmann et al. 2005). 
This means that the estimated 54% probability that PAL-Nepal is cost-effective for a 
willingness to pay threshold of US $150 per QAL Y gained is likely to be an 
overestimate. 
Recently, analysis of cost and outcomes by comparing net monetary benefits has 
been advocated for meta-analyses of multi-centered trial data, although it has yet to 
be used in cost-effectiveness analysis alongside cluster trials (Drummond et al. 2005). 
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1.6 The effectiveness of guideline dissemination 
and implementation strategies 
In the 1980s and 1990s awareness concerning variations in health care, rising costs 
and failure to translate research findings into practice prompted increased interest in 
and production of clinical practice guidelines. Guidelines have been defined as 
/I systematically developed statements to assist practitioners' and patients' decisions 
about appropriate health care" (Institute of Medicine 1992), and have been widely 
viewed as a means of updating busy health professionals of the latest research 
findings while promoting more appropriate and cost-effective care (Thorsen and 
Makela. 1999). 
1.6.1 Trends in guideline development and implementation in developing 
and developed countries 
Progress in guideline development has followed two distinct trends in the developed 
and developing worlds. In the developing world, guideline developers have focused 
largely on the production and implementation of symptom- and sign-based, or 
syndromic, guidelines focusing on the primary care management of common and 
important clinical conditions. These activities, chiefly co-ordinated by the World 
Health Organisation, have included initiatives such as the Syndromic Management 
of Sexually Transmitted Infections, the Integrated Management of Childhood Illness 
(IMeI), and more recently the Practical Approach to Lung Health (PAL) and 
Integrated Management of Adolescent and Adult Illness (IMAI), overviews of which 
were provided in Section 1.4. In terms of implementation strategy, decision-makers 
have relied largely on traditional didactic methods, usually in the form of intensive 
centralised short courses, often with a practical component, followed by limited 
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Models of change have been used to understand the behaviour of health 
professionals and to guide the development of interventions aimed at changing 
practice. These models include learning theory, social cognition models and models 
of organizational change (NHS Centre for Reviews and Dissemination 1999). 
Although the theoretical basis for changing the behaviour of health professionals is 
widely viewed as incomplete (Grimshaw et al. 2004), social marketing and the 
precede-proceed model have provided useful frameworks for informing the 
planning, design and implementation of various interventions, and in certain cases, 
have been shown to augment effectiveness (Ibomson et ale 1999). 
1.6.4 The evidence for dissemination and implementation strategies 
Multiple reviews of the relative effectiveness of various implementation strategies 
have been completed during the past 15 years, in an attempt to guide policymakers 
as to how best to implement the growing number of clinical practice guidelines. 
Intervention strategies targeting health professionals have been described and 
categorised by the Cochrane Group on the Effective Practice and Organization of 
Healthcare (Bero et ale 2001), and include among others, the passive dissemination of 
educational materials, reminders, educational outreach visits, audit and feedback 
and the use of mass media (Table 1.11i Grimshawet ale 20(4). 
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Prior to 2004, systematic reviews of guideline implementation strategies drew similar 
conclusions (Oxman et al. 1995, Davis et al. 1995, Bero et al. 1998, NHS Centre for 
Reviews and Dissemination 1999, Grimshaw et al. 2(01). Passive dissemination of 
guidelines was insufficient to change practice but may be useful for raising 
awareness. There was no single llmagic bullet" for changing practice but active 
strategies including reminders and educational outreach appeared the most 
promising single interventions particularly when targeting prescribing behaviour 
(educational outreach) or ordering of investigations (reminders). Multifaceted 
interventions, which combine more than one type of intervention and address 
barriers to change, were likely to be the most effective. In all cases, reviewers 
acknowledged that the evidence base for changing professional practice was 
incomplete, and that the resource implications of competing strategies were rarely 
considered. 
These reviews were limited in that they did not provide or compare the effect sizes 
due to various interventions, ignored unit of analysis errors, relied on the authors' 
descriptions of the intervention for classification thereby underestimating the 
number of multi-faceted interventions, and used vote-counting of statistically 
significant comparisons. In 2004 Grimshaw and co-workers published the most 
extensive and methodologically advanced review of interventions designed to 
change professional practice. They identified 235 studies reporting 309 comparisons 
from over 150 000 hits, extracted the main findings and estimated median effect sizes 
for main outcome measures, where possible adjusting for unit of analysis errors and 
interrupted time series designs (Grimshawet al. 2004). Their findings challenged 
much of the conventionally held understanding of interventions to change 
professional practice. 
Grimshaw and co-workers (2004) identified 18 studies involving the passive 
dissemination of educational materials. Most led to improvements in quality of care, 
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based care (Avom and Soumerai 1983). Techniques of educational outreach are 
summarised in Table 1.12 (Fender et al. 1999). 
Table 1.12 Techniques of educational outreach (from Fender et al. 1999) 
• Investigating baseline knowledge and motivations for current practice. 
• Defining clear educational and behavioural objectives. 
• Establishing credibility through a respected organisational identity, referencing authoritative 
and unbiased sources of information, and presenting both sides of controversial issues. 
• Simulating active participation in educational interactions. 
• Using concise graphic educational materials that highlight and repeat essential messages. 
• Providing positive reinforcement of improved practices at follow-up visits. 
In the 1990s guideline implementation and dissemination reviews highlighted the 
potential of educational outreach to change professional practice, particularly its 
impact on prescribing behaviour (Thomson et al. 1999). However, Grimshaw and co-
workers (2004) found it to be of only modest effectiveness with a median effect size 
of +6.01 % (range -4.0 to +17.4) derived from 11 cluster randomised trials. 
Educational outreach was frequently included as a component of multi-faceted 
interventions, but subgroup exploratory analyses showed no advantage of 
combining it with dissemination of educational materials. The combination of 
educational outreach with educational materials and educational meetings proved 
most effective (median effect size from four cluster randornised trials +11.0%, range 
+8.4 % to +16.4%). However, educational outreach was viewed as impractical by key 
infonnants in a survey of NHS decision-makers (Grimshaw et al. 2004). Concerns 
were also expressed about its resource implications, although these could not be 
adequately addressed given the low number of educational outreach studies (n=10) 
which have included some form of economic evaluation. Although published as 
recently as 2004, the review includes only studies published between 1966 and mid-
1998. During a limited search, 40 studies of educational outreach interventions 
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The majority of studies (72.5%) originated from North America and Europe, 
although 8 studies were conducted in Australia. lbree studies from the developing 
world were noted, all of them published in 2005. A randomised trial from Sudan 
evaluated the effectiveness of outreach in combination with audit and feedback on 
antibiotic prescribing in primary care practices, run by doctors and medical 
assistants, and found that it reduced the mean number of encounters during which 
antibiotics were prescribed (Awad et al. 2005; Eltayeb et al. 2005). Another 
randomised controlled trial from Thailand evaluated the impact of educational 
outreach combined with educational meetings on the quality of prescribing and 
general management of primary care delivered by nurses across a range of 
conditions (Pagaiya et al. 2005). lhis study noted mixed effects with improvements 
in some, but not all indicators of care. The final study from the developing world 
was from South Africa, where the effectiveness of educational outreach, in this 
instance combined with educational materials, on the provision of kangaroo mother 
care'= was evaluated in 34 hospitals (pattinson et al. 2005). lhis trial observed 
improvements in the provision of kangaroo care which exceeded those obtained with 
the distribution of educational materials alone. This brings the total number of 
studies evaluating the effectiveness of educational outreach in developing world 
settings to 6. Two studies excluded from the 2004 Grimshaw review both evaluated 
the impact of outreach on the management of diarrhoea in children in Indonesia, and 
noted mixed effects (Ross-Degnan et al. 1996, Santoso 1996). The CHAMPd study 
compared the impact of outreach to general practitioners in Cape Town with passive 
dissemination of guidelines on asthma control among children (Zwarenstein et al. 
2005). It showed markedly improved asthma symptoms among children managed 
by intervention group practitioners. 
C Kangaroo mother care is when infants are nursed skin-to-skin against the mother's chest 
d 0iAMP stands for CHestiness and Asthma in Mitchell's Plain. Mitchell's Plain is a large socio-
economically deprived suburb on the outskirts of Cape Town. 
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educational outreach visits (15/34 studies, 44 % ); in six studies two visits were 
conducted (6/34, 18 %), and in 11 studies three or more visits were provided (11/34, 
33 %). This is despite recommendations that wherever possible, interventions be 
multi--event to maximise the effect on changing practice (Hulscher et al. 1999), and 
possibly reflects concerns that resource intensive interventions may be viewed as a 
barrier to scale-up (Grimshawet al. 2004). The identity of the detai1er may also be 
relevant in understanding the effectiveness of the various interventions. Pharmacists 
were most frequently used as detailers accounting for 12 of 29 studies in which the 
profession of the detailer was specified, presumably because of the focus on 
appropriate prescribing in the majority of studies. Specialist or local opinion leaders 
were used in nine studies (9/29, 31 %) and peer doctor general practitioners in four 
studies (4/29, 41 %). Denton and co-workers (2001) compared the effectiveness of a 
single educational outreach session provided by a specialist with one provided by a 
junior resident, and found the former to be more effective at changing prescribing for 
hypertension and cardiac failure. 
Most (31/40,78%) studies used cluster randomised controlled trials to evaluate the 
effectiveness of educational outreach. Seven studies (18%) used non-randomised 
controlled designs, and two used interrupted time series alongside routine 
implementation of the intervention. All studies reported the effect of the 
intervention on process outcomes, but only four studies reported the effect on health 
outcomes. Just over half of the studies (22/40, 55%) reported that the intervention 
was effective at changing process outcomes, 1/4 (10/40,25%) that the effects were 
mixed, and only seven studies (7/40,18%) reported no effect. No study reported 
that the intervention was associated with a deterioration in practice. A meta-analysis 
of observed effect sizes was beyond the scope of this review, but effect changes 
ranged from small (+5.2%, Freemantle et al. 2(02) to substantial (+41 %, Solomon et 
al.2001). 
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Table 1.13a Characteristics of studies evaluating the effectiveness of educational outreach interventions 1998 - 2005 (n = 40) 
Characteristic nlN (%) References 
Year of Dub/ication 
1998 -1999 4/40 (10%) A7 A13 A16 A21 
2000 -2001 11/40 (28%) A3 A5 A8, A10 A14 A17 A28 A31, A33 A34 A40 
2002-2003 11/40 (28%) A2 A9 A11 A18 A19 A25 A29 A30 A36 A37 A39 
2004 -2005 14140 (35%) A 1 A4 A6 A 12 A 15 A20 A22 A23 A24 A26 A27 A32 A35 A38 
Country 
United KinQdom 1 Europe 15/40 (38%) A2 A4 A6 A7, A8 A9 A12, A13 A18 A22 A24 A29 A34 A36 A38 
United States 1 Canada 14/40 (35%) A3 A5 A10, A11 A16 A17 A19 A20, A25 A28 A31 A32 A33 A35 
Australia 8/40 (20%) A14 A15 A21 A23 A30 A37 A39 A40 
Other 3/40 (8%) A1 (Sudan}, A26 (Thailand), A27 (South Africa) 
Setting 
Primary care 35/40 (88%) A1,A2,A3,A4,A6,A7,A8,A9,A10,A11,A12,A13,A14,A15,A16,A17,A18,A19,A20, 
A21 A23 A24 A25 A26 A28 A29 A31 A32 A34 A35 A36 A37 A38 A39 A40 
Hospital-based care 5/40 (13%) A5 A22 A27 A30 A33 
Study Design 
Randomised controlled trial 31/40 (78%) A1,A2,A3,A4,A5,A6,A7,A8,A9,A10,A11,A12,A13,A14,A16,A17,A18,A19,A24, 
A25 A26 A27 A32 A33 A34 A35 A36 A37 A38 A39 A40 
Controlled clinical trial 7/40 (18%) A15 A20 A21 A23 A28 A30 A31 ~ 
Interrupted time series 2140 (5%) A22 A29 
Tameted behaviour 
Prescribing 24/40 (60%) A1,A2,A4,A5,A7,A8,A9,A14,A15,A17,A20,A21,A22,A23,A24,A25,A26,A30,A32, 
A33 A34 A36 A38 A40 
General manaQement 15/40 (38%) A2 A3 A6,A10 A12 A13 A17 A18 A19 A24 A25 A26 A27,A28 A29 
Test-orderinQ/ screeninQ 10/40 (25%) A2 A13 A16 A20 A25 A28 A29 A31 A35 A37 
Counselling 2140 (5%) A11 A39 
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1.6.6 Implementation research in the developing world 
There are few studies of the effectiveness of guideline dissemination and 
implementation strategies in developing countries. Only 2 studies from the 
developing world met the criteria for inclusion in the 2004 Grimshaw review. These 
included a cluster randomised trial of the effectiveness of reminder systems on 
urethral catherisation in Thai hospital wards (Danchaivijitr et al. 1992), and a 
multifaceted intervention to reduce antibiotic prescriptions among Mexican patients 
presenting to primary care facilities with the common cold (perez-Cuevas et al. 1996). 
Both showed improvements in process outcomes following exposure to the 
interventions. It is encouraging to see that the limited search of educational outreach 
studies published after 1998 revealed three studies from the developing world, all 
published last year. These, including two studies excluded from the 2004 Grimshaw 
review and one unpublished study, were reviewed in section 1.6.5. 
Noticing the dearth of studies of the relative effectiveness and efficiency of guideline 
implementation strategies in the developing world, European-based implementation 
researchers partnered with health systems researchers from Southern Africa in the 
late 1990s to promote the uptake of research findings in the region. AfroImplement 
was a European Union funded concerted action which aimed at developing rigorous 
implementation trials in Southern Africa (AfroImplement 1997). Over a period of six 
years, it nurtured collaborations between European and Southern African 
researchers during seven workshops, email discussions and exchange visits. 
Workshops involved interactive teaching sessions and opportunities to develop 
protocols for African implementation studies with input and support from expert 
implementation and health system researchers. The PAISA intervention and study 
protocol were both refined during several of these workshops. 
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1.6.7 Beyond changing professional practice - knowledge translation 
More recently the concept of changing professional practice has broadened to 
acknowledge the range of stakeholders, including policymakers, clinicians, teams, 
managers, patients and populations required to act together to close the gap 
between evidence and practice. Knowledge translation can be defined as lithe 
exchange, synthesis and ethically sound application of knowledge - within a 
complex system of interactions among researchers and users - to accelerate the 
capture of the benefits of research ... through improved health, more effective 
services and products, and a strengthened health care system" (Canadian Institutes 
of Health Research 2005). 
It is not limited to learning situations, but rather concerns the practice environment 
together with its social, organisational and policy dimensions. It targets all possible 
participants in the practice environment, and frequently includes patients and 
policymakers who are usually not addressed by professional interventions. As such, 
it permits greater emphasis on population health (screening, early diagnosis, 
preventive measures) and draws on a broader and interdisciplinary group of experts, 
including those from informatics, patient education, organisational learning and 
social marketing (Davis et al. 2003). 
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Table 1.15a Characteristics of educational outreach studies reporting resource use (1983 - 2005) 
Characteristic nlN (%) References 
Country 
United Kinadom 1 Eurooe 8/17 (47%) B1 B2 B3 B4 B5 B10, B11 B16 
United States 1 Canada 5117 (29%) B6 B9 B12 B14 B15 
Australia 3117 (18%) B7 B8 B17 
Other 1/17 B13 (Thailand) 
Setting 
Primary care 13117 (77%) B1 B2 B3 B4 B5 B6 B7 B11 B12 B13 B14 B16 B17 
HOsDital-based care 4117 (24%) B8 B9 B10 B15 
Studv Des;an 
Randomlsed controlled trial 14117 (82%) B1 B2 B3 B4 B5 B7 B9 B11 B12 B13 B14 B15 B16 B17 
Controlled non-randomised trial 2117 (12%) B6 B8 
InterruDted time series 1/17 B10 
TalDeted behaviour 
Prescribina 12117(71%) B1 B2 B3 B4 B7 B8 B9 B10 B12 B13 B14 B16 
General manaaement 3117 (18%) B3 B11 B13 
T est-ordering/ screenlna 5/17 (29%) B1 B4 B11 B12 B17 
Counsellina 2117 (12%) B3 B4 
Intervention 
Educational outreach alone 1/17 B6 
Educational outreach + educational materials 13117 (77%) B1 B2 B4 B5 B7 B8 B9 B10 B13, B14, B15 B16 B17 
Educational outreach + educational meetings 7/17 (41%) B1 B8 B9 B11 B13 B15 B17 
Educational outreach + audit & feedback 3117 (18%) B3 B9 B13 
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Almost all studies (71 %) aimed to change prescribing practices; this is not 
unexpected since outreach had been earmarked as a promising tool for changing 
prescribing behaviour in the 1990s (Oxman et al. 1995, Thomson et al. 1999). 
Several studies also targeted test-ordering, general management and patient 
advice/ education. Improved management and cost containment were the 
objectives of most of the studies, although one focused exclusively on cost 
containment (Hill et al. 2002). 
1.7.2 Type of educational outreach evaluated 
Most studies evaluated the effect of outreach in combination with educational 
materials. Other co-interventions included educational meetings and audit and 
feedback. The maximum number of interventions was six (Leviton et al. 1999). 
The majority of studies evaluated the effectiveness of a single educational 
outreach visit, and only four studies evaluated two or more visits (maximum 
four - Ofman et al. 2003). Around 40% were on a one-to-one basis and the rest 
were to groups of practitioners, or both. Pharmacists were the professionals 
most frequently employed as detailers, reflecting the emphasis on changing 
prescribing practices. In three studies specialist physicians provided the 
outreach training (Banait et al. 2003, Hill et al. 2002, Soumerai et al. 1983) and in 
two researchers did (Feder et al. 1995, Hansen et al. 1999). 
1.7.3 Methodological quality of economic evaluations 
Only two studies reported economic evaluations as separate publications (Mason 
et al. 2001, Stone et al. 2005). The primary focus of the remaining publications 
was mainly of the impact of educational outreach on the quality of care, with the 
result that reporting of economic data was very limited. For the purposes of this, 
and the 2004 Grimshaw review, the term /I economic evaluation" was loosely 
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1.7.3.3 Estimates of costs 
Methods for estimating and reporting of costs were poorly described in most 
studies, but this may reflect limited space in what are primarily publications 
describing effectiveness. Most studies restricted their cost analysis to an aspect 
of medical care, usually a limited number of drugs. Ofman.'s evaluation of a 
dyspepsia guideline intervention was a notable exception, and provided 
detailed, disaggregated information on health service expenditure with resource 
use reported separately (Ofman et al. 2003). The source of unit costs was stated 
in nine studies, and the price year in seven, although details of adjustment for 
inflation were never provided. 
Eight studies reported intervention costs, usually restricted to the resource 
implications of implementing the outreach visits. Materials were variably 
included. Only Morrison and co-workers (1999) reported the cost of guideline 
development, despite several studies reporting extensive local tailoring and 
adaptation of guidelines specifically for the intervention Mason and colleagues 
(2001) argued that guideline development costs could reasonably be excluded 
because guidelines for common primary care conditions are generated 
nationally, and readily available for implementation. They also argued that the 
opportunity cost of health worker time need not be considered, as health workers 
are expected to spend a portion of their time in continuing education activities. 
However, two studies noted that whether or not this opportunity cost of target 
practitioner time is considered, it is important in determining comparative cost 
effectiveness of competing intervention strategies (Watson et al. 2002, Simon et 
al. 2005). No study considered all costs relevant to guideline development, 
implementation and subsequent changes in treatment costs. 
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Morrison (1999) found increased primary care costs without improvement in 
outcomes for the investigation and management of infertility, and cautioned 
against the use of outreach for conditions that span the primary-secondary care 
interface. Feder (1995) and Simon (2005) provided no clear economic conclusion 
to their studies, although costs appeared similar between groups. 
1. 7.3.4 Summary 
There are too few methodologically sound or sufficiently comprehensive studies 
of educational outreach interventions to draw any firm conclusions about its 
cost-effectiveness. Also, resource costs are likely to differ between different 
countries. Despite this, compared with alternative implementation approaches, 
educational outreach has been widely viewed as resource intensive, and many 
decision-makers have expressed resistance to its routine use in health services 
(Grimshaw et al. 2004). Gandjour (2005) makes an important distinction between 
the resources required to launch outreach initiatives and their cost-effectiveness. 
While resources required to launch outreach initiatives may appear substantial 
and serve as a disincentive to 3rd party payers who need to stay within a given 
budget, incremental cost-effectiveness may still be favourable, even if effect sizes 
for process outcomes are relatively small (Freemantle et al. 2002). Mason 
distinguishes between treatment cost-effectiveness, or the incremental costs and 
benefits of a treatment, and policy cost-effectiveness, which can be determined 
by combining treatment cost-effectiveness with the magnitude of change 
achieved by the implementation method. Many factors interact to influence 
policy cost-effectiveness. These "loading factors" include the treatment cost-
effectiveness but also the prevalence of the target disease, duration of effect, 
effectiveness and cost of the implementation strategy. 
So, while educational outreach might be perceived to be expensive, it may still be 
highly cost-effective if the prevalence of the disorder being targeted is high (like 
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1.8 Summary of literature review 
This chapter has highlighted the large and growing burden of adult respiratory 
diseases in the developing world and in South Africa. Nurses in primary care 
facilities are facing increasing numbers of infectious diseases, many of which are 
manifestations of underlying HN infection, superimposed on a moderate 
chronic respiratory disease burden. Traditional nurse training and short-course 
intensive workshops have failed to equip nurses adequately for independent 
clinical practice, although in reality many nurses assess and treat patients with 
no or extremely limited doctor support. 
The response to suboptimal primary care has differed substantially in the 
developed and developing worlds. In the developing world, efforts have largely 
been channelled into the development of syndromic treatment guidelines 
although their implementation has been characterised by the use of traditional, 
largely didactic, and untested training methods. In the developed world, much 
has been done to develop, implement and evaluate the relative effectiveness of 
various implementation strategies which draw on theoretical frameworks for 
changing behaviour among adult professionals. 
The P ALSA project arose from the AfroImplement collaboration which sought to 
promote the uptake of evidence-based care in Southern Africa through rigorous 
implementation trials. It is unique in combining the syndromic approaches 
widely used in the developing world with evidence-based approaches to its 
implementation, in this case educational outreach visits, in a non-physician 
resource-limited setting like the Free State public health sector. 
The pragmatic randomised controlled trial of its effectiveness, cost and cost-
effectiveness undertaken in the Free State contributes to two areas of primary 
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1.9 The Practical Approach to Lung Health in 
South Mrica (P ALSA) 
1bis thesis forms part of a larger collaborative project which developed, 
implemented and evaluated the PAISA intervention in the Free State. While a 
detailed explanation of intervention development is beyond the scope of this 
thesis, the events leading up to the trial will now be briefly described in order to 
provide background to the trial and economic evaluation. 
1.9.1 Establishment of the research collaboration and engagement 
with the Department of Health 
The South African adaptation of PAL, PAISA or Practical Approach to Lung 
Health in South Africa, arose out of a collaboration formed between health 
systems researchers, clinicians and Free State Department of Health managers in 
the late 199Os. A 1999 request from the Free State Department of Health to the 
Medical Research Council for assistance with research on priority setting and 
cost-effectiveness widened to a broader discussion of the need for health systems 
research in the province. At that time, Stop TB at the World Health Organisation 
had engaged the Medical Research Council as how to best adapt and implement 
the PAL guidelines in South Africa. Development of the PAISA intervention 
and study proposal was aided by AfroImplement workshops in late 1999 and 
2001, and the Free State soon agreed to implement the package within a 
pragmatic randomised trial evaluation. 
Contact with Stop TB at the World Health Organization led to important 
engagements with two further stakeholders. The first of these was with the head 
of the South African National Tuberculosis Control Programme, who supported 
the initiative and contributed technical expertise to the process of guideline 
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provided useful information on the distribution and prevalence of respiratory 
diseases in South African primary care settings (Fairall et al. 2001). The 
management of acute respiratory infections, tuberculosis and obstructive lung 
disease was emphasised and, due to high rates of HIV co-infection among 
patients with respiratory diseases, a section on HIV added. This guideline was 
adapted before antiretroviral treatment was made available through the South 
African public sector health service (South African National Department of 
Health 2003b), and so the HIV section instead emphasised the provision of 
cotrimoxazole prophylaxis to those with symptomatic HIV infection. 
Several workshops were held with approximately 60 Free State clinicians, 
managers and nurses. A wide range of stakeholders, including the National 
Tuberculosis Control Programme Manager, Stop TB from WHO, and local 
respiratory and primary care physicians were consulted during the adaptation of 
the guideline. One key concern was to ensure consistency with national 
tuberculosis policies (South African National Department of Health 2000a) and 
the South African essential drugs list which regulates prescribing provisions for 
primary care nurse practitioners (South African National Department of Health 
1998b). 
Several deficiencies in the prescribing provisions relevant to the guideline were 
noted. Inhaled corticosteroid initiation was restricted to doctors in the Free State, 
and nurses were not permitted to prescribe short courses of oral corticosteroids 
for patients with acute exacerbations of obstructive lung disease, although they 
were allowed to provide intravenous corticosteroids prior to emergency referral. 
At a national level, the recently established Belgium government funded TB-HIV 
portfolio had successfully motivated for nurses to initiate cotrimoxazole 
prophylaxis in patients with symptomatic HIV infection, and the 2003 Primary 
Care Essential Drug list was revised to include Stages 3 and 4 HIV infection 
among the indications for primary prophylaxis (South African National 
Department of Health 2003a). Nurses in the Free State nonetheless reported 
feeling confused by conflicting recommendations as to when to start 
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1.9.3 Development of the PALSA training support materials and 
educational outreach intervention 
Selection of the implementation strategy was informed by the AfroImplement 
collaboration (see section 1.6.6) which aimed to promote the development of 
rigorous implementation trials in Southern Africa. An earlier trial arising from 
the collaboration has investigated the impact of educational outreach to Cape 
Town general practitioners on the frequency and severity of asthma symptoms 
among children in their practices, and found marked improvements despite 
limited exposure to the intervention (Zwarenstein et al. 2006). We selected this 
model for implementation of P ALSA in the Free State using nurse middle 
managers as outreach trainers, over offsite education because it was sustainable, 
drawing on and expanding the educational role of existing supervisory 
personnel, and because it minimised disruption in under-staffed front line 
facilities. Also, at the time systematic reviews of guideline implementation 
strategies identified educational outreach as a particularly promising strategy for 
changing provider behaviour, especially prescribing (Oxman et al. 1995, 
Thomson et al. 1999, Grimshawet al. 2001). It was only later, with the 
publication of the state-of-the-art review by Grimshaw and colleagues in 2004, 
that it was considered not as effective as previously thought. 
The selection of educational outreach as the primary implementation strategy 
was tested with nurses, nurse trainers and managers during further workshops 
in the Free State, where video-taped educational outreach sessions based on the 
childhood asthma intervention for general practitioners in Cape Town were 
presented. Nurses felt that the model was suitable, as a lack of onsite and clinical 
follow-up was perceived to be the main shortcoming of existing centralised 
training courses, where selected nurses were trained intensively but not re-
evaluated or supervised once back at their clinic. The social marketing elements 
of outreach were recognised by nurses who emphasised that it was important to 
" sell" the package to nurse practitioners. Nurses provided many suggestions for 
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Table 1.16 P ALSA Key Messages 
Respiratory Key Message 
Syndrome 
Tuberculosis Coughing ~ 2 weeks - Send sputa for TB. 
TB/HIV co-infection Test for HIV because TB is common in HIV patients. 
Cotrimoxazole prophylaxis delays symptoms and prolongs healthy life 
in HIV patients. 
Lower Respiratory Diagnose LRTI in patients with cough plus difficult breathing and/or 
Tract Infection (LRTI) pain on coughing/breathing and/or fever. 
If severe refer; if new or purulent sputum prescribe amoxicillin for 7 
days and follow-up in one week. 
Upper Respiratory Diagnose URTI in patients with blocked or runny noses and/or sore 
Tract Infection (URTI) throats and/or mild fever but no difficult breathing and no chest pain. 
Prescribe symptomatic treatments only. 
Obstructive Lung Diagnose asthma in patients with recurrent wheeze, difficult breathing 
Disease (Asthma and and cough. Prescribe inhaled corticosteroids. 
COPD - Chronic Diagnose COPD in patients with persistent wheeze, difficult breathing 
Obstructive Pulmonary and cough (and a history of smoking). Prescribe bronchodilators. 
Disease) 
Smoking Cessation People are more likely to stop smoking if advised to do so by a health 
professional. ... and smoking makes all lung conditions worse so teU 
your patients to quit today! 
Eight nurse trainers, selected from among the district tuberculosis coordinators 
in the Free State, attended a 5 day workshop on techniques of interactive 
educational outreach and the clinical content of the guidelines, especially the key 
messages. The workshop was led by an experienced trainer, with specialist 
interests in facilitative training techniques, experiential learning and medical 
education. Content support was provided by two medical researchers, including 
the author and lead guideline developer. Free State nurse trainers were provided 
with the guideline and materials, and asked to model outreach sessions to their 
colleagues, and later in the week to groups of nurses in primary care clinics. 
These sessions were video-taped and reviewed, with feedback provided by 
content and process facilitators and colleagues. The training strategy for the 
trainers has been described in detail elsewhere (Bheekie et al. 2006). 
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considering whether or not to implement PAISA. Research questions for each 
dimension of the evaluation are provided in Table 1.17. They underpin a 
continuum of enquiry ranging from questions of effectiveness to those of 
efficiency, and together provide a comprehensive framework for understanding 
the impact of PAISA on health services. 
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- Health related quality of life 
- Mortality 
- Patient satisfaction 
- Health care utilisation within and beyond the public sector 
- Cost of respiratory care for the health service and for patients 
- Patient productivity 
- Cost per additional case of tuberculosis diagnosed, and per 
additional case appropriately treated 
• To translate the EuroQol5D generic health status questionnaire for use 
among Sesotho speakers, and to evaluate the construct validity of the 
translated version among primary care patients with cough and/ or 
difficult breathing 
• To estimate the incremental cost-effectiveness of P AlSA in addition to 
usual training and support from the perspective of the health service and 
society. 
2.2 Study Design 
The study was a pragmatic cluster randomised trial with a prospective economic 
evaluation. The unit of randomisation was the clinic, and outcomes were 
assessed at the level of individual patients. 
2.2.1 Reporting 
Reporting is consistent with the CONSORT checklist for cluster randomised 
controlled trials, insofar as possible given the trial's pragmatic orientation 
(Campbell et al. 2004a). Similarly the economic evaluation conforms to 
guidelines for reporting economic evaluations (Drummond and Jefferson 1996). 
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tuberculosis protocol, received by fewer than 5% of staff each year, continued in 
both groups. 
In the trial PAISA, in addition to usual training and support, was compared 
with usual practice. Ideally, PAISA should have been compared with, and not 
in addition to, usual training and support. However, this would have required 
that intervention clinic nurse practitioners be refused any usual training for the 
duration of the trial. This was considered unreasonable, especially given that 
such training generally applied to less than 5% of eligible nurse practitioners in 
any given year. 
2.2.4 Economic Evaluation 
2.2.4.1 Study question 
Cost has been perceived as a barrier to implementation of similar interventions in 
other developing countries (Khan et al 2000, Kolstad et al. 1998). The economic 
evaluation aimed to estimate the cost of PAISA and evaluate whether, in 
addition to usual training and support for respiratory diseases, it represented an 
effective and efficient use of scarce resources from the perspective of the health 
service and society. 
2.2.4.2 Form of economic evaluation and hypotheses 
Without a priori estimates of effectiveness, the economic evaluation set out to 
complete a cost consequence analysis, comparing the costs and effects of the 
PAISA intervention in addition to usual training and support. In the event that it 
the trial showed a difference in outcomes (more or less effective) a cost-
effectiveness analysis was planned; if no difference was observed a cost-
minimisation analysis. 
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Table 21 Clinic Characteristics at baseline (beginning 2003) 
Characteristic PALSAGroup Control Group 
Number of clinics 20 20 
Total adult attendances 12749 12935 
(median per Quarter during 2002) 
Nurses per clinic (median) 9 8.5 
TB Treatment Service available 19/20 (95%) 20/20 (100%) 
24 Hour Emergency Service available 4/20 (20%) 2120 (10%) 
Distance from local referral hospital (median) 7km 5.5km 
In general, these clinics service impoverished communities, predominantly in 
rural areas with high tuberculosis and HIV rates [tuberculosis notification rate 
(all cases) 494/100 000 in 2002 (South African National Department of Health 
2oo3c), estimated HIV prevalence of 30.1 % among antenatal attendees in 2003 
(Makubalo et al. 2003)]. On a typical day around 200 patients attend one of these 
clinics; approximately 1/3 of these are children. A clinic is staffed by a median of 
nine nurses, some of whom see only pregnant women or children. Problem cases 
are referred to doctors who visit weekly. 
2.2.5.2 Randomisation 
Oinics were randomised to receive or not to receive P ALSA in addition to usual 
training and support. Randomisation was completed in blocks of four and 
stratified by district (Figure 3.1). Randomisation was performed before outreach 
training commenced in clinics, by a statistician unfamiliar with the clinics or the 
intervention. After randomisation, but before educational outreach or data 
collection commenced, one clinic randomised to the control group closed down. 
Both staff and patients were moved to a nearby clinic. Given that the staff and 
patients to whom the intervention had been randomised had simply been 
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took two key factors into consideration: the number of patients in separate II fast 
track" queues for tuberculosis care, and the overall number of patients in the 
waiting room. These recruitment procedures were piloted before the trial, and 
guided the ratio which fieldworkers used to sample patients from the waiting 
room. Thus, if review of the daily headcounts suggested that total attendances 
numbered less than 70 patients, fieldworkers were asked to request e:very patient 
who reported cough and/ or difficult breathing to meet with the team after 
consultation with the nurse. If the total attendances numbered between 71 and 
140, every second patient was approached to meet them after the consultation, if 
total attendances numbered between 141 and 210, every third patient and if 
greater than 210, every fourth patient. This was necessary to ensure that patients 
with acute symptoms, who may present at any time, were not systematically 
excluded should sampling be completed early during the day. 
The proportion of tuberculosis care visits for each clinic was also calculated 
before the trial, using 2002 statistics for each clinic collected routinely by the Free 
State Department of Health. This was used to guide recruitment from the 
general and tuberculosis queues. Thus, each clinic was set a "tuberculosis queue 
target", proportional to the burden of tuberculosis care visits in that particular 
clinic. For example in Pabollong clinic, where 24 % of visits in 2002 were 
attributed to tuberculosis care, fieldworkers were instructed to recruit 38 (76%) 
patients from the general queue, and 12 patients (24%) from the tuberculosis 
queue. Inclusion and exclusion criteria were applied equally to patients 
recruited from either queue. 
2.2.6.3 Patient interviews 
Fieldworkers interviewed patients after their consultation, and three months 
later by appointment at the clinic (Figure 2.2). Those patients who did not return 
to the clinic for the follow-up interview were traced and interviewed at home or 
at their workplace. Interviews were conducted in one of five local languages, 
chosen by the patient. Questionnaire content, development and translation are 
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2.2.8 Outcomes 
Multiple primary outcomes were pre-specified for the trial to accommodate the 
syndromic nature of the intervention whereby multiple conditions and 
behaviours were targeted. Outcomes are summarised in Table 2.2. 
2.2.8.1 Effectiveness Outcomes 
Primary outcomes included process indicators of quality care and were defined 
for four disease categories. For tuberculosis, the primary goal was to increase 
case detection, documented on the patient-held tuberculosis treatment card or as 
reported by the patient. Tuberculosis sputum testing, the South African standard 
for diagnosis (South African National Department of Health 2OOOa), was 
indicated by patient report. For obstructive lung disease, the primary goal was 
to improve therapy, indicated by inhaled corticosteroid prescription For 
respiratory tract infections, the primary goal was to rationalise prescribing, 
indicated by antibiotic prescription. P ALSA also aimed to improve HIV and 
AIDS care, indicated by cotrimoxazole prescription among tuberculosis patients. 
Outcomes were assessed one and four months after the intervention began and 
were deemed present if reported at either interview. This follow-up period is 
brief for an economic evaluation but was decided because of concerns about 
tracing patients in a difficult context characterised by urban migration of people 
in search of work, and the absence of infrastructure including road names in 
rural areas. We planned to extend follow-up if we received additional funding 
and wanted to interview participants on a third occasion, six to twelve months 
after the intervention started. 
Secondary outcomes included counselling indicators (proportion receiving 
smoking cessation advice, readiness to quit, smoking cessation, motivation to 
undergo VCf), health related quality of life, frequency and severity of 
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2.2.9 Validation of the Sesotho Adaptation of the EuroQol-SO 
The EuroQol was translated into Sesotho for use in the trial. A secondary 
objective was to assess the construct validity of the Sesotho translation for 
respiratory patients in an outpatient setting. The ability of the translated 
EuroQoI to distinguish between sick and less sick patients, and diagnostic 
categories was examined using ordinal logistic regression. Results are reported 
in Chapter 6 Section 6.2.5.2. 
2.2.10 Sample Size Calculations 
Sample size calculations were based on the effectiveness outcomes given the lack 
of consensus on and methods for determining sample sizes for economic 
evaluations (AI et al. 1997). The minimally important health service 
improvement for tuberculosis case detection was specified by policymakers in 
advance of the trial to be 25%. Review of routine tuberculosis data showed that 
too few tuberculosis patients attend within a feasible study duration to detect 
this difference. A more common measure, sputum sampling for tuberculosis, 
was selected as a surrogate. It was estimated that 1000 patients per arm, in 
clusters of 50, provided 90% power (alpha = 0.05) to detect a 10% improvement 
in sputum screening for tuberculosis. 
Further sample size calculations were based on preliminary survey work 
completed during piloting of the questionnaire. In total, 30 patients were 
interviewed. Of these, 70% reported receiving an antibiotic prescription, 17% an 
inhaled corticosteroid and half reported problems with their usual activities. 
From this it was estimated that 1000 patients per arm provided 90% power 
(alpha = 0.05) to detect a 10% improvement in inhaled corticosteroid 
prescriptions, a 10% reduction in antibiotic prescriptions, and a 10% reduction in 
the number reporting problems with usual activities. In all calculations, an intra-
cluster correlation coefficient (ICq of 0.02 was assumed, based on primary care 
studies elsewhere (Adams et al. 2004, Campbell et al. 2004b). 
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2.2.10 Ethical Issues 
The study was approved by the Research Ethics Committee of the Faculty of 
Health Sciences, University of the Free State. In cluster randomised trials of 
guideline interventions, the risk to patient participants is low, given that the 
interventions do not target individual patients, and rarely introduce untested 
elements of care such as new drugs or investigations, but rather focus on the way 
in which proven interventions (like cotrimoxazole prohylaxis for HIV infection, 
or inhaled corticosteroids for asthma) are organised and delivered to patients 
attending health services. 
Patients were required to be consented for their contribution to data collection, 
but not to the random allocation of the intervention. In this case data collection 
posed minimal risk to patients since it involved participation in two interviews 
and no invasive or additional monitoring. Access to routine clinical care was in 
no way disrupted, and fieldworkers were instructed to conduct exit interviews 
only once all care procedures had been completed. All patients were consented 
in their own language in accordance with South African Good Oinical Practice 
Guidelines (GCP), and gave written informed consent before participating. The 
English copy of the consent form is provided in the appendix. 
2.3 Data Collection 
Almost all data required for the analysis was obtained by patient report at exit 
and follow-up interviews. Record review was not used as a means of collecting 
data because clinical record-keeping is generally of poor quality. Furthermore, 
clinical records may have contributed potential bias as the intervention might 
have improved documentation of consultations by nurse practitioners. 
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Royal College of Physicians Asthma Control Measure contains 3 items covering 
night-time waking, day-time symptoms and interference with usual activity. 
Each item is answerable as a simple yes/ no but can be supplemented with the 
Tayside grading system to improve responsiveness (Hoskins et al. 1998). The 
original instrument was intended for use among asthmatics but needed to be 
modified to accommodate all patients with respiratory symptoms in the trial. 
The word II asthma" was therefore substituted with generic terms including 
II chest symptoms" and "chest problem". The decision to use this instrument was 
later supported when the World Health Organization recommended its use in 
multi-country PAL evaluations at the first review meeting in Morocco in 2002 
(WHO 2003d). 
2.3.1.3 Generic health related quality of life (enrolment questionnaire, 
questions 61-72, follow-up questionnaire, questions 18-29) 
The EuroQol-5D was chosen ahead of other measures because it is brief, has been 
widely tested across countries and conditions, had already been translated into 
several local languages and because it has a credible social preference weighting 
system capable of supporting cost-utility analysis (Brazier et al. 1999). 
The EuroQol-5D comprises a descriptor section of five domains of health-related 
quality of life: mobility, self-care, usual activities, pain/ discomfort and 
anxiety/depression. Each domain in the descriptor section is divided into three 
levels indicating no problems (level 1 ), some problems (level 2) or extreme 
problems (level 3). The classification defines a total of 243 health states which 
can be combined with tariffs to yield a single index score with an upper limit of 
one, where one corresponds to perfect health, zero death, and scores less than 
zero to states considered worse than death. 
Limited responsiveness to changes in clinical status among respiratory 
outpatient populations elsewhere (Harper et al. 1997) prompted correspondence 
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The questionnaire also made provision for collection of tuberculosis care details, 
if relevant. These included date of first dose of treatment, past tuberculosis 
history and frequency of clinic attendance to receive treatment. Date of first dose 
of treatment was validated by checking the patient-held tuberculosis treatment 
card. 
2.3.1.5 Smoking cessation (enrolment questionnaire, questions 73- 91, 
follow-up questionnaire, questions 16 -168) 
In addition to being asked whether they had been advised by the nurse 
practitioner to stop smoking, the stage of change (pre-contemplators, 
contemplators, preparation, action) was assessed among current smokers using 
questions developed by Prochaska and Oimente (1986). These questions have 
been tested in other trials evaluating the effects of various interventions to 
increase smoking cessation (Riemsma et al. 2002). Patients were also asked 
whether they had actually quit smoking at the time of the follow-up interview. 
2.3.1.6 Health care utilisation (enrolment questionnaire, questions 19 -
468, follow-up questionnaire, questions 30-98 and 280- 486) 
Details on health care utilisation were collected for the economic evaluation. 
Patients were asked to provide details of care received at their index clinic and 
elsewhere for the preceding three months (three months before the enrolment 
interview, and the 3 months between interviews). Steps were taken to improve 
recall. In the Free State, most clinic records are patient-held, and interviewers 
were asked to refer to these to validate visit information. Patients were 
sensitised at the time of the first interview, and issued verbal and written 
reminders that information concerning health care utilisation would be required 
at the follow-up. For each clinic visit, interviewers were instructed to record the 
date, and reason for visit as reported by the patient. Provision was also made to 
capture a maximum of five visits to other health care providers; for these visits 
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2.3.1.10 Patient satisfaction (foUow-up questionnaire, questions 527-
547) 
Patient satisfaction was assessed using a modified version of the Consultation 
Satisfaction Questionnaire, first developed for use in general practice in the 
United Kingdom (Baker 1990). It has since been used to assess satisfaction with 
nurse practitioner services (Shum et al. 2000) and demonstrates construct validity 
compared with other satisfaction indicators (Baker and Whitfield 1992, Poulton 
1996). It comprises 18 statements graded using Likert scales. Formulae are 
available to convert responses to a score ranging from 0 to 100 for each of four 
domains: general satisfaction, professional care, depth of relationship and 
perceived time. Usual scores are in the range of 60 to 80. 
2.3.2. Translation of the Questionnaire 
The questionnaire was translated by researchers from the Centre for Health 
Systems Research and Development and Department of Community Health of 
the University of the Free State. Forward and back translations were completed 
in keeping with internationally accepted practices (Guillemin et al. 1993). The 
EuroQoI was translated into Sesotho separately from the rest of the questionnaire 
in accordance with protocols from the EuroQoI group (EuroQoI Group 2003). 
The EuroQol translation is described in detail in Chapter 5. 
2.3.3 Utilisation of handheld computer technology during fieldwork 
An interview software application for handheld computers, developed by the 
Biomedical Informatics Research Division of the Medical Research Council, was 
used during the trial (Zwarenstein et al. 2006). This was the first time the 
application had been used to complete a large fieldwork exercise, and it has 
subsequently been used for several other large studies. Strengths and 
weaknesses of the application are discussed in Chapter 7 Section 7.2. 
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fieldworkers were shown how to operate them. Fieldworkers were also shown 
how to record a respiratory rate and how to mask this activity by simultaneously 
feeling the pulse to avoid prompting voluntary control of breathing by subjects. 
Fieldworkers were provided with an opportunity to test these skills on their 
colleagues, while researchers observed and gave feedback. Each team was 
provided with a video of a subject with respiratory distress using accessory 
muscles during breathing, so that they might recognise this when in the field. 
Should fieldworkers recognise a seriously ill patient they were advised to refer 
them back to the clinic nurse practitioner for management. 
lbree senior and experienced fieldwork supervisors were recruited, each to 
oversee between one and two teams. Supervisors visited teams once during each 
week of fieldwork at a clinic (enrolment and follow-up weeks). They assessed 
whether patient recruitment was being completed in accordance with the study 
protocol, were responsible for quality control procedures and helped solve any 
logistic difficulties (lack of transport etc.). 
Researchers accompanied supervisors on field visits approximately once a 
month. During these visits they sat in on team meetings where feedback on 
quality control procedures was provided, witnessed interviews, provided 
feedback to interviewers and audited recruitment procedures. During later 
months of fieldwork, these visits provided important opportunities to resolve 
any queries arising from the reconciliation of enrolment and follow-up 
interviews for clinics where fieldwork had already been completed. 
A second training workshop preceded the start of follow-up interviews. At this 
workshop, problems arising from past fieldwork were discussed, and the follow-
up questionnaire was introduced and again worked through question by 
question. During follow-up fieldwork, team leaders were no longer required to 
recruit patients; instead they were asked to trace patients who did not arrive for 
follow-up interviews, and complete a time and motion work study of 
consultation duration (see section 2.3.7). 
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2.3.6 Cost identification, measurement and valuation 
Patient-level costs were collected using a programme ingredients approach with 
resource quantities collected separately from unit costs (Drummond et al. 1989). 
Costs were considered from the perspective of the health system (health service 
costs and the cost of the PAISA intervention) and society (household and out-of-
pocket health related expenditure). A template for measuring and valuing costs 
is provided in Table 2.3. 
2.3.6.1 Intervention costs 
The costs of developing the guideline and training intervention were determined 
after developing a diary template recording all related activity since the project's 
inception in 1999. Researchers were then interviewed to gauge their level of 
contribution, measured in time and valued using cost of employment. These 
costs were then inflated by 30% to reflect overhead costs borne by participating 
research institutions. The time of doctors and nurses who participated in 
workshops was valued using cost of employment obtained from the FSDOH 
Finance Division. Flight, accommodation, catering and graphic artist costs were 
obtained from project expenditure records. The opportunity cost of using 
university and health department venues for workshops and pilots was 
estimated using rates for a popular Bloemfontein conference centre. 
Nurse trainers were required to complete attendance registers at all educational 
outreach visits. These forms also made provision for the collection of cost data 
directly related to visits (transport, refreshments etc.). 
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2.3.6.2 Treatment costs 
Infonnation on the quantities of health service and household resources used 
was collected during patient interviews. Unit costs were determined as follows: 
• Oinic visits: 2003 equivalents for staff, management and administrative 
component costs were derived from a 1997/98 study of Cape Town 
primary care clinics (Daviaud 1999). 
• Tuberculosis monitoring visits: Oinic visit unit costs were weighted using 
the findings of a tuberculosis treatment costing study (Sinanovic et al. 
2(01). Visits to monitor tuberculosis treatment were estimated to cost 52% 
that of a routine clinic visit. 
• Inpatient days: An estimate generated during a study of inpatient care at a 
Cape Town district hospital was used (Haile 2000). The estimate was 
similar to the 2003 tariff for an inpatient day obtained from the FSDOH 
Finance Division. 
• Outpatient visits: The inpatient day unit cost was weighted using the 
findings of a study completed at a Cape Town hospital (Oeary et al. 2004). 
Outpatient visits were estimated to cost 27% of an inpatient day. 
• Ambulance trips: Public sector costs for emergency services were not 
available. Board of Healthcare Funder (2004) tariffs were used instead, 
and where applicable, adjustments made for trips in excess of l00km in 
keeping with the Board of Healthcare Funder fee structures. 
• Medication: Acquisition costs were obtained from the Free State 
Pharmaceutical Services, and included a 8% handling fee. Patients were 
assumed to have received two packets of short course medications (e.g. 
antibiotics) if they reported receiving this medication at both interviews; 
one unit if reported at only one interview. Tuberculosis treatment and 
inhaled corticosteroids were assumed to have been taken for all three 
months between interviews. 15% of tuberculosis patients were assumed 
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elapsed time to be calculated. Stopwatches were not used in keeping with 
recommendations for completing such studies (International Labour Office 1969). 
2.4 Analysis 
2.4.1 Effectiveness 
Effectiveness outcomes were analysed on an intention-to-treat basis. In the 
context of a cluster randomised controlled trial this means that clinics, and the 
patients recruited in these clinics, were analysed in the group to which they were 
randomised. Robust logistic regression models which accounted for the trial's 
design (cluster randomisation within district strata) were used to evaluate the 
effect of the intervention. Odds ratios are presented with 95% confidence 
intervals, corresponding p values and intra-cluster correlation co-efficients. Risk 
differences and numbers needed to treat (NNT) were estimated for effectiveness 
outcomes used in the economic evaluation. 
2.4.2 Allocation of intervention costs 
The cost of developing the guideline and training intervention, but not the cost of 
the training itself, was treated as a capital cost. This is because the guideline and 
training intervention represent an asset which will depreciate over time, owing 
to changes in medical knowledge and technology and in health services. Linear 
depreciation to zero over six years was assumed based on a study which 
evaluated the current validity of 17 quality guidelines and estimated that half the 
guidelines were outdated after 5.8 years (Shekelle et al. 2001). It follows that the 
cost of depreciation during the three months during which trial patients were 
followed-up was 3/72 times the total capital cost. 
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(Kind et al. 1998). During this survey over 3000 members of the United Kingdom 
general population were interviewed and asked to value EuroQol health states 
using time trade off and standard gamble exercises. This permitted the 
estimation of tariffs for a11243 states defined by the EuroQoI classification (Dolan 
1997). The York tariffs are the most widely used, and were combined with 
EuroQol-5D responses to calculate index scores for patients enrolled in the trial. 
A local set of EuroQol weights, derived from 2384 Zimbabweans using time 
trade off exercises, is available, and was applied in a secondary analysis Oelsma 
et al. 2003). For analysis of the five level EuroQol scores, value decrements for 
levels 2 and 4 were set to the midpoint decrements for the three level version 
(Kind and Macran 2002). Patients were asked to reflect on their health status on 
the day of the interview, and separately during the course of the last month. 
Responses for the day of the interview were used in the primary analysis. 
2.4.5 Valuation of Lost Productivity Time 
This remains a controversial area of health economics especially when applied to 
populations with high rates of unemployment, where the friction period between 
replacing a person lost from the employed pool may be reduced compared with 
settings with lower rates of unemployment (Koopmanschap et al. 1995, 
Koopmanschap and Rutten 1996). 
One common strategy is to value lost unemployed time at half the minimum 
wage. In some countries recommendations exist to ensure standard practice 
across evaluations (HM Treasury n.d.). This is not true for South Africa, 
although minimum wage categories have been determined (Basic Conditions of 
Employment Act 1997). In the trial employed days lost were valued at gross 
income, if provided, and full minimum wage if not. Unemployed days lost were 
valued at half minimum wage and school days lost were not assigned a 
monetary value. 
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Willingness to pay levels ranged from zero, in increments of 100 South African 
Rand (ZAR), up to ZAR2000. 
Non-parametric bootstrapping, with replacement, was conducted with Stata 9 
software. Individual subjects' costs and outcomes were re-sampled 1000 times 
with Stata, with individual and then with cluster sampling. Differences in mean 
costs and mean effects for each individual bootstrap sample were plotted on a 
cost effectiveness planes. The cost difference, outcome difference, incremental 
cost effectiveness ratio, incremental net benefit and the probability that the 
intervention was cost effective was calculated at each willingness to pay level. 
Confidence intervals were estimated using the bias corrected accelerated 
percentile method (Carpenter and BitheIl2000). 
Each individual's net benefits were individually bootstrapped with Stata. Also, 
entire clusters were sampled together and differences in mean net benefits were 
calculated for each bootstrap sample with Stata. 
Linear regression analyses were conducted with Stata with robust adjustment for 
intra-cluster correlation of outcomes. Analyses were repeated without robust 
adjustment to provide the results that would be obtained if cluster randomisation 
was ignored. 
For cost effectiveness acceptability curves, the probability that the intervention 
was cost effective at each level of willingness to pay was as follows. For 2D 
bootstrap, it was the proportion of samples for which the cost difference was less 
than the outcome difference multiplied by willingness to pay. For 1D bootstrap, 
it was the proportion of bootstrap samples for which the incremental net benefit 
was more than zero. For regression analyses the probability that the intervention 
was cost effective was one minus half the respective p value, if the mean 
incremental net benefit was greater than zero. If the mean incremental net benefit 
was less than one it was half the respective p value. 
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Figure 3.1 Trial Profile 
236 primary care clinics in the Free State 
25 Bloemfontein clinics excluded (circulation of staff) 
11 Thaba'Nchu clinics excluded (piloting of materials) 
200 primary care cliniCS 
• 
40 largest primary care clinics selected. Randomisation completed within 5 health dlsbict strata. 
Thabo Mofutsanyana (12), Lejweleputswa (12), Northern Free State (10), Motheo (4). Xharlep (2) 
~ ~ 
20 clinics rendomlsed to PALSA 20 clinics randomised to usual care 
~ ~ 
Patient Enrolment Patient Enrolment 
Screened: 1 006 Screened:1012 
Refused consent 0 Refused consent 1 
Qualified: 1000 patients Qualified: 999 patients 
Median clinic patient cohort size = 50 Median clinic patient cohort size = 50 
(range 47 - 52) (range 48 - 51) 
! ! 
Follow-up: Follow-up: 
Clinics: 20 Clinics: 20 
Patients: 930 Patients: 926 
70 patients lost to follow-up 73 patients lost to follow-up 
(22 deceased, 2 hospitalised I too III (26 deceased, 3 hospitalised I too ill 
for Interview, 46 unable to trace) for interview. 44 unable to trace) 
Patient characteristics at enrolment are shown in Table 3.1. They did not differ 
between intervention and control arms. Around 2/3 of the patients were women, 
with a mean age in the forties (44.9 in the P AlSA group and 44.2 in the controls). 
On the whole, patients were from very poor socioeconomic circumstances. 16% 
of patients had never attended school at all, and only 39% reported secondary 
school education while less than 10% completed school. Over half were 
unemployed, and 1/4 reported receiving welfare. Less than 20% indicated that 
they were employed. 
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and received a median of two educational outreach visits (range: 0 - 4, Table 3.2). 
In five clinics the median number of outreach visits received was less than two, 
and in one clinic where staff turnover during the study period was especially 
high (PAX clinic), zero. Sessions lasted on average 2 hours. 
Table 3.2 Exposure to educational outreach visits at intervention clinics 
District Intervention Location Number of Number of Median 
Clinic sessions eligible number of 
delivered nurses sessions 
by per eligible 
outreach nurse 
trainer 
Thabo Riverside QwaQwa 5 10 2.5 
Mofutsanyana Mpohadi Bethlehem 3 6 3 
Bethlehem Bethlehem 3 5 3 
Tseki QwaQwa 2 7 2 
Tebang QwaQwa 3 22 1 
Namahadi QwaQwa 2 15 2 
Lejweleputswa Tshepong Welkom 2 14 2 
K-Maile Bothaville 3 7 2 
Albert Luthuli Wesselsbron 3 6 3 
Phomolong Henneman 2 5 2 
Welkom Welkom 3 13 3 
Boithusong Odendaalsrus 2 7 3 
Northern Free Phahameng Frankfort 5 5 3 
State Thusanong Kroonstad 6 9 4 
PAX Viljoenskroon 3 15 0 
Seeisoville Kroonstad 2 9 1 
Tumahole Parys 3 8 2 
Motheo Botshabelo B Botshabelo 3 18 1 
Botshabelo U & S Botshabelo 3 11 1 
Xhariep Bophelong Petrusburg 2 11 2 
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3.4 Effect on tuberculosis case detection and 
diagnostic processes 
Sputum screening for tuberculosis (fable 3.4) was higher among intervention 
patients but not significantly so (OR 1.22, 95% CI 0.83 to 1.80). Despite this, 57 
new cases of tuberculosis were diagnosed in intervention clinics during the study 
period compared with 34 new cases in controls (OR 1.72, 95% a 1.04 to 2.85). 
The number of study patients diagnosed with tuberculosis before outreach 
commenced was ascertained by retrospective questioning and was similar in the 
two groups (108 in intervention and 109 in control clinics). Significantly higher 
rates of chest x-rays (fable 3.4) and within-clinic referrals to sessional doctors 
(see Section 3.7) suggest that the increased case detection may be attributed to 
increased compliance with the full range of diagnostic processes contained in the 
tuberculosis diagnostic algorithm. 
Table 3.4 Effect of P ALSA on TB case detection and diagnostic processes 
Outcome PALSA Control Odds ratio p ICC· 
group group (OR) value 
No. 0f0 No. % OR 95% 
CI 
Sputum screening for 2261 22.6% 193/ 19.3% 1.22 0.83- 0.32 0.056 
tuberculosis 1000 999 1.81 
TB case detection among 571 6.4% 341 3.8% 1. 1.04 - 0.04 0.007 
patients not known with 892 890 2.85 
tuberculosis at start of 
intervention period 
Chest x-ray completed during 551 5.5% 311 3.1% 1.83 1.13 - 0.01 0.015 
study period 1000 999 2.96 
*Intracluster correlation co-efficlent 
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sample reported symptoms consistent with an URTI. All other patients reported 
more severe symptoms and, against the background of high tuberculosis and 
HIV prevalence, may have warranted antibiotic prescription. The effect of 
P AI.SA on antibiotic prescription for those with severe lower respiratory tract 
infections could not be examined as only 15 patients «1 %) met definition criteria 
(cough for less than two weeks with temperature ~8°q. 
Cotrimoxazole prophylaxis provision to tuberculosis patients, a group with a 
known high HIV co-infection rate (Corbett et al. 2(03), was alarmingly low and 
similar in both groups (7.5% vs. 7.3%, OR 1.19,95% CI 0.37 to 3.80). This is in 
part explained by the fact that only 16% of tuberculosis patients reported ever 
having undergone voluntary counselling and testing for HIV, all of them during 
the study period and significantly more of them from the intervention group 
(Table 3.7). In addition interruptions in cotrimoxazole drug supply during the 
study period were reported by nurse practitioners in two of the health districts 
included in the trial, affecting 24 clinics. 
3.6 Effect of P ALSA on counseling practices 
Counseling practices highlighted in the P AI.SA intervention included advising 
smokers to quit and motivating patients, particularly tuberculosis patients, to 
undergo voluntary counseling and testing (Vel) for HIV infection (Table 1.16). 
3.6.1 Smoking cessation counseling 
112 smokers (68.3%) in the intervention group and 127 (65.8%) in the controls 
reported receiving advice to quit smoking from a nurse practitioner during the 
study period (OR 1.16,95% CI 0.74 -1.82; Table 3.5). 
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completed vcr was more than double that in the control group (21.1 % vs. 10.1%, 
OR 2.49, 95% CI 1.27 - 4.89). 
Table 3.6 Effect of PALSA on counselling to undergo vcr and vcr 
completion 
Outcome PALSA Control Odds ratio p 
group group (OR) value 
No. % No. % OR 95% 
CI 
Counselled to undergo VCT 249/ 24.9% 237/ 23.7% 1.07 0.62- 0.808 
1000 999 1.84 
Tuberculosis patients 63/ 42.9% 4 32.6% 1.55 0.83- 0.167 
counseled to undergo VCT 147 138 2.90 
I VCT completed 97/ 9.7% 73/ 7.3% .37 0.85- 0.202 
1000 999 2.20 
VCT completed among 31/ 21.1% 14/ 10.1% .49 1.27- 0.008 
tuberculosis patients 147 138 4.89 
*Intracluster correlation co-efficient 






Referral to a doctor was more frequently reported by intervention group patients 
than by controls (7.8% vs. 4.7%, OR 1.71,95% CI 0.95 to 3.09, Table 3.7). Within-
clinic referral to a sessional doctor, and referral of patients with pre-defined 
markers of severe respiratory disease (see Chapter 2 Section 2.3.1.1) were both 
significantly higher among intervention group patients (Table 3.7). 
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intervention group patients reported more frequent symptoms than their control 
group counterparts. There was no difference in scores at follow-up even if 
unadjusted for scores at enrolment, or in the difference between scores at 
interviews. 
Table 3.8 Effect of P ALSA on respiratory symptoms (modified Royal College 
of Physicians Asthma Measure): index scores at enrolment and follow-up 
Outcome PALSA Control Odds ratio p ICC· 
group group (OR) value 
OR 95%CI 
At enrolment 
Mean 6.19 5.70 1.37 1.06 0.015 0.067 
Median 7 6 -
IQR 4,9 4,9 1.76 
At follow-up 
Mean 5.32 4.89 1.25 0.99 0.056 0.065 
Median 6 6 -
IQR 3,9 2,8 1.57 
Change 
Mean -0.87 -0.80 0.98 0.76 0.866 0.033 
Median 0 0 -
IQR -3, 1 -3,1.5 1.26 
At follow-up adjusted for 




*Intracluster correlation co-efficlent 
Examination of domain scores (fable 3.9) shows that the slightly higher index 
scores at enrolment among intervention group patients is explained by more 
patients reporting more frequent interference with their usual activities (OR 1.40, 
95% CI 1.04 to 1.87). 
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usual activities (OR 1.39,95% CI 1.06 to 1.81) although there was no difference in 
index scores, even when not adjusted for enrolment values (fable 3.9). 
3.9 Effect of P ALSA on health related quality of 
life 
Health related quality of life was evaluated using the EuroQol 5D health status 
measure (Brooks 1996) which was translated into Sesotho for the purpose of the 
trial (see Chapter 6). The five level version (Kind and Macran 2002), where two 
additional categories are inserted between the three standard response categories 
(no problem, moderate problem, extreme problem), was used in the hope that 
this would improve responsiveness in a respiratory outpatient setting (see 
Chapter 2 Section 2.3.1.3). Differences in index scores, domain scores and visual 
analogue scale scores between groups were analysed and are presented in Tables 
3.10 through 3.15. The primary analysis was restricted to participant's responses 
concerning their health status on the day of the interview, not in the preceding 
month. 
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Table 3.11 Effect of P ALSA on health related quality of life (EuroQol): index 
scores at enrolment and follow-up (Slevel EuroQol, York tariffs) 
Outcome PALSA Control Odds ratio p ICC* 




Mean 0.40 0.44 0.86 0.65 0.318 0.093 
Median 0.51 0.55 -
Interquartile range 0.09,0.70 0.16,0.73 1.15 
At follow-up 
Mean 0.54 0.59 0.79 0.61 0.087 0.107 
Median 0.69 0.73 -
InterQuartile range 0.19,0.85 0.29,0.86 1.03 
At. follow-up adjusted for 




Mean 0.14 0.15 0.94 0.76 0.601 0.036 
Median 0.11 0.14 -
Interquartlle range -0.10,0.43 -0.08,0.41 1.17 
*Intracluster correlation co-efficlent 
The analysis was repeated with Zimbabwean weights (Table 3.12), which are the 
only EuroQol weights to be valued and tested in sub-Saharan Africa ije1sma et al. 
20(3). In general, index scores were higher than when the standard York tariffs 
were applied. This is because a different formula was fitted for the Zimbabwean 
weights. Nonetheless, no difference between groups was noted at enrolment or 
follow-up. 
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Table 3.13 Effect of P ALSA on health related quality of life (5 level EuroQol): 
domain scores at enrolment 
Domain PALSAgroup Control group Odds ratio p ICC· 
(OR) value 
No. % No. % OR 95% 
CI 
Mobility 
No problem 440/996 44.2 496/997 49.8 1.29 0.90 0.163 0.115 
Level 2 126/996 12.7 93/997 9.3 -
Moderate problem 327/996 32.8 368/997 36.9 1.86 
Level 4 71/996 7.1 34/997 3.4 
Severe problem 321996 3.2 6/997 0.6 
Self care 
No problem 785/996 78.8 8111997 81.3 1.21 0.77 0.414 0.098 
Level 2 73/996 7.3 75/997 7.5 -
Moderate problem 102/996 10.2 96/997 9.6 1.89 
Level 4 19/996 1.9 9/997 0.9 
Severe problem 17/996 1.7 6/997 0.6 
Usual activities 
No problem 2721996 27.3 329/997 33.0 1.47 1.15 0.002 0.048 
Level 2 114/996 11.5 100/997 10.0 -
Moderate problem 318/996 31.9 405/997 40.6 1.88 
Level 4 115/996 11.6 47/997 4.7 
Severe problem 177/996 17.8 116/997 11.6 
Pain! discomfit 
No problem 142/996 14.3 185/997 18.7 1.25 0.95 0.116 0.078 
Level 2 76/996 7.6 76/997 7.6 -
Moderate problem 4231996 42.5 441/997 44.2 1.66 
Level 4 1221996 12.3 83/997 8.3 
Severe problem 233/996 23.4 2121997 21.3 
Anxlety/ depression 
No problem 1821996 18.3 190/997 19.1 0.88 0.68 0.370 0.069 
Level 2 701996 7.0 40/997 4.0 -
Moderate problem 308/996 30.9 3101/997 31.1 1.16 
Level 4 119/996 12.0 98/997 9.8 
Severe problem 317/996 31.8 359/997 36.0 
*Intracluster correlation co-efficient 
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Table 3.15 Effect of P ALSA on health related quality of life (EuroQol): visual 
analogue scores (V AS) at enrolment and follow-up (limited to patients with 
secondary school education)'" 
Outcome PALSA Control Odds Ratio p ICCt 
group group (OR) value 
OR 95% CI 
At enrolment 
Mean 50.8 54.6 0.80 0.51 0.059 0.183 
Median 50 50 -
InterQuartile ranoe 40 60 45 60 1.01 
At follow-up 
Mean 59.8 61.3 0.79 0.62 0.053 0.116 
Median 60 60 -
InterQuartile range 50 70 50 75 1.00 
At follow-up adjusted for 





Mean 8.8 7.1 1.02 0.77 0.885 0.075 
Median 10 10 -
InterQuartile ranoe -5 20 -5 20 1.34 
* VAS scores were considered reliable In patients With more than 7 years' education (Gudex et al. 
1996). The analysis was therefore limited to 363 intervention group patients (of whom 344 were 
re-interviewed at follow-up) and 409 control group patients (of whom 380 were re-interviewed at 
follow-up). 
t Intracluster correlation co-efficient 
3.10 Effect of P ALSA on mortality 
At follow-up 48 patients (2.4 %) were reported by their families to have died since 
enrolment, 34 reportedly because of tuberculosis or other respiratory illnesses. 
Three month mortality was not different between the two groups (2.2% vs. 2.6%, 
OR 0.84, 95% CI 0.46 -1.53). 
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Table 3.16 Effect of P ALSA on patient satisfaction with clinic health services 
(modified Consultation Satisfaction Questionnaire) 
Domain PALSA Control Odds ratio p ICC* 
group group OR 95% value 
CI 
General satisfaction 
Mean 60.3 60.4 0.96 0.59 0.878 0.224 
Median 58.3 58.3 -
InterQuartile range 50.0 75.0 50.0 75.0 1.57 
Professional care 
Mean 70.4 70.9 0.98 0.53 0.946 0.312 
Median 75 75.0 -
InterQuartile range 60.7 78.6 60.7,82.1 1.81 
Depth of relationship 
Mean 50.6 51.7 0.92 0.57 0.720 0.358 
Median SO.O 50.0 -
Interauartile range 35.0 65.0 40.0 65.0 1.48 
Perceived time 
Mean 39.7 44.8 0.73 0.49 0.138 0.160 
Median 33.3 41.7 -
InterQuartile range 25.0,58.3 25.0 75.0 1.10 
*Intracluster correlation co-efficient 
3.12 Effectiveness outcomes used in the cost-
effectiveness analysis 
Two effectiveness outcomes were defined as the basis for the cost-effectiveness 
analysis. The first was tuberculosis case detection, because of its public health 
importance and as the driving force behind the rationale for PAL. The second 
was appropriate care which combined three process outcomes: case detection of 
tuberculosis, inhaled corticosteroid prescription for asthma and appropriate 
referral of patients with pre-defined markers of severe disease (see Chapter 2 
Section 2.3.1.1). Such a composite indicator was necessary in evaluating a 
syndromic intervention like P AlSA which targeted multiple diseases for 
improved management and outcome. 
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3.13 Summary 
The randomized trial showed that, in spite of limited exposure to outreach 
training, P AlSA markedly improved the quality of care across several priority 
respiratory illnesses. 
Among patients with respiratory symptoms it increased case detection of 
tuberculosis (OR 1.72, 95% CI 1.04 - 2.85). It also increased vcr uptake among 
patients with tuberculosis (OR 2.49, 95% CI 1.27 - 4.89), although it failed to 
improve provision of cotrimoxazole prophylaxis to this subgroup (OR 1.19,95% 
CI 0.37 - 3.80), presumably because, despite increased uptake of vcr in the 
intervention arm, overall HN testing rates among those with tuberculosis 
remained low (16%). 
Among patients with obstructive lung disease, it improved the provision of 
inhaled corticosteroids (OR 1.93, 95% CI 1.25 - 2.99) as well as other essential 
medicines, including beta-agonists and theophylline. There was no impact on 
the provision (OR 1.16,95% CI 0.74 -1.82) or uptake (OR 1.09,95% CI 0.62 -1.90) 
of smoking cessation advice. Nurse practitioners' inattention to smoking may be 
due to relatively low levels of smoking, both in terms of prevalence (16.5% in the 
P AlSA group and 19.4% in the controls) and intensity (pack year history of 8.9 in 
the P AlSA group and 8.3 in the controls), among the patients enrolled in the 
trial. Increases in the rate of within-clinic referral (OR 2.21,95% CI 1.11- 4.38) 
and referral of those with severe respiratory disease were also noted (OR 2.59, 
95% CI 1.06 - 6.19). 
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Table 4.1 Cost of developing the P ALSA guideline and training intervention 
Year Activity Items and number included Cost 
2001 Guideline adaptation including 77 junior researcher days 87537 
workshop to review original WHO 9 senior researcher days 19162 
PAL guidelines and identify barriers 6 doctor and 6 nurse days 7602 
to care Venue and catering costs 1452 
Subtotal in 2001 ZAR 115753 
2002 Guideline adaptation including two 110 junior researcher days 127540 
workshops to obtain end user input 15 senior researcher days 33076 
on drafts 3 doctor and 9 nurse days 7467 
7 local flights 19609 
Graphic layout 18488 
Venue and catering costs 2714 
Training development including two 75 junior researcher days 84317 
pilot sessions with nurses 35 senior researcher days 42255 
8 nurse days 3021 
3 local flights 7297 
Illustrations & graphic layout 21407 
Venue and catering costs 925 
Liaison with World Health 4 junior researcher days 4329 
Organization 3 senior researcher days 6547 
6 WHO consultant days 19092 
2 international and 3 local flights, 6 39978 
days' accommodation 
Venue and catering costs 2473 
Subtotal in 2002 ZAR 442946 
2003 Finalisation of guideline 4 junior researcher days 5028 
1 senior researcher day 2536 
Graphic layout 11264 
Finalisation of training and support 38 junior researcher days 48885 
materials 8 senior researcher days 18880 
Graphic layout 4890 
Motivation for revised FSDOH 12 junior researcher days 15491 
nurse prescribing provisions 1 senior researcher day 2536 
1 local flight and 2 days' 3057 
accom modation 
Subtotal in 2003 ZAR 112570 
TOTAL (in 2003 ZAR) with 2001 and 2002 costs discounted at 3%* and adjusted 753362 
for inflation using CPIX averaget 
'* Russell et al. 1996 
t Statistics South Africa 
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costs (25%). Local road travel costs were also quite high, as district trainers 
travelled from remote areas of the province to central airports. 
Table 4.3 PALSA intervention costs: Training the Trainers workshop 
number included Subtotal in 2003 ZAR % total cost of training the 
trainers 
10 junior researcher days 12740 8 
10 senior researcher days 28881 18 
55 nurse days 31650 20 
11 local flights and 55 days' 
25 accommodation 39800 
Road travel (4567 km) 10599 7 
PALSA trainer material packs 14501 9 
Venue and Catering 17935 11 
Video hire 1700 1 
Total in 2003 ZAR 157805 100 
4.1.1.2 Educational Outreach Visits 
Educational outreach took place between April and October 2003. The number 
of outreach sessions per clinic ranged between two and six. Relocation of nurses 
through night duty, leave and attendance at other offsite training courses meant 
that it was unusual for the same nurses to attend all sessions at a clinic (Mayers 
2004). The median number of sessions received by an intervention clinic nurse 
practitioner was two, and in five intervention clinics it was one session or less. 
Sessions ranged in length from 1 to 4.5 hours; on average a session lasted 2 
hours. In total P AlSA training occupied 893 health staff hours, including time 
spent travelling to clinics in remote areas. This is equivalent to the time required 
to train eight nurse practitioners in IMCI (assuming the standard 11 day offsite 
course and two trainers per course). By comparison 148 nurses were exposed to 
P AlSA training during the study period. 
178 
Table 4.4 Cost of educational outreach visits to the 20 intervention clinics 
Clinic No. of staff No. of Median no. Km Cost of Cost of Cost of Cost of Total cost 
trained* outreach of sessions travelledt FSDOH PALSA travel refreshments per clinic 
sessions per nurse staff timet materials (2oo3ZAR) (2oo3ZAR) 
(2003ZAR) (2oo3ZAR) 
Albert Luthuli 3 3 0 1190 907 0 141 2099 
Bethlehem 5 3 3 601 2195 756 1034 360 3987 
Boithusong (Odendaalsrus) 7 2 3 177 1191 1059 381 106 2632 
Botshabelo B 13 3 1 89 3192 1966 117 95 5277 
Botshabelo U&S 7 3 1 30 1881 1059 40 30 2981 
K-Maile 5 3 2 317 1408 756 682 124 2848 
MDohadi 5 3 3 663 2790 756 1140 219 4688 
Namahali 11 2 2 50 2103 1663 66 0 3834 
PAX 7 3 0 322 1674 1059 692 0 3427 
Bophelong (Petrusburg) 12 2 2 889 4788 1815 1911 0 8516 
Phahameng 5 5 3 732 1715 756 1815 150 4289 
Phomolong 4 2 2 240 1426 605 516 0 2548 
Riverside 6 5 2.5 1117 2438 907 2770 150 6117 
Seeisoville 6 2 1 19 1599 907 41 35 2549 
Tebang 12 3 1 77 1926 1~ 1 0 3875 Thusanong (Kroonstad) 9 6 4 114 3252 13 ');1 4860 
Tseki 4 2 2 20 955 605 0 1588 
Tshepong 4 2 2 290 1190 605 0 2420 
Tumahole A 3 2 551 1933 1210 727 0 3872 
Welkom 12 3 3 271 4357 1815 583 273 6757 
Total cost of outreach visits 
(55%) I (28%) (17%) (2%) 79165 
in 2003 ZAR (% total) . . . . 
* In one clinic (Petrusburg), a doctor and 2 pharmaCIsts also attended training sessions. The cost of their time has been Included . 
t FSDOH: Free State Department of Health. Several trainers conducted non-PALSA activities at the time of outreach training. In these cases travel costs, 
including time spent travelling and km travelled, have been weighted by the proportion of total time at the clinic spent delivering PALSA training. 
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4.1.1.3 Allocation of PALS A intervention costs 
Intervention costs were allocated to patients' clinic visits as follows (Table 
4.5). The cost of the guideline and training package, but not of the training 
itself, was treated as a capital cost, and linear depreciation to zero over six 
years was assumed. So the cost of depreciation over the three months during 
which trial patients were followed up was 3/72 times the total capital cost. 
Training the trainer and educational outreach visit costs were summed for all 
20 intervention clinics. This was conservatively allocated (100% to the 
intervention clinics for the duration of the trial) on the assumption that the 
training would never be utilised outside of these 20 clinics, or beyond the time 
horizon of the trial. Total P ALSA intervention costs allocated to the 
intervention clinics during the trial thus included 100% of training the trainer 
costs, 100% of educational outreach visit costs and 3/72 or 4.15% of 
guideline/ intervention development costs. 
The number of total attendances at the 20 intervention clinics during one 
quarter (corresponding to the three month period between interviews) was 
obtained from FSOOH data routinely reported by the chief nurse in each 
clinic and centrally collated. 30% of these patients were assumed to have 
cough and/ or difficult breathing. This estimate was based on previous work 
completed in a Cape Town primary care clinic (Fairall et al. 2001). This is 
substantially lower than the 61 % noted during the work study completed 
during the trial (Table 4.9). The higher estimate was explored in the 
sensitivity analysis and is reported in Section 4.4. The work study estimate 
was not used for the primary analysis because it was not based on a random 
sample of consultations, even though it was based on a random sample of 
clinics and days in intervention and control clinics. Also, as reported below, it 
found no significant difference in the duration of consultations between 
intervention and control clinics. Total PALSA costs for the trial were allocated 
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Item 
Patients attending intervention clinics reported more visits to clinics, mainly 
due to a near doubling of the number of tuberculosis monitoring visits in this 
group (Table 4.6). Control group patients reported more, and longer, hospital 
admissions, accounting for the difference in the number of inpatient days 
between groups. While these differences in tuberculosis monitoring visits 
and inpatient days are largely responsible for the difference in health service 
costs (Table 4.10), neither reached statistical significance, because of the low 
numbers of patients involved. 
Table 4.6 Health service utilisation: visits and admissions 
No. in each rou IRR* 95%CI pvalue 
PALSA Control 
1385 1284 1.08 0.89 -1.31 0.466 
2340 1215 1.91 0.088 




37 0.80 0.55-1.15 0.240 
* Incidence rate ratio from Poisson regression 
Utilisation of respiratory drugs is reported in Table 4.7. It shows significant 
increases in the use of drugs for the treatment of obstructive lung disease 
(budesonide, inhaled salbutamol, fenoterol and theophylline). This is 
consistent with findings reported in Chapter 3. No difference in the use of 
antibiotics or symptomatic treatments was observed. Although the number of 
patients diagnosed with tuberculosis during the study period was higher in 
the intervention group, there was little difference in the use of tuberculosis 
medication, as the total number of patients who reported receiving 
tuberculosis treatment at follow-up (new and old cases) was similar between 
groups. 
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Table 4.8 Health service utilisation: number of investigations 
Item No. in each group IRR* 95%CI pvalue 
PALSA Control 
Sputum tests for AFBs 676 506 1.34 0.91 -1.98 0.143 
Chest x-rays 84 51 1.67 1.08- 2.57 0.020 
HIV rapid test kits 92 72 1.28 0.82 -1.99 0.275 
* Incidence rate ratio from Poisson regression 
Health service costs are summarised in Table 4.10. The work study (Table 4.9) 
timed 715 consultations in 19 trial clinics (10 intervention and 9 controls) and 
found no difference in the consultation duration for patients fulfilling trial 
eligibility criteria and those who didn't between groups (see Chapter 2 
Section 2.2.6.1 for discussion of trial eligibility criteria). Consequently the 
same clinic visit unit cost was applied to both groups. 
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Table 4.10 Health service costs: mean per patient in 2003 ZAR for the 3 month period between enrolment and follow-up 
Item PALSA Control 
Mean Median IQR· % Totalt Mean Median IQR· % Totalt 
Visits, admissions 
Clinic 104.75 70.34 70.34 -140.68 32.0 97.53 70.34 o-~ TB monitoring visits 92.04 0 0-0 28.1 48.00 0 o 18.0 
Clinic visits (non-trial) 1.82 0 0-0 0.6 2.43 0 0- 0.9 
Outpatient visits 3.07 0 0-0 0.9 2.48 0 0-0 0.9 
Inpatient days 27.04 0 0-0 8.2 44.04 0 0-0 16.5 
Ambulance trips 19.69 0 6.0 25.86 0 0-0 9.7 
Medication 39.61 7.0 12.1 29.35 5.86 0-24.30 11.0 
Beta-agonists 7.63 0 0-0 (2.3) 4.82 0 0-0 (1.8) 
Inhaled corticosteroids 5.12 0 0-0 (1.6) 2.60 0 0-0 (1.0) 
Antibiotics (excluding TB drugs) 3.48 0 0-5.86 (1.1 ) 3.22 0 0-5.86 (1.2) 
TBdrugs 14.68 0 0-0 (4.5) 13.12 0 0 0 (4.9\ 
Other drugs 8.70 0.62 0-3.32 (4.0) 5.58 0.62 0-2.19 (2.9 
Investigations 22.77 0 0-24.93 7.0 16.70 0 0-0 
Sputum tests for AFBs 18.12 0 0-0 (5.5) 13.62 0 0-0 (5.1) 
Chest x-rays 3.25 0 0-0 (1.0) 1.98 0 0-0 (0.7) 
HIV rapid test kits 1.39 0 0-0 (0.4) 1.10 0 0-0 (1.1) 
PALSA 16.20 5.79 5.79-11.58 ~ 
N/A N/A N/A 0 
Total health service costs 326.98 160.74 78.27 - 282.07 266.39 144.02 70.34 - 241.18 100.00 
• IQR: interquartile range 
t % costs in parenthesis shown to demonstrate breakdown of drug and investigation costs. Total not equal to 100 because of rounding errors. 
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The mean cost of care for a patient attending a PAISA clinic was R6O.59 more 
expensive than in the controls (R326.98 vs.R266.39). These costs reflect all health 
service costs, at primary, secondary and tertiary levels, for the three month 
period between interviews. Primary care clinic visits account for the bulk of the 
costs (60.7% in the PAISA group vs. 55.5% in the controls). Overall costs were 
consistently higher in the PAISA group, with the exception of costs of inpatient 
care and ambulance transport which were higher in controls. Differences in cost 
between groups tended to be small «1 %) except for the relatively large 
differences (5-10%) observed for tuberculosis monitoring visits, inpatient days 
and ambulance trips. Different unit costs for these items, and for clinic visits, 
were explored in the sensitivity analysis; results are reported in Section 4.4. The 
most important of these was the cost of tuberculosis treatment (tuberculosis 
monitoring visits + tuberculosis drugs) which accounted for 75% of the 
difference in health service costs between groups. In contrast with health care 
utilisation, PAISA intervention costs accounted for a relatively small proportion 
of total health service costs in the intervention group (5%). 
4.2 Household costs 
Household costs include out-of-pocket expenses associated with travel to the 
clinic and other health care providers, as well as any fees paid to these health 
care providers. In South Africa health care services have been provided free to 
pregnant women and children since 1994, and primary care service free to all 
citizens since 1996. 
Most patients usually walk to the clinic; not surprising given that most South 
Africans live within a 5km radius of their local clinic (South African Human 
Rights Commission 2003). The next most popular form of transport is the 
minibus taxi, followed by private vehicles. Interestingly, no-one in the Free State 
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significantly more visits to private sector doctors reported among the PAISA 
group (OR 1.29, 95% 01.02 -1.61), but use of other private providers was 
similar between groups. 
Table 4.13 Visits to private health care providers 
Item No. In each group IRR* 95% CI pvalue 
PALSA Control 
Private doctors 238 183 1.29 1.02-1.61 0.028 
Pharmacy 49 56 0.87 0.48 -1.55 0.632 
Traditional healer 10 8 1.23 0.40 - 3.81 0.714 
Work clinic 1 0 - - -
* Incidence rate ratio from Poisson regression 
Table 4.14 Average fees (in 2003 ZAR) paid to private health care providers 
Mode Average fee (including medication)* 
PALSA Control 
Private doctor 82.80 84.31 
Pharmacy 30.67 29.06 
Traditional healer I herbalist 102.00 65.29 
* Average fee calculated only on respondents reporting a visit to a private health care provider. 
Household costs are summarised in Table 4.15. All costs (taxi fare, private 
provider fees etc.) were derived directly from patient interviews, with the 
exception of the travel cost related to private vehicles. Door-to-door travel time 
was used to estimate distance travelled, and 2003 Automobile Association rates 
for a standard sedan vehicle were used to value these journeys (Automobile 
Association n.d.). Travel costs associated with clinic attendances were estimated 
by multiplying the cost of travel (taxi fare, car costs) by the number of 
attendances (including tuberculosis monitoring visits) during the period between 
interviews, assuming that the same mode of transport was used on each 
occasion. Travel costs associated with other health care providers include the 
cost of attending public (e.g. hospital) and private providers and were collected 
separately for each visit. 
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respiratory symptoms. In the case of employed patients, caregivers or 
companions, patients were asked. to estimate the number of days of work lost as 
a result of illness or seeking care; in the case of scholars the numbers of days of 
school missed; and in the case of the unemployed, the number of days 
potentially spent looking for work that were lost. Numbers of productive days 
lost are summarised in Table 4.16. 
Table 4.16 Changes in productivity among index patients, caregivers and 
companions 
Item No. in each group IRR* 95%CI pvalue 
PALSA Control 
Index patients 
Employed days lost 442 372 1.19 0.58-2.4 0.631 
Unemployed days lost 816 418 1.96 0.83-4.63 0.125 
School days lost 26 77 0.34 0.12-0.97 0.043 
Caregivers 
Employed days lost 124 85 1.47 0.79-2.76 0.225 I 
Unemployed days lost 263 171 1.63 0.69-3.88 0.265 
School days lost 68 175 0.39 0.19-1.26 0.114 
Companion (trial clinics) 
• Employed days lost 206 7 29.15 8.01-106.13 <0.001 
Unemployed days lost 372 247 1.50 0.64-3.51 0.350 
School days lost 25 10 2.46 0.83-7.28 0.105 
Companion (other health care, ,",vlders) 
Employed days lost 18 21 0.85 0.34-2.09 0.717 
Unemployed days lost 18 5 3.61 0.53-24.2 0.186 
School days lost 10 13 0.76 0.17-3.41 0.72 
* Incidence rate ratio from Poisson regression 
In total 3987 productive days were lost to illness during the three month period 
(1624 employed days, 1961 unemployed days and 404 school days). The 
distribution is highly skewed and 21 patients account for 19% of employed days 
lost (all in the PAISA group), 51 % of unemployed days lost (31 % in the PAISA 
group, and 20% in the controls) and 19% of school days lost (all in the control 
group). This explains why the median, 25th and 75th percentiles for all societal 
cost items equal zero (Table 4.17). 
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Table 4.17 Costs arising due to changes in productivity: meanlt per patient in 
2003 ZAR for 3 month period between enrolment and follow-up 
Item PALSA Control 
Mean % Total % Total 
Among index patients 46.32 61.8 32.2 68.7 
Among companions (trial clinics) 15.91 21.2 6.14 13.1 
Among companions (other HCPs) 1.13 1.5 1.48 2.4 
Among caregivers 11.71 15.6 7.02 15.0 
Total 75.01 100 46.84 99.2 
*Medlans and Interquartile ranges are not given, as all these values equal zero. That is, all costs 
were incurred by less than 25% of patients. 
4.4 Sensitivity Analysis 
One-way sensitivity analysis was used to explore assumptions concerning the 
allocation of intervention costs to trial patients, different unit costs for health 
service expenses (e.g. inpatient days) and the inclusion of tuberculosis treatment 
costs. 
By far the most important factor affecting cost was the inclusion of tuberculosis 
treatment costs. Tuberculosis treatment costs were defined as the cost of 
tuberculosis medication and monitoring visits. In intervention clinics, not only 
were more cases of tuberculosis managed during the study period, but there was 
also increased compliance with five-times-a-week clinic-based directly observed 
treatment, resulting in a big difference in the number of monitoring visits (2340 
visits among tuberculosis patients attending P ALSA clinics vs. 1215 visits among 
tuberculosis patients attending controls, IRR 1.91,95% a 0.91- 4.03, P = 0.088). 
This proved the most important driver of cost differences between arms, 
accounting for 75, 71 and 60% of the differences in health service, societal and 
societal- including lost productivity costs - respectively (Table 4.18). 
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Table 4.18 Summary of mean cost per patient in 2003 ZAR for 3 month period between enrolment and follow-up: disaggregated 
by perspective, and cost of tuberculosis treatment 
Perspective PALSA Control Difference Intra-
Mean Median Interquartlle Mean Median Interquartlle In 95%CI* cluster 
















(excluding TB treatment costs) 261.27 190.04 235.52 152.68 25.75 -12.56,65.06 0.009 
312.50 253.42 
Societal with lost productivity 
114.27 - 76.82-
costs 460.76 228.92 345.13 190.00 115.63 40.01,201.76 0.012 
(including TB treatment costs) 
392.66 326.34 
Societal with lost productivity 
112.00 - 76.34-
costs 325.57 224.86 279.44 170.68 46.13 3.74,95.00 0.009 
(excluding TB treatment costs) 
369.39 301.36 
* From cluster bootstrapping 
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Results for allocation of intervention costs to trial patients are presented in Table 
4.19. In the base analysis the following applied (Table 4.5): 
• Capital costs associated with the development of the guideline and training 
materials were discounted at 3% and linear depreciation to zero over six years 
was assumed. 
• 100% of training costs were allocated to intervention clinics, assuming the 
training was never used outside of these clinics or beyond the time horizon of 
the trial. 
• Intervention costs were equally allocated among intervention clinics and 
allocated to patient visits, on the assumption that 30% of adult attendances 
have respiratory symptoms, and stood to benefit from the intervention. 
In general, sensitivity analysis revealed that the evaluation was robust to variations 
in these assumptions, presumably because intervention costs accounted for only 5% 
of health service costs for patients attending intervention clinics (Table 4.10). 
Changes in assumptions concerning the allocation of the cost of guideline and 
training material development (choice of discount rate, depreciation of asset over 
time) had almost no effect on costs, because these costs constituted a small fraction of 
the intervention cost per visit, in comparison to training costs. 
Assumptions regarding allocation of these training costs were also explored. In the 
base analysis, 100% of these costs were allocated to trial patients assuming that this 
training did not benefit patients beyond the time horizon of the trial. In the 
sensitivity analysis depreciation of training over longer periods (up to 8 months) was 
explored. The proportion of patients with respiratory symptoms, to whom the cost 
of the intervention was allocated, was also varied, from 20% to 60%. Despite large 
effects on the cost of the intervention per visit (halved, and doubled) the effect on 
health service and societal co~ was minimal, again reflecting the relatively low 
contribution of intervention costs to overall cost per patient. 
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unit cost is doubled. The results were also sensitive to the cost of inpatient days, 
clinic visits and ambulance trips, more so when tuberculosis treatment costs were 
excluded (Table 4.21). Modest changes were noted with differences in the cost of 
sputum tests, and small changes with asthma drugs (theophylline, budesonide, beta-
agonists). 
Table 4.20 Sensitivity Analysis: effect of unit costs on difference in health service 
costs when tuberculosis treatment costs are included 
Item % change in difference in health service costs between intervention 
and control 
Change in unit cost -0.5 -0.25 0.1 +().1 +().25 +().5 +1.0 
TB monitoring visits -38 -19 -8 +8 +19 +38 +75 
I npatient days +14 +7 +3 -3 -7 -14 -22 
Clinic visits -6 -3 -1 1 3 6 12 
Ambulance trips -4 -2 -1 +1 +2 +4 +8 
Sputum tests for AFBs -4 -2 -1 +1 +2 +4 +8 
Theophylline -2 -1 0 0 +1 +2 +5 
Budesonide -1.8 -0.9 -0.4 +0.4 +0.9 +1.8 +3.5 
Salbutamol -1.6 -0.8 -0.3 +0.3 +0.8 +1.6 +3.2 
TB drugs -1 -1 0 0 +1 +1 +3 
Chest x-rays -1 -1 0 0 +1 +1 +2 
Clinic visits (non-trial) +1 0 0 0 0 -1 -1 
Salmeterol -1 0 0 0 0 +1 +1 
Fenoterol -0.2 -0.1 0 0 +0.1 +0.2 +0.3 
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than usual care; in large part it is due to the cost of tuberculosis treatment which 
accounts for 75, 71 and 60% of the differences in health service, societal and societal 
costs including lost productivity costs respectively. This does not necessary 
represent an unfavourable outcome as the costs associated with treating tuberculosis 
can be considered an appropriate and necessary use of resources. 
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• society (using health service and patient household costs) and 
• society including lost productivity costs (using health service, patient 
household and lost productivity costs). 
For patients with tuberculosis, a large proportion of their health service costs were 
due to treatment after diagnosis. As one of the primary outcomes was diagnosis of 
tuberculosis - which would have been before the costs were incurred - all analyses 
were repeated either including or excluding tuberculosis treatment costs. 
Thus ICERS were estimated separately for each perspective with and without 
tuberculosis treatment costs yielding 12 scenarios (two outcomes, three perspectives 
each includingj excluding tuberculosis treatment costs). The two primary analyses 
of interest were those using health service costs (excluding tuberculosis treatment) 
and appropriate care or tuberculosis diagnosis as outcomes. 
The cost-effectiveness analysis was undertaken using multiple methods as described 
in Chapter 2 Section 2.4.6. The appropriate methods of analysis for cluster 
randomised data are the cluster bootstrapping, and linear regression adjusted for 
stratification and clustering. The other analyses were conducted for methodological 
purposes, to assess the extent of cluster sampling design effects - that is, the potential 
bias that could result if the cluster randomised design were ignored. 
5.2 Cost-effectiveness planes 
Cost-effectiveness planes were generated from 2D cluster bootstrap of differences in 
costs and effects using Stata (1000 resamples), and 2D individual bootstrap of 
differences in costs and effects using Excel (1000 and 10000 resamples). Planes for 
these methods, using 1000 resamples, are shown in Figures 5.1 through 5.12. 
For appropriate care, the outcome difference was always greater than zero; the cost 
difference was also usually positive, but sometimes less than zero. Thus it appears 
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Figure 5.1 Cost-effectiveness p l an(!~: approl'ri.lte ure (health sen'ice perspective 
excluding tuberculosis treatment costs) 





• • • . .' • 
• 
~~ JI~I -----.--r.--.--.~.--~·-·------,_------_r , OS 1 15 
OuIcome dJllerenat (AIl""",riate ea r.) 
, 






• • , • 
•• •• , .. ." • 
• • . ' . • • 
• • 
Fihure 5.3 Co~t·eHe.: t h·('n('~~ rl.Hu:~: .lprropTidte ('are (socie tal co~t~ .'>.elud ing 
til berel.! 1 o~i~ tU'3tment eosl ~I 
rrcom \1,'0 dlOlCn~ion.l[ duster b..xotstT.1P I..'{ cas t~ and effects (Stat.l) 
• •• 
• • • 
• • 
• • • • • 
!'rmll two d imcnsiona 1 ind i,-jUU,11 boolsl Til p of Cl."><; t!o il nu effects (E~ce I) 
--• 
'06 
Figure 5.5 Cost-t'ffectivenes5 p lanes: appropriate carl' (societal c05t,- indud ing 
lost producth·lty costs · excluding tuberculosis treatment costs) 
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Figure 5.7 Cost-effectiveness planes: newly diagnosed TB (health sen -ice 
perspectiv(' excluding tuberculosis treatmen t costs) 
From two dimensional duster bootstrap of costs and effec~ (Sbta) 
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From two dimensional individual bootstrap of costs and dfects (Excel) 
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Figure 5.~ Cost-effectiveness planes: newly diagnosed TB (sode!,11 costs ('Xcluding 
luberculo~i' treatment costs) 
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Figure 5.11 Cost-effectiveness planes: newly d iJgJlOsed TB (societal - includ ing 
los t productivity costs - costs eXcluding tu berculosis tre .. tment costs) 
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5.3 Net Monetary Benefits 
Diffl'Tences in costs and effects were red uced to a single variable by calculating net 
monetary bl!nefits for each subject, at willingness to pay levels (rom l..ero to R2000 in 
RIOO increments, using the formu],l described in Chapter 2 Section 2.4.6 
5.3.1 Distr ibution of net monetery benefib 
Figure 5.13 shows the distribution of nel benefits at th ree willingness to pay levels (0, 
1000, 2(00) for appropriate care and newly diagnosed tuberculosis from a health 
services perspective (excluding tuberculosis treatment COSL~). The distribution of nel 
benefits ... , most wiUingncss to pay levels was roughly symmetrical for appropriate 
care, bu t Jess so for newly diagnosed tuberculosis because fewer pa tients experienced 
this outcome. Distribution also di ffe red a l different levels o f willingness to ~y. At 
willingncss to pay of zero, the d istribut ions wen> negatively skewed with net benefits 
equal to the nl'gative of patient costs. At higher levels of willingness to pny, the 
distributions tended to be bimodal depending on whether or not patients had 
experienced the outcome. The net benefits are nol Normally distributed, so it is 
possible that confidena- intervals and P va lues from the following regression 
nnalyscs thJ! use these variables as outcomes may be im·alid. However, the central 
limit theorem proves Ihilt, with IJrge s.lmples, they mny indeed be valid (Altman 
1999) Bootstrap methods do not assume Normal distributions o f outcomes, so it is 
thus of methodological inte rest whether confidence intervals and probilbihties from 
regrl"'SSion and bootstrap methods differ, as is shown towards Ihe end of Ihis chapter 
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5.3.2 Incremental net benefits attributable to the intervention 
Incremental net benefits attributable to the intervention were estimated in three 
d ifferent ways: 
• Linear regression analysis of Il('\ OColl('fits using StaLl with the trial arm 
(intervention/ control) as the explanato ry variable 
• 20 individual bootstrapping using Excel (by calculating the mcan.~. and 2.5 
and 97.5 percentiles of incremental net benefits for corresponding bootstrap 
rcplicil tcs) 
• 10 duster bootstrappinB of net mon<:tary benefits using Stata 
All analyses were conducted separately at each willingness to p."ly Icye1.lncrcmental 
net benefits, with 95% confidcnce interYals, were plottcd against willingness to pay 
levels (Figures 5.14 lind Figu res 5.1 5). IncremC'ntal IlCt benefits prooictabl.y increased 
with incrC'asing willingness to pay lcvcJs. l bC'y wen:: hlghcr for appropriate can:: than 
for newly diagnosed tubcn:ulosis bc<:au.sc morc patients b.p<'riencoo this oulOOTn(' 
Confidence intervals were wider for those methods which adjustoo for d ustering 
(robust regression. d uster bootstrap) than for those which did not (regression 
without robust adjustment individual bootstrap) (Figurcs 5.16 and 5.17). 
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Figllre 5.16 Incremental net benefit at different levels of willingness to pay per 
unit of effect for appropriate care (health service costs without TB care): 95'\'o 













Figure 5.17 Incremental net benefit at different levels of willingness to pay per 
unit of effect for newly diagnosed tuberculosis (health service costs with.out TB 
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The c06t-effectiveness plots obtained. for these analyses show that the plots 
corresponding to negative confidence limits fell in the bottom right quadfilnt of the 
c06t-effectiveness plane and that no plots fell in the top left quadrant. This suggests 
that the negalwe confidence limits reflect the possibility that the intervention is 
dominant (more effective and rost-$;Ivlng) (Drummond et al. 2(05). For newly 
diagnosoed tubercul06is, analysis yielded negative confidence limit estimates for 
multiple scenarios. These could not Ix> in terprete.:1 becaust' the corresponding plots 
fell across all fou r quadrants of the cost-effectiveness plane (Figures 5.7 through 
5.12). 
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Table 5.1 incre nlentai cos t-effectiveness ratios per additional patient appropriately managed (mealUl and 95% confidence 
intervals) 
PefWOC\ive Mean leERS and 95% confidence Intervals 
S~sticoI Met>OO ~~~ Rog_ -. -~ Rye.-. --, -~, 
f'lov"",mo - ,- s, .... , .. m •• - ,.~ ",,"_'Ior du$t..nng '" '. ,. " ~ ~ Or>o Of"" <!ime~ ~ ~ ,- ~ ,- " . 
No. a~~ - ,- ,~ - ,~ ,-
~~- -155. -198, -305, -137. -176, -159. 
1 •• <:1 TIl Y"*" ...... 000,,1 '" '" '" '" '" '" '" m '" m '" '" "" _.-
-116. -59, -76, '" 117, 113. lim>, re "._""'''''''''1 "" "" 800 "" "" 823 "" "'" , "" 1576 1223 "" "''' 
Soc.ootol Dls,. . 72. -101, -2 18 . oW, ""', -92, 
1.'cI, ro ''''''''' .... """'") '" '" '" '" '" '03 '" m "'" ,m '" '" '" 
S<tieI .. Dls" ", 122, 143, 261 , 283, 270, 1100, T6 "urn",,' <=><1 '" m '" 881 '" "" '" '008 2191 2124 1659 "W "" 
s..;.; •• " ,I .-.;l, ""I ~1')' ", ", ,W, '5, 28, " =" "" "5 '" "" '" '" "" Ie";, T\l .. -., .... OOSISJ "'" "'" ""3 ,n '" "5 
~ In<! "'1 ~oW<o1I~1')' "'3, "", 261, "', W5, 479, <>0.1, 1162 '''' 1162 1162 1162 1176 1201 
(Icc!, TIl~" """"'I 
2403 '000 '303 2112 "'" 2055 
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5.5 Cost effectiveness acceptability curves 
Figures 5.18 and 5.19 show the probability that the int\!rvention is cost-effoctive 
for different ceiling "a!ues of willingness to pay (from zero to 2000, in 2003 South 
African rands). Cost-clfectiven<s5 acceptability curves from robust regression are 
shown for all 12 sccoarios. For appropria te care (Figure 5.18) the probability that 
the intervention was cost-effectin' exceeded 50% no matter what pt-'rspectiVI! \VIIS 
used, or whether the cost of tuberrulosis care was considered. For the primary 
analysis (health service perspective t.'Xduding the cost of tuberculosis care) a 50% 
probability that the intervention corrl'Spondcd to a willingness to pay value of 
Rl70 per additional case appropriat\!ly managed, and a 90% probability R400. 
For ~wly diagnosed tube.ll:ulosis (Figure 5.19) the estimated probability that the 
intervention was cost-eff~tive exceo.oded 50% for most scenarios except when 
tuberculosis treatment costs were included, and in the case of societal costs 
(including lost producth'ity costs), also when they were excluded. For the 
primary analysis (health service IX'l"Sp(!Ctive excluding the cost of tuberculosis 
care) a 50% probability that the intervention COlTespondt...:I to a willingnC5S to pay 
value of R680 per additional case appropriately mill"lilb'ed, and an 80% 
prooobility R2000 (90% prooobihty would exceo:d IUOOO) 
Figure 5. 18 Cost-cfC«liveness ac(Y pt.ilbility curves showing prob.ilbility that the inten'ention is cost eff« live for willingn~'lo 
pay ceiling value. per .ilddilion .... pallent appropriate ly managed (from robust regression) 
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Figure 5.20 shows cost-effectiveness acceptability curves for appropriate care 
from the health service perspective (excluding the cost of tuberculosis care) 
generated using multiple methods. 
The probability that the intervention was cost-effective was lower for methods 
adjusting for clustering (robust regression and cluster bootstrap) than for those 
which didn't (individual bootstrap and unadjusted regression) at willingness to 
pay values above the incremental cost-effectiveness ratio. This suggests that 
methods which ignore the impact of clustering lead to excessive confidence that 
an intervention is cost-effective. 
5.6 Summary 
The cost effectiveness analysis shows that the intervention cost the health service 
about R150 extra for each extra patient appropriately managed, if tuberculosis 
treatment costs were not considered. But analyses of uncertainty showed that 
this leER could be almost as high as R600 per patient, or even that the 
intervention could save almost R200 per patient appropriately managed. 
Similarly, the intervention was more likely than not to be cost effective if the 
health service was willing to pay more than about R150 per extra patient 
appropriately treated. This seems to be exceptionally good value for money. But 
when tuberculosis treatment, and societal costs were considered, lCERs were 
much higher. 
If tuberculosis diagnosis was the only outcome of interest, the extra health 
service cost per extra patient diagnosed was over R600, and could be almost 
RSOOO even if tuberculosis treatment costs were not considered. If all costs were 
considered the mean lCER for newly diagnosed tuberculosis cases was over 
RSOOO. 
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6.1.3 Translatio'n Guidelines of the EuroQol Group 
To date the EuroQoI has been translated into 107 languages including many 
outside of Europe. Translation is guided by rigorous protocols (EuroQol2003), 
and is co-ordinated by the EuroQoI group based in Rotterdam. Groups wishing 
to undertake a translation are required to register with the EuroQol group, 
demonstrate that they have access to adequate resources and skills to perform 
the translation and sign an agreement. The EuroQol group then assigns a 
researcher experienced in translation and cross-cultural adaptation of health-
related quality of life instruments to review reports of the translation process at 
every stage. The proposed Sesotho translation was registered with the Group in 
August 2002 and assigned a health economist as the EuroQol advisor. 
The translation guidelines conform to internationally accepted protocols 
including forward and back-translation, comparison of back-translation with the 
source instrument and review by a committee of translators and, finally, testing 
on a lay panel (Guillemin et al. 1993). In addition the EuroQoI group requires 
that the forward and back translations each be carried out by two independent 
translators, that translators be qualified and/ or experienced and that the forward 
translators be native speakers of the target language but fluent in English, and 
vice-versa for the back translators. An experienced EuroQoI researcher who has 
undertaken the Shona and Xhosa translations advised that at least one of the 
back translators be a native Sesotho speaker (J Jelsma - personal 
communication). This was because she believed the cultural insights provided 
by a native speaker necessary to translate the instrument across widely diverse 
cultures. The EuroQoI translation guidelines also specified the composition of 
the lay panel in that it must comprise at least 12 healthy speakers of the target 
language, and represent an even spread based on age, sex and educational 
characteristics. 
233 
6.1.4 A framework for understanding equivalence 
of HRQOL instruments across cultures 
During the 1990s increased interest in patient-based outcomes (Fitzpatrick et al. 
1998) alongside the proliferation of multi-national drug trials fuelled the 
translation and adaptation of HRQOL instruments across languages and 
cultures, rather than the development of new instruments in different cultures 
(Herdman et al. 1997). Much of this activity was limited to translation itself, and 
was accompanied by the publication of guidelines to standardise and improve 
the quality of translations (Gulleiman et al1993). There was some debate as to 
what constituted equivalence, and whether rigorous translation processes alone 
were sufficient to guarantee this. 
Herdman and colleagues (1998) reviewed equivalence constructs, their 
application in reporting of HRQOL translations and adaptations and proposed a 
model for assessing equivalence using a universalist approach adopted from 
cross-cultural psychology. This model requires that six types of equivalence be 
assessed during the process of cross-cultural adaptation and is summarised in 
Table 6.1. This model was used to appraise the cross-cultural adaptation of the 
EuroQol into Sesotho. The translation itself is summarised in Table 6.2. Further 
reporting of the cross-cultural adaptation process in this chapter is presented 
within the equivalence framework outlined by Herdman. 
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Table 6.2a The Sesotho EuroQol: results of the back and forward translations, and testing on the lay panel 
Domain and FORWARD TRANSLATION BACK TRANSLATION POST LAY POST 
Level 15 Translator 2'lU Translator Post consensus 1 S Translator 2
nu Translator Post consensus PANEL APPROVAL 
& feedback & feedback 
MOBILITY 
Level 1 Ha ke na Ha ke na Ie Ha ke na I do not have I have no Ha ke na Ha ke na Unchanged 
bothata ba ho bothata ba ho bothata ba ho any problems difficulty in bothata ba ho bothata ba ho 
tsamaya tsamaya tsamaya with walking walking tsamaya tsamaya 
Level 2 Ha ke kgone ho Ke na Ie Ke na Ie I have some I have some Ke na Ie Ha ke na Ie Ke na Ie 
tsamaya bothata bo bothata bo problems with difficulty in bothata bo bothata bo bothata bo 
itseng ba ho itseng ba ho walking walking itseng ba ho itseng ba ho itseng ba ho 
tsamava tsamava tsamava tsamava tsamava 
Level 3 Ke hlola ke Ha ke tsamaye Ke ba betheng I can stay in I am confined Ke ba beth eng Ke hlola Unchanged 
robetse ke dutse ka taelo bed on to bed ka taelo betheng 
moalong betheng. command 
(bethenQ) 
SELF-CARE 
Level 1 Ha ke na Ha ke na Ha ke na I do not have I have no Ha ke na Ha ke na Unchanged 
bothata ka ho bothata Ie ho bothata Ie ho problems with difficulty in bothata ba ho bothata ba ho 
itlhokomela itlhokomela itlhokomela self-care caring for itlhokomela itlhokomela 
mvself 
Level 2 Ke na Ie Ke na Ie Ke na Ie I have I have some Ke na Ie Ha ke na Ie Ke na Ie 
bothata ka ho bothata ba ho bothata bo some/certain difficulty In bothata bo bothata bo bothata bo 
itlhatswa kapa ithatswa Ie ho itseng ka ho problems with washing or itseng ka ho itseng ka ho itseng ka ho 
ho ikapesa itentshali kapesa itlhatswa kapa washing or dressing itlhatswa kapa itlhatswa kapa itlhatswa kapa 
ho dressing ho ho ho 
itentshalikapesa myself itentshalikapesa itentshalikapesa itentshalikapesa 
Level 3 Ha ke kgone ho Ha ke kgone ho Ha ke kgone ho I am unable to I am unable to Ha ke kgone ho Ha ke kgone ho Unchanged 
hlapa kapa itlhatswa kapa itlhatswa kapa wash or dress wash or dress itlhatswa kapa itlhatswa kapa 
hona ho ho itentsha ho myself myself ho ho 
ikapesa itentshalikapesa itentshalikapesa itentshalikapesa 
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Table 6.2c The Sesotho EuroQol: results of the back and forward translations, and testing on the lay panel 
pomalnano ~ A ION ts, \{;I\ I ill... 'N ~~~~LLAY ~~~OVAL Level " I ranslator Z I ranslator post T I ranslator Z or post 
consensus & consensus & 
feedback feedback 
1);2bMFORT 
Level 1 !"Ia ke OpalWS !"Ia ke opelWe !"Ia ke opelwe I hayen~aln I am nQt In pain tia ke opalwe tia ke opelWS Unchanged 
ka~honaho ka~hose kapa ho se ordlsco t nor feel unwell ka~ hose kapa ho se 
suafallwa. ikutlwe ikutlwe ikutlwe ikutlwe 
monate. monate. monate. monate. 
Level 2 !"la, ke Op'siwe ~eope~ !"Ia. ke Op'siwe I 00 not I)ave I am not.ln !"Ia ke op'elwe !"Ia ke op'elwe uncnangea 
hakaalo kapa hanyane kapa hakaalo kapa much pain or ~reat pain nor hakaalo kapa hakaalo kapa 
ho sulafallwa ho se ikutlwe ho sa ikutlWe discomfit eel particularly ho sa ikutlwe ho sa ikutlwe 
hakaalo. monate. monate unwell monate. monate. 
hakaalo. 
LeVel ::s ~eopeJ:N8 ~eo~e~we ~e~~~ I n~ve severe lamlnalpt'?,' ~e opel)Na tia ke 0f:lwe !\e,?~~ , hah6l0 kapa ho haho 0 kapa ha ham~kapaha pains and am Peain or I don't ham~ kapa ha ham~ paha ham~kapaha 
sulafallwa kee Ikutlwe keikutlwe very el well at all ke ikUUwe ke ikutlwe ke IkUUwe 
haholo. rnonate. monate ho uncomfortable monateho monate ho 
I Waon~~te ho hano. hano. hana. 
DEPRESSION 
Level 1 Hake tia ~e na !'i~ kea I am,n'?t I am.n,?t Hakea Hakea uncnangea 
tshwenyeha kgatello ya tshwenyeha womedor womedor tshwenyeha tshwen~eha 
kapa hona ho maikutlo. kapa hona ho stressed down or kapa hona ho kapa h na ho 
wa malkutlo. rmaikutiO depressed wa maikutlo. wa maikutlo. 
;H~b~kena 
r Ikutlo. 
Levell ~e ~e na,le "e I am. a !ntle I am :flnuy ~~ !"I~ kea uncnangea. tshwenyehile kgatello ya tshwenyehile womedor worri oram tshwenyehile tshwenyeha 
hanyenyane maikutlo e hanyenyane stressed p'articu::J hakaalo kapa hakaalo kapa 
feela kap'a ke tshesane. kapa hoba Ie (Ie pre kewele kewele 
wele maikutlo kgatello ya maikutlo. maikutlo . 
hanyenyane maikutlo 
feela. hakaalo. 
Level::S ~e !\e op'eJ:N8 !\fJ I am very I am very ~e !'i!'ikea !\e 
tshwencn"e haholo~aha tshwen¥:thile worried and worried or tshwen{ehlle tshwen¥:tha tshwen¥:thile 
haholo pa ke kemalku oe ham~ ~ke very stressed severely hampa a~ke hampa pa ke hampa ~ke 
wele maikutlo mpe. na Ie kgatello distressed wele maikutlo wele maikutlo wele maikuUo 




6.2. 1 Conceptual equivalence 
Both the forward and back-translators expressed concern that the constructs of 
anxiety and depression, as understood by Westerners, did not sit comfortably within 
the Sotho construction of HRQoL. The younger of the translators pointed out that 
while many younger generations of Sotho have adopted the Western terms in their 
everyday language, they often use them within an idiom which may sound 
confusing to a Westerner e.g. "I have an anxiety in my teeth". Although, unlike with 
the Shona and Xhosa translations Oelsma et al. 2000, Mkoka et al. 2003), there was 
less concern that these constructs are not regarded as central to the Sotho construct of 
HRQoL because their origins are perceived to be spiritual or contextual, there was 
some discomfit at them being listed alongside the more physical and tangible 
manifestations of HRQoL. Depression and anxiety are understood within Sotho 
culture, but only in a normative sense relative to stressful life events like 
bereavement. Despite these reservations, the lay panel reported no difficulty in 
understanding the translation or the concept that was being conveyed. 
The quantification of pain and discomfort also appeared to be foreign to the Sotho 
construct of HRQoL. In Sotho, one is either unwell or not, and the extent of the illness 
or pain is rarely described. This difficulty in quantification was also noted by the 
translators of the Shona version, but with regards to the mobility domain Oelsma et 
al. 2000). Because the concept was not well understood, we encountered difficulty in 
selecting an appropriate word to convey" moderate". Two equivalents were 
considered including "hanyane", meaning" slight" or "a little", and 
"hakaalo"meaning "that much"or lito that extent". We eventually settled on 
"hakaalo" as colloquially it better conveyed the construct of "moderate" although it 
required we adjust the adverb for depression "tshwenyehile"to obtain grammatical 
agreement. 
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The minimum school leaving age ("Did your education continue after the minimum 
school leaving age?") posed difficulties in that many adults left school well before 
this age during the apartheid years, when compulsory education until the age of 16 
was enforced only in "white" schools. Many still do, because of poor socio-economic 
circumstances. We therefore chose a more open-ended translation of this question, 
which allowed adults, whether they left school before, at or after the age of 16, to 
answer whether they had continued their education in any way. 
6.2.3 Semantic equivalence 
Several phrases required careful consideration before we were satisfied that semantic 
equivalence had been achieved. The first of these related to the translation of 
"walking about" (mobility domain, levels 1 and 2). When reviewing the back 
translations, we noted that the word "about" had been omitted. We decided against 
including it, as the Sotho equivalent implied idle purposeless walking, and not the 
spatial construct of the English original. Interestingly, a similar decision was taken 
by the group completing the Shona translation who noted that in a previous version, 
the Shona equivalent "kufamba-famba"literally meaning "to walk walk" had a 
connotation of hanging around street comers, which resulted in the questionnaire 
being viewed as relating to HN / AIDS Q"elsma et al. 2000). 
The phrase that proved most difficult to translate was 1/ confined to bed" (mobility 
domain, level 3) for several reasons. Firstly, it proved difficult to provide an 
equivalent that was able to capture all forms of ill health which confine people to 
bed, whether they are severe but self-limiting illnesses like influenza or terminal 
illnesses like AIDS. Versions considered during the translation process were also not 
always free of causality (e.g. confined to bed literally because I cannot walk) or 
external factors (e.g. instructions for bed-rest from a health worker or family 
member). Ultimately two versions were put to the lay panel for consensus: "Ka ba 
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6.2.4 Operational equivalence 
The EuroQol is intended for use as primarily a self-completed questionnaire 
although it is frequently administered by interviewers. We intended to use it as one 
component of a relatively lengthy questionnaire, and because of this, and the 
relatively low levels of literacy among our target users (patients attending 
predominantly rural primary care clinics), we chose to implement it using trained 
interviewers. 
The lay panel testing provided an opportunity to implement the instrument using 
self-completed questionnaires. The mean time taken to complete the questionnaire 
during the lay panel was 17 minutes (range 11 - 19), slightly longer than the 10 - 15 
minutes reported during the Shona lay panel Oelsma and Chivaura 2(00). Our single 
respondent with less than eight years of schooling reported difficulty understanding 
the instructions for completing the visual analogue scale. Her difficulties related to 
the formatting of the numbers on the scale (legend for values 10 through 90, are 
separated by the line of the scale itself, such that the "7" of 1170" is positioned left of 
the scale, and the "0" of "70" to the right of it). Other participants reported that it felt 
odd to be instructed to draw a line from the box (labelled ""your own health state 
today") to the scale, and indicated that they felt it more intuitive to draw a line from 
the lower end of the scale to the point describing their health state. Given this 
feedback and the experience of others who have used the VAS among respondents 
with low literacy levels (Gudex et al.1996), we restricted analysis of the visual 
analogue results to patients with more than primary education during the trial (Table 
3.16). 
During the trial, we also implemented the five level EuroQoI in the hope that it 
would improve the instrument's responsiveness in a respiratory outpatient setting. 
This involves inserting two additional tick-boxes between levels 1 and 2, and 2 and 3 
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6.2.5.2 Construct validity of the Sesotho EuroQol among patients with 
respiratory illnesses 
Construct validity was assessed using ordinal logistic regression of the collapsed 
three level Sesotho EuroQol scores with York tariffs applied. Analysis was restricted 
to the 1678 patients who completed Sesotho interviewer-administered 
questionnaires. Index scores were first compared with respiratory symptoms and 
signs, and diagnostic subgroups as defined in Table 6.3. Results are presented in 
Table 6.4. 
Table 6.3 Description of diagnostic subgroups used in assessment of the Sesotho 
EuroQol's construct validity 
Diagnostic subgroup· Description 
Upper respiratory tract Cough for less than 2 weeks and no marker of severe 
infections illness (i.e. no difficult breathing, temperature ~38°C, 
respiratory rate ~30 breaths/min, use of accessory 
muscles or haemoptysls) 
Lower respiratory tract Cough anellor difficult breathing for less than 2 weeks and: 
Infections temperature ~38°C anell or haemoptysis anell or yellowl 
green sputum 
Suspected tu berculosis Cough andl or difficult breathing for 2 weeks or more and: 
(definition 1) temperature ~38°C anell or haemoptysis anellor self-
reported weight loss andl or night sweats 
Suspected tuberculosis Cough andl or difficult breathing for 2 weeks or more and: 
(definition 2) temperature ~38°C anell or haemoptysis 
Asthma Cough andl or difficult breathing of any duration and: 
responsive to beta-agonists and pack year history <10 
years 
COPO Cough andl or difficult breathing for 2 weeks or more and 
a pack year history ~ 10 years or past tuberculosis 
* Subgroups are not mutually exclusive and patients could fulfill criteria for more than one category. 
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also more likely to have lower index scores than those who didn't, with the exception 
of those with temperatures of 38°C or more, or respiratory rates of 30 or more, the 
latter applying only when the EuroQol was collapsed to three levels. Patients with 
symptoms and signs consistent with an upper respiratory tract infection (Table 6.3) 
were significantly more likely to have a higher index score than other trial patients 
with more severe disease, and those with suspected tuberculosis a lower index score. 
Interestingly, the EuroQol was unable to distinguish those with newly diagnosed, as 
opposed to suspected, tuberculosis. The Sesotho EuroQoI was also unable to 
distinguish those with asthma, but those with COPD reported significantly lower 
index scores. 
Convergent validity with the translated and modified Royal College of Physician's 
asthma control measure was also good, in that for every unit increase in the RCP 
score, the EuroQoI index score decreased (Table 6.5, note that the two instruments 
are reversely scored). This is presumably in part because of shared domain 
constructs (usual activities). 
Table 6.5 Association between deciles of the Sesotho EuroQol index score and 
modified Royal College of Physicians' (RCP) Asthma Measure 
Comparison Odds ratio (OR) of pvalue 
having a higher index 
score* 
95%CI 
Modified Rep Asthma Measure at enrolment 
0.87 0.83-0.92 <0.001 
Modified Rep Asthma Measure at follow-up 
0.75 0.72-0.77 <0.001 
.. From ordinal logistic regression; per unit change In Rep score 
Changes in Sesotho EuroQoI index scores and the modified RCP score at follow-up 
were Normally distributed and so compared using linear regression (Table 6.6). 
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6.2.6 Functional Equivalence 
In summary, the Sesotho EuroQoI perfonned well across all five areas of 
equivalence. Many issues were identified and addressed during the rigorous 
translation process required by the EuroQoI group. The most notable reservation 
concerned conceptual equivalence and whether the anxiety/depression domain 
fitted within the Sotho understanding of HRQoL. This was raised by our team of 
academic translators but refuted by the lay respondents. The presentation of more 
than one alternative at each stage in the translation process helped identify issues 
requiring careful consideration and discussion. So it seems that the EuroQol 
requisite that two forward translators and two back translators undertake the task of 
translation is justified. The selection of a native English speaker as project manager 
(the candidate) resulted in an erroneous adjustment after testing on the lay panel. 
This could have been avoided if she had a working knowledge of Sesotho, and 
should be considered when undertaking additional translations. Nonetheless, once 
corrected, the translated version displayed good construct validity within the context 
of the trial and a respiratory outpatient setting, as well as convergent validity with a 
disease-specific measure for respiratory disease, the modified Royal College of 
Physician's asthma control measure. 
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of the intervention could be as high as R600 per patient appropriately managed, or 
even save R200 for every additional patient appropriately treated. 
The results of this pragmatic trial are widely generalisable to other resource-limited 
settings where non-physicians provide primary care. It was delivered by existing 
staff, and was effective in spite of the low number of educational contacts. It 
suggests that equipping middle managers as outreach trainers is feasible within 
existing staff constraints and could improve quality of care, providing an alternative 
to traditional offsite centralised training courses. 
This chapter provides an overview of results, considers the methodological strengths 
and weaknesses of the study, compares findings with those evaluating the 
effectiveness and efficiency of similar syndromic and educational outreach 
interventions, and discusses implications for policy and research methods. 
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patient-reported responsiveness to inhaled beta-agonists among inhaled 
corticosteroid recipients in the intervention group implies that the treated disease 
was indeed asthma. Taken together these observations suggest that the increased 
provision of inhaled corticosteroids in the intervention group was not solely due to 
expanded prescribing powers, but rather due to the appropriate detection and 
management of obstructive lung disease. Nonetheless, the effect of increasing 
prescribing provisions cannot be distinguished from the educational elements of the 
intervention. Expanded prescribing powers and access to a wider range of 
medications have typically been incorporated as elements of syndromic packages in 
South Africa (Harrison et al. 2000) and elsewhere (Grosskurth et al. 1995, WHO 
199&, Kamali et al. 2(03). 
Given the increase in appropriate inhaled corticosteroid prescription, it was 
disappointing that antibiotic prescription rates, whether combined or for individual 
drugs, did not differ between arms (40.5% vs. 39.9%, OR 1.19,95% a 0.74 to 1.41). 
However, the antibiotic prescription rate was substantially lower than that noted 
during the data collection pilot or in comparable surveys (WHO 2004b). 
Additionally, it may well reflect appropriate use given the severe case mix observed 
among enrolled patients. Only 4.8% of the sample reported symptoms consistent 
with an uncomplicated upper respiratory infection, that is, cough for less than 2 
weeks with no difficult breathing, haemoptysis, temperature or raised respiratory 
rate. All other patients reported symptoms consistent with more severe respiratory 
disease. High rates of past and/ or current tuberculosis (23.6% in the PAISA group 
and 23.3% in the controls), current haemoptysis (12% in both PAISA and the control 
group), presence of anyone of four pre-defined severity markers (25.7% in the 
PAISA group and 16.6% in the controls) and 3 month mortality (2.2% in the PAISA 
group and 2.6% in the controls) attest to this. This severe case mix may well have 
warranted antibiotics, and the intervention group nurse practitioners may have acted 
appropriately by not decreasing their use. 
254 
reported being current smokers (16.5% in the PAISA group and 19.4% in the 
controls), compared with 47% among the sample enrolled in the Cape Town primary 
care clinic used in the PAISA validation study (English et al. 2006). Smoking 
cessation may therefore have seemed less of a priority to Free State nurses facing 
high burdens of infectious diseases. 
In summary improvements in quality of care suggest that the intervention was 
effective at changing the practice of target nurse practitioners. It was therefore 
disappointing that these improvements did not lead to improved health outcomes -
respiratory symptoms, quality of life, patient satisfaction or mortality - during the 
study period. There are two plausible reasons for this: either there were no 
improvements in these health outcomes during the course of the trial, or 
improvements were not detected by the instruments used in the questionnaire. The 
follow-up period was short at only 3 months, and improvements in quality of life 
and respiratory symptoms may still not have manifested for patients only recently 
commenced on tuberculosis treatment or inhaled corticosteroids for their asthma. 
Inadequate instrument validity and/ or responsiveness may also explain the lack of 
effect on health outcomes; at the trial's outset no respiratory-specific or generic 
health status measure had been translated and tested in Sesotho. The modified Royal 
College of Physician's Asthma Control Measure and the EuroQol-5D were translated 
into Sesotho specifically for purpose of the trial. Care was taken with both 
translations, which included a minimum of a forward and back translation, and in 
the case of the EuroQol, a rigorous translation protocol was followed in accordance 
with the EuroQol group's translation requirements (EuroQol Group 2003). But 
neither translated version underwent testing before being used in the trial. The 
Sesotho EuroQol was evaluated after the trial and found to compare well with the 
original across 6 types of equivalence, including construct validity for patients with 
respiratory disease (see Chapter 6). This, however, does not necessarily mean that the 
instrument was responsive enough to the small, yet clinically meaningful, changes in 
quality of life one might expect among patients commenced on tuberculosis treated 
or inhaled corticosteroids. Limited responsiveness to changes in quality of life, as 
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priority health outcome, tuberculosis case detection, but also to consistent 
improvements in process outcomes across a range of indicators and conditions. It is 
true that absolute improvements were modest, but because target conditions were 
multiple and affect a high proportion of primary care attendees, these findings are of 
considerable public health interest. Table 3.17 shows that one P ALSA trained nurse 
would need to treat only 11 respiratory patients for one person to benefit; this means 
that during the trial alone close on 30()()9 patients benefited from the intervention, 
assuming that around 30% of adults attended for respiratory symptoms. Should 
P ALSA be scaled- up to cover all primary care facilities in the Free State, this figure 
could be as high as 46 0001°. These are impressive gains given the limited exposure 
to the intervention. 
7.1.2 Health care utilisation and costs 
The cost analysis revealed substantial health service and household costs for patients 
attending both intervention and control clinics. P ALSA was consistently more 
expensive than usual care, although much of this cost difference was due to treating 
tuberculosis in primary care. 
The costing was based on an ingredients approach with resource use collected 
separately from unit costs (Drummond et al. 1989). Health care utilisation patterns 
were, in many instances, consistent with effectiveness outcomes. The single largest 
difference was in the number of tuberculosis treatment visits completed during the 
9 Assumptions: 172 636 adult attendances per quarter in trial clinics, 30% of adult attendances have 
respiratory symptoms, 2003 PHC utilisation rate in the Free State of 2.2, NNT for appropriate care is 
11. 
10 Assumptions: 3 700 000 adult attendances per year (B De Winnaar - personal communication), 30% 
of adult attendances have respiratory symptoms, 2003 PHC utilisation rate in the Free State of 2.2, 
NNT for appropriate care is 11. 
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complex because these reflect point in time estimates and are highly susceptible to 
changes in work load and staffing. For example, it appears that intervention clinics 
had sufficient capacity to increase the number of tuberculosis monitoring visits 
rapidly without employing additional staff. The impact of this on tuberculosis 
treatment outcomes is a priority for future research. On the one hand increased 
compliance with five-times-a-week clinic-based 0015 may be associated with 
improved outcomes. Alternatively, sudden steep rises in tuberculosis case detection 
may have overwhelmed treatment services undermining treatment outcomes. This 
concern was expressed by the National Tuberculosis Control Programme manager at 
the start of the trial. Furthermore, a previous randomised controlled trial found that, 
when compared with self-supervised treatment, clinic-based 0015 was not 
associated with better outcomes for new cases, and was actually associated with 
worse outcomes for retreatment cases (Zwarenstein et al. 1998). 
One-way sensitivity analysis confirmed the sizable contribution of tuberculosis 
monitoring visit costs to the difference in health service costs between groups, and 
showed that results were sensitive to unit costs used for tuberculosis visits. 
Subsequent cost-effectiveness analyses were therefore conducted with and without 
tuberculosis treatment costs. Also, tuberculosis treatment costs constitute 
appropriate expenditure, given the public health implications of undiagnosed active 
tuberculosis and the proven high cost-effectiveness of short course tuberculosis 
treatment (World Bank 1993), and so the decision to exclude them from further 
analysis is justified. Health service costs were also sensitive, although less so, to the 
unit costs used for inpatient days and ambulance trips because of their high unit 
costs. 
Compared with health service costs, household costs contributed relatively little to 
societal costs. Again, household costs were higher among patients attending 
intervention clinics mainly due to transport costs for a handful of tuberculosis 
patients attending the clinic frequently. After public sector primary care services, 
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treabnent costs accounted for 75% and 71 % of the difference in health service and 
societal costs respectively. 
7.1.3 Cost-effectiveness 
The primary incremental analysis of costs and effects (leERs) showed that PAISA 
cost the health service an extra R1S0n for each additional patient appropriately 
treated, and around R650 for each additional patient diagnosed with tuberculosis 
ignoring all other outcomes. These calculations excluded the cost of treating 
tuberculosis. Cost-effectiveness was lower when the societal perspective was 
considered, particularly if lost productivity costs were included. Analyses of 
uncertainty showed that the intervention could cost as much as R600 for every 
patient appropriately treated, or even be dominant, saving up to R200 for every 
patient appropriately treated. Confidence intervals for tuberculosis diagnosis alone 
were particularly wide, but could not be interpreted as corresponding plots fell 
across all four quadrants of the cost-effectiveness plane. The cost-effectiveness 
acceptability curves for appropriate care showed that the estimated probability that 
the intervention was cost-effective exceeded 50% no matter what perspective was 
considered or whether or not tuberculosis treabnent costs were included. A 50% 
probability that the intervention is cost-effective corresponded to a willingness to 
pay value of R170 and a 90% probability of R400 in the primary analysis. 
The cost per quality adjusted life year gained could not be calculated because no 
difference in utilities was observed during the trial. An alternative would have been 
to extrapolate the effects of improved quality of care for tuberculosis and obstructive 
lung diseases beyond the time horizon of the trial. This was not pursued as it would 
have required a complex chronic multi-disease model, and some rather heroic 
11 A1l costs quoted in 2003 South African rands. 
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to include a further 40 facilities without incurring additional intervention costs 
(Gilson et al. 1997). 
The syndromic nature of the intervention, and its effect on multiple target conditions, 
favourably influences the cost-effectiveness of the intervention. This is particularly 
true for respiratory diseases, because they affect a high proportion of patients 
attending health services. If implemented, large numbers of patients would stand to 
benefit from the intervention if one assumes that improvements in process outcomes 
will lead to improvements in health. 
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Sample sizes estimated from the pilot, were realised during the trial. All 40 clinics 
completed the trial. The recruitment target of 50 patients per clinic was met in all but 
four clinics which fell just short of it, and 92.8% of patients were re-interviewed after 
three months. This follow-up rate surpassed expectations as fieldworkers were, in 
some instances, working in particularly rural settings where respondents were 
unable to provide street addresses or were dependent on co-operative farmers for 
time off from work and transport to attend the follow-up interview. This follow-up 
rate can be attributed to two factors. Firstly, the fieldwork was overseen by the 
Centre for Health Services Research and Development who have extensive 
experience completing large fieldwork projects throughout South Africa, and in 
particular the Free State. Fieldworkers were recruited from a pool of experienced 
interviewers, and supervised closely throughout the trial. The decision to use five 
decentralised teams of local fieldworkers proved invaluable in contributing the local 
knowledge of community networks and systems required to track down patients 
who did not return for follow-up interviews. Fieldworkers also used their initiative 
to improve follow-up rates, in one instance eliciting the help of a local community 
radio station when patients were inadvertently given the incorrect date for their 
follow-up interviews. Secondly, respondents were provided with food parcels at 
follow-up interviews to thank them for their participation in the trial. The patients 
enrolled in the study were from very poor socioeconomic circumstances and over 
half were unemployed. The food parcel therefore represented a significant incentive 
to return for the follow-up interview and partly compensated them for their time. 
Almost no patients refused consent to participate in the study. This may in part be 
attributed to the offer of a food parcel within such a socioeconomically deprived 
context. Also, in South Africa patients attending primary care services are 
accustomed to spending the most part of the day at the facility, and so the burden of 
participating in an interview may have posed no additional inconvenience especially 
for the unemployed who were not rushing back to the workplace. 
The intracluster correlation co-efficients (ICC) noted for the primary outcomes (Table 
3.3) were substantially higher than what was adjusted for in the sample size 
calculations. This may have underestimated the study's power to detect differences 
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reported by patients attending clinics; consultations were not observed and all 
intervention group patients were included in the trial whether or not they had been 
exposed to a trained nurse practitioner, that is, we analysed by intention to treat. The 
improvements in quality of care are therefore likely to represent what would happen 
under usual circumstances, and not when a nurse practitioner is aware her or his 
performance is being evaluated. They also take into account variable exposure to the 
intervention, which was lower than expected, reportedly due to difficulties 
accommodating visits in clinic schedules and to absenteeism because of night shifts, 
usual and sick leave, and time off to attend offsite training courses (Mayers 2004). 
The short duration of follow-up was by far the most serious limitation of the study. 
Typically trials of this nature follow-up participants for between six months and a 
year. In this case, six month follow-up interviews had to be curtailed owing to 
limited funding available for the fieldwork exercise. It is therefore difficult to be sure 
that improvements in quality of care led to improved health outcomes, although this 
seems plausible given the proven effectiveness of inhaled corticosteroids for asthma 
(Cates and FitzGerald 2001, Adams et al. 2(01), and impact of diagnosing 
tuberculosis early. It also makes it difficult to comment on the durability of the 
training effect. Little is known about the durability of in-service training 
programmes. Evidence on the durability of active dissemination strategies is starting 
to emerge, and suggest that such interventions may well have lasting effects, with 
improvements in quality of care sustained, in some instances, even years later (Sand 
et al. 2000; Morgenstern et al. 2003). The short duration of follow-up may have also 
biased cost estimates upwards especially for those patients diagnosed with 
tuberculosis and who required intensive monitoring during the initial stages of 
treatment. These short term expenses were included while health effects, which 
would plausibly have manifested several months later, were not captured. 
It was unfortunate that tuberculosis case detection was demoted to a secondary 




practice busy schedules and responsibility for up to 70 clinics at a time meant that 
monitoring and evaluation visits were infrequent and brief. The possibility that 
trainers would engage in educational outreach type activities during these visits was 
therefore limited, especially considering that they had each been assigned several 
other clinics to train, in addition to their usual activities. Support materials were 
distributed by the research team, and only exact numbers of materials were 
distributed to minimise the chance that excess copies would find their way into 
control clinics. Contamination may have also occurred if nurse practitioners 
transferred between clinics. ainic managers were questioned about such transfers at 
the end of the trial, and reported none during the study period. 
The failure to measure the effect of P ALSA on tuberculosis treatment outcomes is 
another shortcoming of the study. Because of the duration of tuberculosis treatment, 
routinely collected outcomes are only finalised a year to 18 months later. This went 
beyond the funded timeline of the study, and so a decision was made not to include 
them in the primary analysis. 
The economic evaluation represented a comprehensive attempt to estimate the costs, 
and cost-effectiveness of P ALSA, in comparison with usual training and support for 
respiratory diseases. Wherever possible, it attempted to comply with internationally 
accepted guidelines for performing and reporting economic evaluations (Drummond 
and Jefferson 1996). A completed checklist of criteria from these guidelines can be 
found in the appendix. 
The costing component of the evaluation was reasonably comprehensive, and 
included changes in treatment costs as well as all aspects of guideline development 
and implementation costs. The estimation and inclusion of guideline development 
costs sets it apart from most economic evaluations of guideline dissemination and 
implementation strategies. Intervention costs may therefore appear quite high when 
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estimate confidence intervals for incremental cost-effectiveness ratios (ICERs) and 
estimate probabilities that the intervention was cost-effective. To our knowledge, 
this was the first time regression of incremental net benefits was applied to data from 
a cluster randomised controlled trial. Comparison with standard methods showed 
that those methods which do not explicitly adjust for clustering yield confidence 
intervals that are misleadingly precise, and higher probabilities that the intervention 
is cost-effective. 
Questionnaires to collect data on resource use and costs tend to be long, and must 
make provision for capturing relevant costs if respondents have made repeated use 
of health related services. Given that the distribution of health costs is typically right 
skewed, with few patients accounting for the majority of health service expenditure 
(Briggs and Gray, 1999), it can be inferred that, for most respondents, there will be 
large sections of the questionnaire that are not applicable. This imposes a burden on 
researchers and fieldworkers; bulky paper questionnaires are expensive to print, 
need to be transported to the field, are a disincentive to participation, and require 
that the fieldworker pay careful attention to instructions for skipping non-applicable 
questions. When skip instructions are not carefully followed, errors may arise and 
the rate of missing information increases. In practice, this requires careful editing of 
completed questionnaires, imposing yet further demands on fieldwork logistics. 
The questionnaire compiled for the trial made provision for details of several visits to 
the trial clinic as well as other health care providers to be collected. Despite careful 
consideration of elements for inclusion, the final enrolment questionnaire numbered 
36 pages and the follow-up questionnaire 34 pages. There were also multiple skip 
instructions to be followed by fieldworkers, presenting a substantial burden to both 
fieldworker and participant. At the time of going to the field, the Biomedical 
Informatics Research Division of the Medical Research Council had completed 
development of an interview software application for portable handheld computers 
or PDAs (personal digital assistants) (Zwarenstein et al. 2006). This Handheld 
Personal Interoiew application, or HAPI, interfaced with available computerised 
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visual aid. Also, the application was dependent on a small amount of battery power. 
H the device battery was allowed to become completely exhausted, the application, 
together with any information stored on it, was lost. One such incident occurred 
during seven months of fieldwork. Six follow-up interviews were lost but 
fortunately the fieldworker was able to track down all patients and re-interview 
them the following day. 
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The P ALSA intervention differs from the other syndromic interventions in that it did 
not depend on the usual intensive offsite short courses for implementation IMO 
training numbers 11 days, the PAL-Nepal training five days, and Syndromic STI 
Management in Mwanza three weeks. High levels of coverage were obtained within 
these research contexts, but this may not be the case when routinely implemented. 
Certainly in the case of IMCI many countries have struggled to achieve comparable 
levels of coverage with the result that the programme either petered out, was sub-
optimally implemented or at such low coverage that it failed to net population level 
benefits (WHO 2002c, Nsungwa-Sabiiti et al. 2004; Huicho et al. 2(05). P ALSA 
equipped usual nurse middle managers as outreach trainers, making the intervention 
more likely to be sustainable and suitable for taking to a larger scale. The training of 
trainers, conducted by the research team and skilled contractors could now be 
conducted by the trainers who were trained for this province, with some initial 
assistance. Furthermore, P ALSA prioritised the delivery of some training to many 
frontline health workers, instead of high-level training for a few. Improvements in 
quality of care were obtained despite a low number of educational contacts, and are 
therefore more likely to be reproduced when taken to scale. 
The use of disparate methods for the economic evaluations of syndromic 
interventions makes it difficult to draw meaningful comparisons between studies. 
Like this study, the Mwanza cost-effectiveness analysis of the impact of syndromic 
STI care on HIV incidence, and the PAL-Nepal study are both based on cluster 
randomised controlled trials, whereas the IMCI economic evaluation is based on a 
non-randomised controned study. Top-down costings were employed in the 
Mwanza and IMCI evaluations limiting the possibilities for a detailed assessment of 
the impact of uncertainty, like in the P ALSA trial. Patient-level data were used in the 
PAL-Nepal cost-effectiveness analysis with individual bootstrapping of costs and 
effects to estimate the level of precision, ignoring the trial's cluster randomised 
design. The P ALSA trial was methodologically more rigorous than the other 
evaluations in several respects. It considered both the health service and societal 
perspectives, as wen as the impact of lost productivity costs; it undertook a detailed 
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guidelines (Awad et al. 2005, Santoso 1996). It should be noted that quality of care is 
generally very low in these health services, and any implementation strategy may be 
effective at improving practice in comparison to usual care. 
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recruiting extra nurses, although the impact on staff workload and morale should be 
considered. Decision-makers should also consider that widescale implementation 
would require managers to co-ordinate training of trainers, outreach training in 
clinics and distribution of guidelines and materials. This function was carried out by 
researchers during the trial, and was limited because of the relatively small number 
of clinics involved. 
This study also provides evidence to support the role of integrated care programmes 
in improving quality of care and strengthening health services. In sub-Saharan 
Africa the recent explosion in the tuberculosis epidemic has evoked responses which 
are vertical and selective. Examples include the WHO's declaration of tuberculosis 
as a global emergency (Raviglione 2003), and, in South Africa, the crisis status 
attributed to tuberculosis last year (2005) by the National Deparbnent of Health 
(Cullinan 2006). Amid these responses little attention is paid to horizontal 
programmes which favour medium to long-term service strengthening and 
sustainability (Victora et al. 2004b). Instead vertical programmes, frequently donor 
funded, which promise large and immediate gains are prioritised. Victora and 
colleagues (2004b) argue that multitrack approaches that address both short term 
gains, and longer term health system strengthening, are required, instead of forcing 
competition between approaches. Globally, PAL is slipping on the health care 
agenda, as tuberculosis and AIDS take centre stage amid initiatives such as the 
Global Fund for AIDS, Tuberculosis and Malaria, and the 1/3 by 5" campaign. 
Ironically, it is the skilling-up of frontline multipurpose health workers, as achieved 
through programmes like P AlSA, that is required to ensure that Millennium 
Development Goals for priority diseases like tuberculosis and AIDS will be met (fask 
Force on Health Systems Research 2004). 
This study is the first to demonstrate that an integrated approach to the case 
management of respiratory diseases can augment passive case detection of 
tuberculosis. This premise was central to PAL's inclusion as one of five components 
of the Global DOTS Expansion Plan in the late 1990s (Raviglione 2003). Until now, 
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public sector antiretroviral treatment programme (South African National 
Department of Health 2003b). The expanded package, which also included 
expanded support materials and outreach training, has since been tested in a second 
pragmatic randomised controlled trial, the results of which are expected before year 
end. Since upgrading P ALSA to include HN / AIDS, results of the trial have been 
disseminated to local decision-makers, both nationally and at provincial level, in the 
Free State, and in the Western Cape. This has led to several important developments. 
P ALSA Plus is being implemented throughout approximately 300 clinics in the 
Western Cape, and a further 150 in the Free State. The Human Resources Directorate 
of the National Department of Health is supporting a bid for the programme to be 
adopted nationally as the official training strategy for the Comprehensive Care, 
Management and Treatment of HN and AIDS Programme and PALSA Plus is being 
expanded yet again, this time to support fully nurse-initiated and nurse-monitored 
antiretroviral treatment. The initial invitation to expand the P ALSA approach to 
include the management of HN / AIDS occurred before the trial was completed, and 
followed positive feedback from managers and recipients of the educational outreach 
training. Decisions to adopt the programme widely in the Free State, the Western 
Cape and as national policy have followed dissemination of trial results over an 
extended period of time spent engaging local and national managers. Thus is 
appears that while high face validity is an important element in attracting initial 
attention from decision-makers, evidence is contributing substantively to decisions to 
take the programme to a larger scale. 
This work has several implications for health services research methods. The 
shortage of implementation research in middle and low income countries has been 
identified as one of the key conStraints to equipping weak health systems towards 
realising the Millennium Development Goals (Task Force on Health Systems 
Research 2004; Sanders and Haines 2006). Evidence on the relative effectiveness and 
efficiency of delivery strategies in lower and middle-income countries is urgently 
needed to guide decision-makers to make the best use of scarce resources. This study 
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study used regression of incremental net benefits, adjusted for the trial's design, to 
estimate confidence intervals for ICERS, and compared it against a range of 
techniques including individual bootstrapping of costs and effects, cluster 
bootstrapping of incremental net benefits and unadjusted regression. Techniques 
that adjusted for clustering yielded wider confidence intervals, and lower 
probabilities that the intervention was cost-effective. Linear regreSSion may be 
invalid if small samples are used, and results should be compared with those from 
cluster bootstrapping. This study is, to our knowledge, the first economic evaluation 
alongside a cluster randomised trial to explicitly account for cluster randomisation in 
reporting adjusted ICER confidence intervals and probabilities that the intervention 
is cost-effective. Comparison of techniques suggests that regression of incremental 
net benefits is valid and simple to perform. Furthermore, it permits adjustment for 
all aspects of trial design, including cluster randomisation and stratification, and if 
required, adjustment of outcomes for baseline characteristics. This represents an 
important methodological contribution to cost-effectiveness analysis based on 
patient-level data from cluster randomised trials. 
In conclusion, this pragmatic trial shows that combining syndromic integrated case 
management of adult respiratory diseases with educational outreach, delivered by 
nurse managers, provides a feasible, effective and efficient means of changing the 
practice of clinic nurse practitioners towards evidence-based choices. These findings 
are likely applicable to similar resource-limited settings characterised by high 
burdens of HIV and tuberculosis where non-physicians provide primary care. This 
model is being used to implement an expanded package, including guidelines on the 
management of HIV I AIDS and other sexually transmitted infections. The results of 
the trial suggest that such efforts should continue, and be accompanied by ongoing 
evaluation. 
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Title Cost-effectiveness OT ImDrovea treatment services for ;:s liS In Mwanza. Tanzama 
References Grosskurth et al.1995 
Gilson et al. 1997 
Grosskurth et al. 2000 
Description Community randomised controlled trial (closed cohort followed-up for 2 years) with prospective economic evaluation and cost-
effectiveness analvsis reoorted 
CountrY Mwanza district in north-west Tanzania 
Settina 12 rural communities matched into 6 pairs on basis of aeoaraohicallocation tYoe of community and rates of presentation with STls 
Period 1991 -1994 
Intervention implemented in intervention communities between 1991 and 1992, delivered to control communities starting in 1994. 
2 community surveys of adults aged 15-54years living in the 12 comm~rities completed 2 years apart. 
Cost data collected in December 1993 (reference year for cost analvsis . 
INTERVENTION 
Description • Establishment of STI reference clinic and laboratory 
• Health care worker training in syndromic management (3 week course, including 1 week lectures and 2 week's practical) 
• Regular supply of drugs 
• SuperviSOry visits 
• 6 monthly health education visits to villaQes 
EPOC classification Health care worker training: 
Educational meetings and educational materials 
Village health education: 
Mass media 
Level of trainina 
I ~reSCribi~ Targeted behaviour 
k reduction) 
STUDY DESIGN 
Desian controlled trial 
Unit of allocation 
No. of allocation 
units in studY 
Grouo 1 5 comoonent intervention as described above 
Group 2 Usual STI services 
Randomisation N/A. 
concealment 
Protection against Yes, communities well demarcated geographically and separated by large distances (>50km). 
contamination 
Blinded assessment: Not clear. 
Reliable outcomes Yes. HIV incidence established from blood samples from survey partiCipants according to clear protocols, including ELISA assay, 
confirmatory ELlSAs and western blot tests. 
Baseline Yes. First community survey preceded intervention. 
measurement 
CoveraQe amonQ health workers not reoorted at any time point. 
71 % of people included in oriQinal survey re-interviewed 2 years later' 83% if deaths and those who have moved awav oermanently 
326 
I discussed 
Quantities of Yes. Ingredients approach used to estimate costs. 
resources reported 
separately from their 
unit costs 
Methods for Quantities: information obtained from 1993 survey of prescriptions in intervention and control communities, review of labour costs 
estimation of associated with training, supervision and administration and running of the reference clinic. 
quantities and unit Unit costs: Labour costs estimated using 1993 salaries, drug costs estimated using 1993 prices supplied from Essential Drugs List 
costs described programme. 
Details of currency, Yes. Costs converted from Tanzanian shillings to U$ dollars in December 1993 (U$1=479.87 Tanzanian shillings). 
price adjustments for 
inflation, currency 
conversion civen. 
Details of any model 
used 
Yes. Mathematical model to estimate cost per HIV infection averted, and per DALY saved. 
Choice of model Yes. 
used and key 
parameters on which 
it is based justified 
AnalySis 
Time horizon of Yes. 
costs and b 
stated 
Discount rate(s) Yes-3%. 
stated 
Choice of rate(s) Panel on Cost Effectiveness in Health and Medicine's recommendations. 
justified 
Explanation given if Benefits discounted at same rates (0%,3%,6%). 
costs and benefits 
are not discounted 
Details of statistical Yes, for effectiveness estimates. 
tests and confidence 
interval given for 
stochastic data 
Approach to Yes - one-way and multivariate sensitivity analysis used. 
sensitivity analysis 
civen 
Choice of variable Yes - discount rate used in costing and to estimate DAL Ys, proportion of prescribed drugs received, proportion of central support staff 
for sensitivity time allocated to the intervention, average catchment population, reduction in HIV incidence (Cllimits from effectiveness study). 
analySis iustified 
Ranges over which 
variables are varied 
Yes. 
stated 
Relevant alternatives Yes. Communities with and without STI intervention. 
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Title: Enectiveness and cost of faci -based :1 In TanZania 
References Adam et al. 2004a 
Adam et al. 2004b 
Adam et al. 2005 
Armstrong Schellenberg et al. 2004a 
Armstrong Schellenberg et al. 2004b 
Gouws et al. 2004 
Description Controlled non-randomised trial with prospective economic evaluation (cost analysis and cost consequence reported, cost-
effectiveness not vet reported) 
Country Tanzania 
Setting Public sector primary care facilities (health facilities and dispensaries) 
Period IMCI implementation commenced in intervention districts in 1997; 80% coverage of healthcare workers achieved by mid 2000. 
Implementation commenced in control districts in 2002. 
Effectiveness data collected in 2000 (quality of care), and 2000-2002 (mortality from demographic surveillance systems). 
Cost data collected in 1999 (household and hospital costs), and 2000 (national, district and primary care facility costs). 
Cost data includes start-up costs incurred since 1997. 
Reference vear for cost data is 1999. 
INTERVENTION 
Description Facility based IMCI: 
11 day centralized training workshops based on locally adapted integrated case management guidelines, with 30% of time allocated 
to practical case management. 
Minimum of one follow-up visit in health facility within one month of training. 
Health system IMCI: 
Basic drugs need for IMCI case management not included in national essential drugs list available for purchase in special kits from 
medical stores. 
Integrated supervision cascade (component of TEHIP): health centres charged with supervision of dispensaries in local catchment 
areas, and provided with solar operated radios and motorcycles to facilitate this. 
Community-based IMCI: 
Not implemented but strategies consistent with the approach (e.g. social marketing of insecticide-treated bed nets) present in all 4 
districts. 
EPOC classification Facility based IMCI: 
Educational meetings (workshops traineeships) and educational materials. 
Level of trainina Hiah· within 3 vears of implementation 80% of health workers were trained. 





Design Non-randomised controlled clinical trial ("plausibility"studV) 
Unit of allocation District 
No. of allocation 4 
units in studv 
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effectiveness studY 
Methods of N/A, because CEA for pre-defined indicators (years life saved, child appropriately treated) not reported. 
synthesis of 
estimates of health 
aiven 
Primary outcome Yes-
measure clearly Total cost of start up and implementation of IMCI in a district. 
stated Incremental cost of introducina and run nina IMCI in a district. 
Methods to value N/A because health states not included. 
health states and 
other benefits stated 
Details of subjects 
from whom 




(if included) reported 
Collected, but not reported. 
Not valued monetarily and included in estimate of total cost. 
seDarately 
Relevance of No. Unclear why productivity changes were not reported. May be planned for future publications. 
productivity changes 
to study question 
discussed 
Quantities of Collected separate from unit costs; not always reported separately. Hospital costs reported separately, but not drug costs. 
resources reported 
separately from their 
unit costs 
Methods for Quantities: information obtained from 1999 household survey and 2000 health facility survey 
estimation of Unit costs: From various sources including national department (salaries), and previous studies (cost per hospital day). 
quantities and unit 
cribed 
s of currency. Limited to methods for adjustment - costs incurred pre-1999 were inflated to 1999 using gross domestic product deflators. 1999 costs 
price adjustments for in Tanzanian shillings were converted to U$ using official exchange rates but exact rate not specified. 
inflation, currency 
conversion aiven. 
Details of any model Ordinal least squares regression model used to explore whether the facility cost of caring for under 5s was correlated with IMCI after 
used controlling for other factors influencing cost (facility clustering, type of facility. annual number of U5 attendances, capital availability), 
Proxys for complexity of services offered (presence of dental chairs and microscopes) exclude due to multicollinearity. Note that 
district was not included in the model as a dummy variable. 
Choice of model Yes - key parameters described above. 
used and key 
parameters on which 
it is based justified 
Analvsls 
Time horizon of Yes but not clear whether adiustments were made when relatina costs (referenced to 1999) to Quality of care indicators (measured in 
332 
been suitably detailed, including a time and motion stu~ to estimate the effect of IMCI on consultation time. 
• Methodology of economic evaluation appears reasona e with adequate attention to detail regarding cot measurement and 
valuation, inclusion of a rearession model to exolore factors imoactina on facility-based costs and a sensitivity analysis. 
Weaknesses • Non-randomised design with high level of commitment to IMCI in intervention districts, and rapid achievement of 80% 
coverage compared with other countries, consistent with bias. 
• Small number of allocation units. 
• Co-intervention effect of strengthened district management (TEHIP) may explain reductions in mortality. 
• Training interventions in comparison district not well described; unclear whether similar interventions occurred in intervention 
districts. 
• Claim that the 4 study districts are typical of others in rural Tanzania not well substantiated, as have introduced demographic 
surveillance systems not implemented elsewhere. 
• Unit of error analysis errors probable in cost analysis and quality of care indicators (inconsistent adjustment for clustering by 
health facility, and stratification by district). 
• Mortality reduction non-significant when results adjusted for clustering, and may be explained by interventions other than IMCI 
~.g. social marketing of treated bed nets given that malaria leading cause of death in this region). 
• tart up costs, including trainin~ of health workers, annualised over 10 years without justification for choosin~ such a 
prolonged period. Reassuring t at varying this period between 5 and 15 years did not impact on results, but years may have 
been too long. Difficult to assess this without further information on coverage after mid 2000. 
• National level costs associated with TEHIP not included in costing. 
• Reference year for cost is 1999, yet effects to which they relate were collected in 2000 (health facilities) and 2000 - 2002 
(mortality). Effects have not been discounted or costs inflated to reoresent the year in which the effects occurred. 
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ECONOMIC EVALUATION 
Design of economic evaluation 
Research Question What is the cost-effectiveness of PAL? 
Importance of Concern whether it merits the best use of scarce health resources in Nepal. 
research Question 
Viewpoint Societal (health service and households). 
Productivity costs data collected from patients but subsequently excluded because of 'measurement problems'. 
Alternative clearly Yes, but not described in any detail. Usual care, implementation of STS (standard treatment schedule) guidelines assumed. 
defined 
Form of economic Cost analysis (prescription costs). 
evaluation stated Cost-effectiveness (cost-utility) analysis. 
Choice of form of Cost analysis justified because of concerns around increasing prescribing costs. 
economic evaluation Cost-effectiveness analysis based on projection model justified using recommended WHO methodology for modeling the cost-
iustified effectiveness of health interventions. 
Data collection 
Source of Yes - from cluster randomized trial. Difference in acute state utilities used in model, but not clear whether the difference in acute state 
effectiveness utilities between intervention and control groups is a) statistically significant (on~ difference in mean and SO reported, no Cis) or b) 
estimate stated clinically sianificant(not com oared with clinically significant imorovement in HR ol). 
Details, design and Yes - see above. 
results of 
effectiveness study 
Methods of Yes. Methods for estimating acute state utilities clearly described. 
synthesis of 
estimates of health 
given 
Primary outcome Prescription cost analysis: 
measure clearly Average cost per prescription 
stated Wasta~e cost per prescription (Actual cost per prescription less expected cost per prescription) 
Cost-e ectiveness analysis: 
Incremental cost of introducing and running IMCI in Nepal per QAl Y gained by the Nepal population. 
Methods to value Choice of tariffs for converting EQ5D responses to index scores not specified. 
health states and Sources for selection of model parameters based on burden of disease estimated for Nepal, and literature (number and duration of 
other benefits stated exacerbations ). 




Productivity changes Collected, but not reported because of 'measurement problems'. 
(if included) reported 
seoarately 
Relevance of No. 
productivity changes 
to study question 
discussed 
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Ranges over which 
variables are varied 
Yes - see above. 
stated 
Relevant alternatives Yes. 
compared 
Incremental analysis Yes. 
reoorted 
Major outcomes Yes. 
presented in 
aggregated as well 
as disaggregated 
form 
i Answer to study Cost analysis: 
. question given Yes. SignifICant reduction in number of items prescribed per visit, and significantly increased prescribing of generics and from the 
essential drug list did not reduce average prescription or wastage costs. 
Cost-effectiveness analysis: 
Countrv wide imolementation of PAL considered cost-effective com oared with DAL YI GOP benchmarks. 
Conclusions follow Cost analysis: Yes. 
• from data reoorted Cost-effectiveness analvsis: Yes. 
Conclusions Cost analysis: 
accompanied by Further cost-effectiveness analysis recommended. 
appropriate caveats Cost-effectiveness analysi: 
Yes. Substantial uncertaintv limits orobabilitv that intervention is cost-effective. 
Strengths • Draws on effectiveness estimates from well-designed and implemented cluster randomized trial. 
• Costing appears to have considered almost all relevant costs at multiple levels (national and distriCt, patient including facility 
and out-of-pocket costs). 
• Unique multi-disease model developed to extrapolate trial findings to country-wide implementation. 
• Uncertainty of cost-effectiveness estimates considered usino bootstraoping. 
weaknesses • Analysis of prescription costs may have been confounded by diagnosis recorded by health workers in intervention and control 
facilities. 
• Different criteria applied to prescription details in intervention and control groups to assess appropriateness. 
• Prescription cost outliers were excluded from the analysis without justification. 
• Logistic regression of transformed cost data was used to determine difference between groups, but bootstrapping may have 
been more appropriate. 
• Not clear whether the difference in utilities between groups is statistically or clinically Significant, yet this forms the basiS of the 
comparison in the model. 
• Not clear why the model is based only on the acute state utilities, and not the chronic state ones, given the dominance of 
chronic conditions in the model. 
• The model does not account for differences in the duration of disease states between groups, or the incidence of acute 
exacerbations for chronic conditions, which could be expected to change as a result of the intervention. 
• Many effects (mortality, admissions) were not considered. 
• Depreciation of training effects was not considered, and adaptation costs were written off over a prolonged period (10 years) 
without justification. 
• Cost analvsis but not the cost-effectiveness analvsis exolicatina adiusted for clustering. 
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No. Ref9rencel countryl settingl study 
design 
Ar~a of Interestl targeted 
be avlour 
Intervention groups Main findings 
A1 Awad et al. 2005 Prescribing (antibiotics) Grp 1: Audit & feedback Effective (Grps 2 and 3) 
Eltayeb et al. 2005 Grp ~: Audit & feedback, educational Reduced mean no. of 
meetings encoum:r where antibiotics 
prescrl 
SlJdan, doctor and medical assistant 
Grg 3: Audit & Fee~back educational primary care 
ou each (individ~a , sing'e visit, detailer = tional outreach more 
clinical ptiarmaco agist) tive than adding 
cRCT (n=20) Inss to audit anti 
ba k 
Grp 4: Usual carel no intervention 
A2 Banait et al. 2003 General mana~ement, GrH 1 :Jducational outreach (grour,' 2 Effective 
r.rescribing, tes -orderl)g ~ ts, . etai/er = hQSfsital specialist, 
acid-related disorders ucationa materia s 
United Kingdom, doctor-led primary care IncJeases in H. Pylori testing 
Grp 2: Educational materials 
~~p ~ppropriate referrals in 
cRCT (n=114) 
A3 Brown et al. 2000 General management 
( depression) 
Grp 1: Educational outreach Mixed effects 
US, doctor-led primary care Grp 2: Usual carel no intervention ~crease in treatment rates 
ut no improv~ment In 
s~Ptoms or unctlonal 
cRCT s tus 
A4 Coenen et a\. 2004 Pres~ibinH. (antibiOaiCS fQr 4rp 1: E;Qu~tio~al outreach (iQd~VidUall Effective 
cou~ las Ing < 30 ays In Single VISit, etal er = pharmaCist, 
adu ) educational materials 
Belgium, doctor-led primary care Reduction in no. of uatients 
receivi.n~ an antibio ic 
Grp 2: Usual carel no intervention prescnp Ion 
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No. Referencel country/ setting! study Area of Interest! targeted Intervention groups Main findings 
desian behaviour 
A6 Dey et al. 2004 General management Grp 1: Educational outreach, educational Mixed effects 
United Kingdom, doctor-led primary care 
(acute lower back pain) materials 
No effect on referral for Xray, 
cRCT (n=24) 
Grp 2: Usual carel no intervention issuing of sick certificates, 
prescribing of opiods or 
muscle relaxants 
Increased referral to a 
physlo, and educational 
proaramme 
A7 Fender et a!. 1999 Prescribing and referrals Grp 1: Educational outreach (group, 2 Effective 
United Kingdom, doctor-led primary care 
(menorrhagia) visits 6 months apart, detailer = 
Lower no. of referrals and researcher) 
cRCT (n=100) 
more use of tranexamlc acid 
Gro 2: Usual carel no intervention among Intervention oractices 
A8 Figueiras et a!. 2001 Prescribing (non-steroidal Grp 1: Educational outreach (individual, Effective 
Spain, doctor-led primary care 
anti-inflammatory drugs single visit, detailer = pharmacist) 
Improved NSAID prescribing (NSAID1 in primary care) 
Grp 2: Educational outreach (group, single sustained after 9 months' 
cRCT (n=595) visit, detailer = pharmacist) follow-up 
Grp 3: Usual carel no intervention (individual> group 
educational outreach) 
A9 Freemantle et a!. 2002 General management, Grp 1: Educational outreach (group, 4 Effective 
United Kingdom, doctor-led primary care 
prescribing across 4 visits, detailer = community pharmacist) in 
Improvement in prescribing disease areas (aspirin as 214 guideline topics, educational materials 
cRCT(n=60) anti platelet therapy, ACE Grp 2: Educational outreach (group, 4 
practices and compliance 
inhibitors in cardiac failure, with guidelines (smaller 
NSAIDS for pain due to visits, detailer = community pharmacist) in practices> larger practices) 





No. Reference/ countryl setting! study Area of interest! targeted Intervention groups Main findings 
design behaviour 
A15 Jackson et al. 2004 Prescribing (antithrombotics Grp 1: Educational outreach (individual, Effective 
Australia, doctor-led primary care 
for stroke prevention in multiple visits, detailer = not specified), 
Increase in warfarin patients with atrial educational materials 
CCT (n=2) fibrillation) Grp 2: Usual carel no intervention 
prescriptions among patients 
attending intervention group 
GPs 
A16 Kim et al. 1999 General management of Grp 1: Educational outreach (individuall No effect 
US, doctor-led primary care 
preventive medicine group, 2 visits, detailer = pharmacist), 
(immunisation, cancer educational materials, educational 
cRCT (n=41) screening, smoking meetings 
cessation counselling) 
Grp 2: Educational materials, educational 
meetings 
A17 Lin et al. 2001 General management, Grp 1: Educational outreach (individual, No effect 
US, doctor-led primary care 
prescribing (depression) single visit, detailer = pSYChiatris~, On diagnosis or prescribing educational meetings, audit and eedback 
cRCT (n=109) Grp 2: Usual carel no intervention 
A18 Lobo et al. 2002 General management Grp 1: Educational outreach (group, 15 Effective 
The Netherlands, doctor-led primary care 
(cardiovascular preventive visits over 21 months, detailers = nurses) 
Improved provision of care) 
Grp 2: Usual carel no intervention cardiovascular preventive 
cRCT care 
A19 Majumdar et al. 2003 General management (type Grp 1: Educational outreach (group, 2-6 Mixed effect 
Canada (rural), doctor-led primary care 
2 diabetes) visits, detaiter = specialist physician), Significant improvement in educational outreach (individual, 6 visits, 
cRCT (n=2) detailer = pharmaCist), educational 
BP control, non-significant 
meetings improvement in HbA1C and 
cholesterol 
Grp 2: Educational meetings 
Improved patient satisfaction 
A20 Majumdar et al. 2005 T est-ordering, prescribing Grp 1: Educational outreach (group, no. of Educational outreach 
US, doctor-led primary care 
(acid-related disorders) visits not specified, detailer = effective - increased test-
gastroenterologist [initial] and pharmacist ordering for H. Pylori and 
CCT (n=14) [follow-up]), educational materials reduced PPI prescriptions 
Grp 2: Educational materials 
Grp 3: Usual carel no intervention 
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No. ReferenceJ countryl setting! study Area of Interest! targeted Intervention groups Main findings 
desian behaviour 
A26 Pagaiya et al. 2005 Prescribing ~ntibiotiCS for Grp 1: Educational outreach (group, sinple Mixed effects 
Thailand nurse-led primary care 
childhood A I & diarrhoea, visit, detailer not specified ), educationa 
Improved management of diazepam for adults), meetings (3 day workshop) 
cRCT (n=18) general management Grp 2: Usual carel no intervention 
ARI, provision of rehydration 
(diabetes in adults) solution for diarrhoea, no 
improvement in antibiotic 
prescribing for diarrhoea, 
diazepam prescribina 
A27 Pattinson et al. 2005 General management Grp 1: Educational outreach (group, 3 Effective 
South Africa, hospital-based practice 
(provision of kangeroo visits, detailer = not specified), educational 
Increase in provision of mother care) materials 
cRCT (n=34) Grp 2: Educational materials 
kangeroo care in educational 
outreach hospitals after 8 
I months 
A28 Preston et al. 2000 Screening (mammography Grp 1: Educational outreach, audit & Effective 
US, doctor-led primary care 
among women aged 65-74 feedback, local opinion leaders, reminders, 
Increase in mammography years) educational materials 
CCT (n=not specified cleariy) Grp 2: Usual carel no intervention 
rates among women 
attending intervention 
practices 
A29 Ricordeau et al. 2003 General management, test- Intervention: Educational outreach Effective 
France, doctor-led primary care 
ordering (diabetes) (individual! group, single visit, detailer = 
Increase in number of not specified, telephone calls) 
HbA 1 C and urine 
ITS microalbuminuria tests 
ordered 
A30 Shaw et aI. 2003 Prescribing (errors in Grp 1: Educational outreach (individual, Effective 
Australia, hospital-based practice 
prescriptions for drugs of single visit, detailer = not specified), 
Reduced error rates in addiction) educational materials 
CCT (n=2) Grp 2: Usual carel no intervention 
prescriptions 
A31 Sheinfeld Gorin et al. 2000 Cancer screening {cervical, 1: Educational outreach (individual, No effect 
US, doctor-led primary care 
breast, lung, coIorectal, visits on average, detailer = research 
No change in screening rates prostate) staff), educational materials 
Non-randomised CBA (n=122) 
among patients 
Grp 2: Usual carel no intervention 
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No. Reference/ country! setting! study Area of interest! targeted Intervention groups Main findings 
design behaviour 
A36 Watson et al. 2002 Prescribing ~over-the- Grp 1: Educational outreach (group, single No effect 
United Kingdom, community-based 
counter anti ungals for visit, detailer = pharmaCist), educational 
pharmacies 
vulvovaginal candidiasis) meeting 
cRCT (n=60) 
Grp 2: Educational outreach(group, single 
visit, detailer = pharmacist) 
Grp 3: Educational meeting 
Grp 4: Usual carel no intervention 
A37 Weller et al. 2003 Screening (PSA for Grp 1: Educational outreach (two visits, Mixed effects 
Australia doctor-led primary care 
prostate cancer) detailer = trained pharmacist), educational 
Significantly lower PSA materials 
cRCT(n=40) 
testing rates among 70-79 
Grp 2: Educational materials year old men (only age grp 
Grp 3: Usual carel no intervention 
with effect) in outreach 
group, but not sustained at 
12 months 
A38 Witt et al. 2004 Prescribing (asthma Grp 1: Educational outreach (individual, No effect 
Denmark doctor-led primary care 
medication among children) single visit, detailer = peer doctor), No change in prescribing in educational materials 
cRCT (n=100) 
the short or long (1 year 
Grp 2: Educational materials follow-up) term 
A39 Young et al. 2002 Counselling (smoking Grp 1: Educational outreach (group, 3 Mixed effects 
Australia, doctor-led primary care 
cessation) sessions, detailer = peer doctor) for 
Increased use of nicotine smoking cessation 
replacement but nothing else 
cRCT (n=39), balanced incomplete block Grp 2: Educational outreach (group, 3 (advice etc.) 
design sessions, detailer = peer doctor) for 
cervical screenina 
A40 Zwar et al. 2000 Prescribing Grp 1: Educational outreach (individual, No effect 
Australia, doctor-led primary care 
(benzodiazepines) single visit, detailer = not specified) 
RCT (n=157) 
Grp 2: Usual carel no intervention 
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No. Reference(s) I Country I Setting IntervenDon Type of economic evaluation 
Area of Interest I Targeted behaviour Study design and main effectiveness findings Main findings 
Comment on Quality of evaluation 
B1 Ref: Banait et al. 2003 Intervention: Type of economic evaluation: 
Country: England (North West) Educational outreach (single visit. group. hospital Cost analysis limited to drug (H2 receptor 
Setting: Primary care (doctor-led) 
specialist detailer) antagoniSts. proton pump inhibitors) costs 
Educational meeting 
(reported in methods. results and discussion) 
Area of Interest: Main findings: 
Educational materials 
Dyspepsia in adults Significant. and unexpected, increase in cost 
Targeted behaviour: 
Study design and main effectiveness findings: of acid suppressing drugs in intervention 
Prescribing (acid-suppressing drugs) 
From cRCT (n=113) group. 
Test ordering (Helicobater Pylori) 
Mixed effects: increase in appropriate referrals and Comment on quality: 
H. pylori testing in intervention group; no increase in Not all methods for costing (price year, 
proportion of major findings at endoscopy and inflation adjustment) given. Source of unit 
increase in prescribing costs of acid-suppressing costs and no. of units given. 
droos 
B2 Ref: Coenen et al. 2004 IntervenDon: Type of economic evaluation: 
Country: Belgium Educational outreach (single visit, individual, Cost analysis limited to drug (reimbursed 
Setting: Primary care (doctor-led) 
pharmacist detailer) antibiotics only) costs (reported in methods, 
results and discussion) and cost of intervention 
Area of Interest: 
Educational materials (key messages) (implementation only, €236 per visit [2000, 
Acute cough in adults «30 days) 
Study design and main effectiveness findings: 2001]). 
Targeted behaviour: 
From cRCT (n=85) Main findings: 
Prescribing of antibiotics 
Effective: reduction in number of adults with acute Significantly reduced antibiotic costs per 
cough prescribed antibiotics with no difference in time patient in intervention group without 
to symptom resolution. re-consultation or compromising patient outcomes. 
hospitalisation rates. Comment on quality: 
Not all methods for costing (price year, 
inflation adjustment) given. Source of unit 
costs given. Discounting appropriate (>1 year) 
but not clear if done. Guideline development 
costs not reported vet orocess extensive. 
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No. Reference(s) I Country I Setting Intervention Type of economic evaluation 
Area of interest I Targeted behaviour Study design and main effectiveness findings Main findings 
Comment on Quality of evaluation 
85 Ref: Hansen et al. 1999 Intervention: Type of economic evaluation: 
Country: Denmark Educational outreach (single visit, individual, GP Cost analysis limited to comparison of 
Setting: Primary care (doctor-led) 
researcher detailer) intervention costs for different dissemination 
strategies. Cost implications reported in results 
Area of interest: 
Educational materials (key messages on advice, and discussion. 
questionnaire to screen for problem drinkers) 
Problem drinking in adults Study design and main effectiveness findings: 
Main findings: 
Targeted behaviour: Direct mailing vs. telephone vs. educational outreach 
Costs of educational outreach 16 times, and 
cost of telephone 10 times, higher than direct 
Screening using educational material mailing. Costs reported in Danish kroner 
Patient education! advice From cRCT (n=143) (year?). 
Effective: Telephone and educational outreach Comment on quality: 
increased requests for package. Utilisation of Very limited costing (methods not given), 
package with outreach similar with mailing, but lower based exclusively of cost of time related to 
for telephone. implementation. Costs not considered: 
treatment costs material development. 
86 Ref: Hill et al. 2002 Intervention: Type of economic evaluation: 
Country: United States Educational outreach (single visit, individual, Cost analysis limited to drug costs (reported in 
Setting: Primary care (doctor-led HMO) 
physician peer detailer) results). 
Area of Interest! Targeted behaviour: 
Study design and main effectiveness findings: Main findings: 
Prescribing 
CCT (n=>600) Drug expenditure among intervention group 
phYSicians increased by 0.9% compared with 
Main outcome is change in drug costs per physician. 2.9% in the control group (estimated cost 
saving: US$ 232 219 [2000]). 
Comment on quality: 
Significance of difference in groups not 
reported, and not adjusted for case-mix 
differences. Price year and source of unit costs 
given. Discounting appropriate (>1 year) but 
not clear if done. Intervention costs not 
considered. 
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No. Reference I Country I Setting Intervention Type of economic evaluation 
Area of interest I Targeted behaviour Study design and main effectiveness findings Main findings 
Comment on Quality of evaluation 
B9 Ref: Leviton et al. 1999 Intervention: Type of economic evaluation: 
Country: United States Educational outreach (single visit, individual, Comment on cost implications in discussion 
Setting: Inpatient 
pharmacist detailer) only. 
Area of interest Targeted behaviour: 
Multiple others: Educational materials, educational Main findings: 
meetings, reminders, audit and feedback, local 
Corticosteroids for preterm labourl rupture of opinion leaders, local consensus process 
Favourable policy cost-effectiveness ($77 to 
$1231 per neonate) given high treatment cost 
membranes Study design and main effectiveness findings: effectiveness ($3000 saved per neonate 
cRCT (n=27) 
treated). 
Effective: significant increase in prescription of 
Comment on quality: 
corticosteroids. Insufficient detail provided to comment. 
B10 Ret. Mol et al. 2005 Intervention: Type of economic evaluation: 
Country: The Netherlands Educational materials (tailored guideline) Cost analysis limited to drug (antimicrobials 
Setting: Hospital care (intemal medicine) 
introduced first only) costs (reported in methods, results and 
discussion). 
Area of Interest! targeted behaviour: 
Educational outreach (group and individual) with 
audltlfeedback component followed. Main findings: 
Antimicrobial prescribing among inpatients. Study design and main effectiveness findings: No significant change in drug costs following 
From ITS 
introduction of guideline or outreach. Increased 
compliance with guidelines not associated with 
No additional effect of educational outreach: cost savings. 
guideline led to increased compliance (up to 86%) Comment on quality: 
with antimicrobial prescribing. No additional 
improvement noted following outreach (limited by Price year and source of unit costs given. 
ceiling effect?). Discounting appropriate (>1 year) but not clear 
if done. Guideline development costs not 
reported vet DrocesS 'intensive'. 
368 
No. Reference/ Country / Setting Intervention Type of economic evaluation 
Area of Interest / Targeted behaviour Study design and main effectiveness findings Main findings 
Comment on auallty of evaluation 
B13 Ref: Pagaiya et al. 2005 Intervention: Type of economic evaluation: 
Country: Thailand Educational meetings (3 day workshop) Cost analysis limited to drug costs (reported in 
Setting: Primary care (nurse-led) Educational materials (guidelines) 
methods, results and discussion). 
Area of interest: Educational outreach (single visit, group) 
Main findings: 
Chidren: ARTI, diarrhoea Audit and feedback (at outreach) 
S~nificantly reduced drug costs per p'atient in 
in ervention group' (because less antibiotics and 
Adults: diabetes, anxiety Study design and main effectiveness findings: diazepam prescnbed). 
Targeted behaviour: From cRCT (n=18) Comment on quality: 
PreSCribin~: antibiotics for childhood illness, Mixed effects: improved antibiotic prescribing for Methods for costing (price year, inflation 
diazepam or adults ARTI, ORS for diarrhoea, diazepam for anxiety. No adjustment, source 0 unit costs) not given. 
General management: diabetes 
cha~ in diabetes management or antibiotics for 
dia ea. 
B14 Ref: Simon et al. 2005 Intervention: Type of economic evaluation: 
Country: United States Educational outreach (single, group vs. individual, Cost analysis limited to anti-hypertensive costs 
Setting: Primary care (doctor-led) 
'physican educator' detailer) (reported In methods, results and discussion). 
Area of Interest 
Educational materials Main findings: 
Hypertension 
Com~red passive dissemination vs. group vs. Reduction of dru~ costs in passive dissemination 
individual outreach group and indivi ual outreach ~roups, no change 
Targeted behaviour: Study design and main effectiveness findings: 
In Mroup outreach grou~. Not c ear whether 
di erences significant. ndividual outreach costs 
Prescribing (diuretics and beta-blockers) cRCT(n=9) more than group outreach. 
Mixed effects: increased prescription of diuretics and Comment on quality: 
beta-blockers with outreach (p'roup and individual); Price year and source of unit costs given. 
no improvement in BP contro . Discounting appropriate (>1 year) but not clear if 
done. Not clear what is incluaed In intervention 
costs. 
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No. Reference/ Country / Setting Intervention Type of economic evaluation 
Area of Interest / Targeted behaviour Study design and main effectiveness findings Main findings 
Comment on Qualltv of evaluation 
617 Ref: Weller et al. 2003; Stone et aI., 2005 Intervention: Type of economic evaluation: 
Country: Australia Educational outreach (2 visits, individual, trained Cost-effectiveness analysis reported separately. 
Setting: Primary care (doctor-led) 
pharmacist detailer) Model used developed for cancer programmes. 
Area of Interest 
Educational meetings (single group seminar) Main findings: 
PSA screening for prostate cancer 
Educational materials Cost-effectiveness comparable with that 
estimated for colorectal cancer screening 
Targeted behaVIour: 
Study design and main effectiveness findings: programmes. 
Screeningl test-ordering 
From cRCT (n=40) Comment on quality: 
Mixed effects: reduction (19.1%) in PSA testing, but Model of CEA and details provided. Excluded 
only in >70 year age group, and not sustained at 12 cost of guideline development; not clear what was 
months. included in cost of educational outreach visit. 
Methodologically advanced with discounting of 
costs and benefits, sensitivity analysis, reporting 
of 95% confidence intervals. 
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9.4 Consent form 
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I ...................................................................................................... . 
(Name of Patient in block letters) 
have read and understood all the infonnation given to me about my participation in this study and I have 
been given the opportunity to discuss it and ask questions. 1 voluntarily agree to take part in this study 
and understand that I will receive a copy of this consent fonn. 
Signature of Patient Date 
Printed name of Patient 
1 have explained the nature and purpose of the study to the Patient named above. 
Signature of Principal Investigator or delegate Data 
Printed name of Principal Investigator or delegate 
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need 10 know ......, 
Patient Initials: Date: Clinic; Interviewer code: 
PATIENT CONTACT DETAILS 
'" W ..... IIS YOU' _ Odd,uo? 
." Do you hove Ole l<p/lone.1 ho .... ? 
~ 
'" + 1_ 513 ["""_ I : ,,,;;:;> ~ T '" , 
I .". ".,.. ".~, -~. 
~ '" 
'" Do y .... hOV •• won. add ,uo? En",._ 
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-!\ZI. E_IIow,.,. _ -... '" II", C\JnUld ..... ttlfltld 
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. 0 ~ 
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SC flE OUU: PATIENT FOR F01.1.0W-UP INTERVIEW AFTER l MONTH S 
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' 0 ~ En t. , ag. a t I. " bortMoy '" 9" 10 q .... S1lon " 
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SYMPTOM SEVERITY IN THE LAST MONTH 
you ""'" q ..... uOon. about ....... yo,", en,./ n •• be,"., It\t 1." """,m you ..... r~. "'" qu._ 
PIUs.. Ihn ~ e."flJlly .boul you, I ymptornt IN THE lAST MONlrI tflb. Inl'drino ,1Ch QUHIIOn 
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To help peopl" lIa~ how good or bad a he.lth state is . we have drawn a 
scale (rather Ioke a thermometer) on which the best state yOtl can ImagIne 
III marked 100 and Ihe worst stale vou can Imagine ~ marl<!'d O. 
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I la;o~! -EI!<lit~3;'" '" ~ ,.1 "'~.i " .. g~- - :. ':I ~ ,&5~"2 t- ;.5 .. ,[ ~ %:.' 
3 -'~'I' ii"~" :> -
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Ju$llor ... purpou of lie in ....... ,.. - sIup 10 quesbon 230 (top 01 11.00_ 171 
Abo ,o _. n~o. 
- 90 10 !he ne>l quUPOn 
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REUEVER INHALERS RECEIVED TOOAY (10 __ " Ch~kAllIh.,..,plyl 
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_ 173. Doe,thls ;n hlll .. , Improve ~OU, d<lf",l,j, 
'" F.noNroIII .... '.ilpMn (Duo,,",) 
~. , 
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INHA'-~RS THAT YOU All<. USI'-IG NOW 
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" _ sk'p!O "","toon 207 (III" pogej 
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242 Does I~ .. """I ... ""P'ove yoU' 1I,rrocl>li , 
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VISIT 1 to other health care provider In the last 3 months queshons 282 322 
28.2 Wi'ltn "" .. ,0\.1111",1" .. 1110 .no"'.< />tall/> U .. 11""" .... < oilier IIUon Ihl, Clinic: In Ill. 1 .. ll "'onlho altO. 01" h.ot 
Inte ... iow? 
Icon,,, ltabOn I .. . medocnl l<>n) " 
1 ., 
VISIT 2 to other health care provIder In the last 3 months. questions 323 • 363 
health ea ... p'(Jy)de, oth~, tlu>n tid. "t;n;c In !he t .. t3 months? 
_ 329 Enter number 
• medication) R 
21 
P't'~n"nd"" _ D .. ~ __ Cln,o ~ '""'",owerGooo _ 
VISITS TO OTHER HEAL TH CARE PROVIDERS IN THE LAST 3 MONTHS coord 
VISIT 3 to other health care provider In the last 3 months. questions 364 . 404 
23 
VISIT 4 to other health tal"(! prOVider III the lasl3 months· questions 405 _ 445 
." " 
25 
"'M~' lo",.I~ _ IJ.'~ __ CI"" __ '"'e"" ... ., «>d~ _ 
VISITS TO OTHER HEAL TH CARE PROVIDERS IN THE LAST 3 MONTHS conrd 
VISIT 5 to other health care prOVider In the last 3 months· questions 446 _ 486 ... " " , 
27 
We WOUld like you 10 len uS aboullhe peflon wIIo;;;h;;:i"'''~ 
We onf;' want to know about people wOO have lool:ed after yo~ 
1/ more than one person has cared for you, please tell us 
o.y. ~ 10 i0oi< 101 _ , 
-
" 
UlS FOllow-up QUell/on"",i,. Enll/i,h ",nion fUll. " 
PaHc~t 1~lh~l. _ !l." __ Chn.c __ ''''. ''''~'''N code _ 
ECONOMIC IMPACT OF ILLNESS cont'd 
'ir I 
526 Hey. you hoad an HIV lui (rapid IHI/ flng.",rick mefllod Of Ikawlng o.bIood ',am you, arm, in It. lall J monihl altlt' 
1r..li""lnl.",io.? 
31 
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Strotlgty Ago'H " .. N..",.I O""Il'N S~ O, .. gteo 
"" 
, , , "_ .... = - ~ -"" ~ .. Strongly """Il'" I ,~ '" , .. "•.. " 
SlJongI)'Ag!N .... N .... "'I ~~- S"on;:ty "eI.; .... 
I "" , '," , , 
SIr""'J'll Agee " .• Nolll, •• Disag_ Slron9!Y " ... gre. 
I ~' , " 
Str<Jrl9ly Agee ,,- No"troi ~~. Strongly di"g_ 
I ~, , , , . 
St'O'lgly All_ 
~, - """ .. ~;O -- 5'""",,,, "lUg_ F> ~ " .. , , 
s~_ty~_ ,,- NolOltll 0i0'11"'" SI~"'""IIr.., 
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S!tOr>gly Ag .... ,,- -~, O;"Q"'. Stron~1)' <!<log, •• 
, .. , , , 
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Strono;:'Y ""_ ",. ,,-, Dls~ ... Strongly Ollog,'" 
~, .. , , , .. , " '" ." . , ., ' , 
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" .. K 
Finally, do you hav o '''Y oth o< c<>mme~ !" or lhougl>ts on lhoe care yOIl recelye.t this clinIC? 
Remember IlOs Info.mation will flOl be shown to any cll~lc 1I_,f membtrS and will be kepI e n ~re!y confiden!I.1 so 
leel !re. 10 U what u wlah . 
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9.8.1 CONSORT checklist for reporting of cluster randomised triats (Campbell et at. 2004a) 
SectIon and I de: "m . Desc,;Dlion R. rtod - -
TITLE & ABSTRACT , How P3rlK:>Pi\nlS v.oere .. lIocated to Intorven\lons spedylng Abst'~cl 
\hal. allocation was based 01'1 (;lusters (e .g ,. "random 
allocatoo", ",oodotlltzed". or ",Mdomly a~ed") 
Al location randomised 
INTRODUCTION 2 Sd&nhflC backgoond Md I!X ~"r\I'It'oo 01 rationale Ir.dudlrlg Chapter I - the 'ationate for us! a dus!eI METHODS 3 Eligibili ty aite<>a for pa~panl$ and d usters and the Clinics. 2.2.5 I 
P1lfticlpanl& &el~nOls and locallOnS wtl6!e lh& dala wet'e C"dlacted 
P~tIenl!l: 2_2_6. I 
Irller~erulOnS • Precise delai!S allhe ioterveoUQI1.$ lnl8ndei:l for each group. ImenrenlO'1 components 222 
_he< they pert3n !O lhe Indlviduilll level. lhe clusler level 
m\9rvefllKlll delivery- 3.2 
Of' boIh. and hnW and when!he _e acI1BItv adminoslered 
Objectives , Speafoc obJectives and h~he$e$ and wtl8lher \tIvy " n !O the ndtvoduailEwel, lhe (;lustflf 1e>'eI. or both 
""'~ 
, Clearly delloed prrmary and ~ary OUICO'Ila measures, Outcomes: 2.2.8 and hble 2 <I 
whether they pertain 10 the individual lllvet. lhe cI\.IS\er level, 
1 rilining of f!eldlWrkers . 23,4 
or boIh. and. wtlen applic<tble, any metlKx!5 used to 
flI)llanetlthe QiXW,ty of measurements (e,g . multiple Quality control procedures; 2.35 
ob$ervaloOns. tramon!l of assessas) 
Sampte size 7 How sample SIze was determfned (irdudng method of 2210 
caiw atioo,numoor aI d usters. duster slle; II ooefficie~t 01 
InlraciuSler correlatoo ICCOl' k). and <JI1 irdication 01 ita 
'" 
, !her witll masons. 
, 
Recruitmool " Dales defining !he IlElrio<:Js 01 recruitment and f~low-up 2.2.6 ROCfI)itmenL M3Y \II September 2003 
'--'- ' , F<:>I"VH.lP _1 2 weeks ,,:fter_,ecn.Hlmenl (f'igure 2 2) 
Baseline data " aaseHne demorfaphtc. :;md cJ!f1ica1 characteristl"" lot the Clinics Table 2.1 (baseline characlerrsUcs) ..,dividual and duster Iilv .. l,; as applicable 
Patients: Table 3. 1 (enr~ment charactensbcs) 
Nl1IlllJers analyzed " Numbe< of clusters iHld parlidpanls (d<!norn,"a\Ol) In each Numoo<s re~!ed for all anal)'Ses groop inek.Jded In each analysis am! whether the analysis AIlalysis by intention-to-treat 24 1 
W<lS by -lillenllon -to-Ireat" Stale the r",,,,,lIs In absolute 
rumtlers when feasible (e,g , 10120, 001 5()%). 
Outcomes and " For ea.;h pr m ...-y and se<;Ondary ""leome, a summ"'Y 01 Pf,mary O<,Iloomes: Table 3.3 estimation resu lts !of each group for tile individual or dusls< levei as 
Secondary oolcomes: Tables 3.4 through 3.17 
OiIpplicable aI10 the estimated !lffeel size and Its procisioo 
(lI.g., 95% cooMerlal Inte<val ) ~nd a roaIf"''''nl of 
in!lacluster correlation ICC or kl for each mar outcome _ 
Ancil lary a"alysoo " Address mulUpllCIty by reportJrJg any other an~yses EXpior(ltory analysis for Inhaled corticosteroids ' 3 :'.1 periO'med. locluding sui:Jgroup analyse'! and adjusted 
an,.yses, Indicating lOOse pre·spec~led ood those 
ex~O(ator~_ 
Adve<se events " Allimponanl adverse events 0( side effects In each Mcdal'ty: 3.10 In\erver1\iOO ~ 
DISCUSSION '" Inte<pretalKm of tI>e results , lakirJg Into account slildy Inte<prelatlon of rewlts . Inlerprelatkin hypotl>eses, soorces 01 potential bias 0( Imptecision <lnd the 




9.8.2 Checklist of criteria for the completion and reporting of economic evaluations of healthcare interventions 
(Drummond and Jefferson 1996) 
Secllon and IOpk: I Reported 
DESIGN OF ECONOMIC EVALUATION 
RHe3rch question sto'lll,d Tab .. 1.17 
22.4.1 
Imi>Ol'lallOO 01 queslion SlatEK! Ass&Ss etfoaency ar>d describe resoorce 'mplications 2 I 
Cost may be wrwod as a disincentive \0 IIlll)IBmellliltioll 224 t 
, 101 anal .... ;s staled IOfId defined 224.2 Health service and sooetal 
Ra\iOor'\ale for ChOOSing alternat~ programmes or intervenllOl'lS 2.2.3 
ccunl)afed staled 
Attentat",," OOO;! oompe.red dearty defllled 2.2.2 ~tervention 
U., "~ 
Form d. econom4c evaluation used slated 2~4_2 Planned cost analysiS. cost-efieclNene" (Ir\CkIOll1g C05Hn~lty) if 
II1lefVeflllOn more <.Xiess effec\Ne Ihiorl usu"t CiI'e. cost-minlmgoOn ~ equivalent 
10 usual care 
COIIIple!ed_.,.,.,\ a"alyslS. CCl5t-effecllYenesS analysos as PALSA mOle effectNe 
Ih3r usual care, cosl,uli!ily analYSHl not oomplated beeal.lse no dltfereoce In u(, lillilS 
obseIved d(..-,ng the tri31 
COOIce of model used and key DJfJm&lefS on whPch it IS based lustified I NIA 
ANALYSIS 
T ., .. , 1 "" 'LOll uI L<n>l~ ",Kl 1>0;" ",f,b ~t..\<><l 2.43 
Discount rate/s) stated 2.4 3 Base analYSis: 3% 
Choice 01 r!l:te{ sl l\.lStified 243 Russal et aI 1996 
ExptanatKln given if oosts aod benef,ts are root discounled 2.43 Benefits and costs if1ClJITed In 2003 oat dlscounled 
[)eta~s of slatistlCaltests and conficleoce Intervats gl ~en tor stochastic Tat)le 4 18 Means cost pe< patients for 3 month period between lnle<v;ews 
do. 
Tab~ 5.1 Cost per add,licmal case appropll31ely managed 
Tabla 5.2 Cost r additional tubercUiOS's case detocted 
I Approach 10 senS41iY lty analysis gIVen 2.4.7 
Choice 01 varJabJes for senslUvltv analysIS justified 2.4.7 
RarK)9 (Net whkll variables <"6 varied stated 24.7. 4,4 
Relevant a~et""tives compared Yes PAlSA '" usual tralfllflg and support tor respiratory diseasas vs usual trainIng 
ar><! sUOOO<1lor resolratorv diseases 
illCtemental arlal is r ,," Chanters 4 ar><! 5 
Major outcomes presented in "0 aggregated as weJl as a (llsaggregaled Chapters 4 arKI5 
f= 
IVlSWIIf to study question ~" 7.1.2ancl7.1.3 
Coodus;ons foll(IW from data '" 7.12and7.13 
C<:mdusions accompanied by nal" cav""ts 7 1.2, 7 t 3.1.2 
465 
